<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> PROTEON THERAPEUTICS INC (Form: 10-K, Received: 03/14/2016 08:43:57) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_AUDITORS_OPINION **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_21 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="198">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="F10K_031416P_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	WASHINGTON, DC 20549
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 0.75PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; BORDER-BOTTOM: BLACK 0PT SOLID">
<B>
	FORM 10-K
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; BORDER-BOTTOM: BLACK 0.75PT SOLID">
<B>
	&nbsp;
<BR>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(Mark One)
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	[X]
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	For the fiscal year ended December 31, 2015
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	or
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	[&nbsp;&nbsp;]
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	For the transition period from&nbsp;
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
	&nbsp;to
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; BORDER-BOTTOM: BLACK 0PT SOLID">
<B>
	Commission File Number: 001-36323
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; BORDER-BOTTOM: BLACK 0.75PT SOLID">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	PROTEON THERAPEUTICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; BORDER-BOTTOM: BLACK 0PT SOLID">
<B>
	(Exact name of registrant as specified
	in its charter)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0; BORDER-BOTTOM: BLACK 0.75PT SOLID">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	Delaware
</B>
</TD>
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	20-4580525
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(State or other jurisdiction of
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	incorporation or organization)
</B>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	(I.R.S. Employer
</B>
<BR>
<B>
	Identification No.)
</B>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0.35PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	200 West Street
</B>
<BR>
<B>
	Waltham, MA
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(Address of principal executive offices)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0.05PT 0 0">
<B>
	02451
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(Zip Code)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0.05PT 0 0">
<B>
	(781) 890-0102
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	(Registrant&#8217;s telephone number, including area code)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	Indicate by check mark whether the registrant (1) has filed all reports
	required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
	shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
	the past 90 days. Yes [X] No [ &nbsp;]
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	Indicate by check mark whether the registrant has submitted electronically
	and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
	405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
	was required to submit and post such files). Yes [X] No [&nbsp; ]
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	Indicate by check mark whether the registrant is a large accelerated
	filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of &#8220;large accelerated
	filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check
	one):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.4PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Large accelerated filer [ ]
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Accelerated filer [X]
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Non-accelerated filer [ ] (Do not check if a smaller reporting company)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Smaller reporting company [ ]
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
	Indicate by check mark whether the registrant is a shell company (as
	defined in Rule 12b-2 of the Exchange Act). Yes [ &nbsp;] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No [X]
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<B>
	EXPLANATORY NOTE
</B>
	: Under the Jumpstart
	Our Business Startups Act, the registrant qualifies as an &#8220;emerging growth company.&#8221; We therefore incorporate the scaled
	disclosures required of an emerging growth company in this Annual Report on Form&nbsp;10-K.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	The aggregate market value
	of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price for such stock
	as reported on the NASDAQ Global Market on June&nbsp;30, 2015, the last business day of the registrant&#8217;s most recently completed
	second quarter, was: $294.0 million.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	As of March 10, 2016 there were 16,507,894 shares of the registrant&rsquo;s common stock, par value $0.001
	per share, outstanding.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
<B>
</B>
<BR>
<BR>
</P>
<P STYLE="MARGIN: 0PT 0">
	Portions of the registrant&rsquo;s definitive proxy statement for its 2016 Annual Meeting of Stockholders,
	which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the end of the registrant&rsquo;s
	fiscal year ended December 31, 2015, are incorporated by reference into Part&nbsp;III of this Annual Report on Form&nbsp;10-K.
	With the exception of the portions of the registrant&rsquo;s definitive proxy statement for its 2016 Annual Meeting of Stockholders
	that are expressly incorporated by reference into this Annual Report on Form&nbsp;10-K, such proxy statement shall not be deemed
	filed as part of this Annual Report on Form 10-K.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<BR CLEAR="ALL">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	TABLE OF CONTENTS
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Page
</TD>
</TR>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	PART I
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_001">
	Item 1.
</A>
</TD>
<TD STYLE="WIDTH: 81%; TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_001">
	Business
</A>
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_001">
	6
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_002">
	Item 1A.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_002">
	Risk Factors
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_002">
	62
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_030">
	Item 1B.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_030">
	Unresolved Staff Comments
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_030">
	130
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_003">
	Item 2.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_003">
	Properties
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_003">
	130
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_004">
	Item 3.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_004">
	Legal Proceedings
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_004">
	130
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_005">
	Item 4.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_005">
	Mine Safety Disclosure
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_005">
	131
</A>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	PART II
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_006">
	Item 5.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_006">
	Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_006">
	131
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_007">
	Item 6.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_007">
	Selected Financial Data
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_007">
	135
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_008">
	Item 7.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_008">
	Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_008">
	137
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_009">
	Item 7A.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_009">
	Quantitative and Qualitative Disclosures About Market Risk
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_009">
	154
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_010">
	Item 8.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_010">
	Financial Statements and Supplementary Data
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_010">
	155
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_011">
	Item 9.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_011">
	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_011">
	155
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_012">
	Item 9A.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_012">
	Controls and Procedures
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_012">
	155
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_013">
	Item 9B.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_013">
	Other Information
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_013">
	157
</A>
</TD>
</TR>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	PART III
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_014">
	Item 10.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_014">
	Directors, Executive Officers and Corporate Governance
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_014">
	157
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_015">
	Item 11.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_015">
	Executive Compensation
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_015">
	157
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_016">
	Item 12.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_016">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_016">
	157
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_017">
	Item 13.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_017">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_017">
	157
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_018">
	Item 14.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_018">
	Principal Accounting Fees and Services
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_018">
	157
</A>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
</TD>
</TR>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	PART IV
</B>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_019">
	Item 15.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_019">
	&nbsp;Exhibits and Financial Schedules
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_019">
	158
</A>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 2.65PT 144.15PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 2.65PT 144.15PT 0">
<B>
	CAUTIONARY NOTE FORWARD-LOOKING STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	This Annual Report on Form 10-K contains forward-looking
	statements, which reflect our current views with respect to, among other things, our operations and financial performance. All
	statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements.
	You can identify these forward-looking statements by the use of words such as &#8220;outlook,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221;
	&#8220;potential,&#8221; &#8220;continues,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221;
	&#8220;approximately,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;anticipates&#8221;
	or the negative version of these words or other comparable words. These forward-looking statements are subject to various risks
	and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially
	from those indicated in these statements. These forward-looking statements include, but are not limited to, statements about:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the timing of completing enrollment or releasing data or results of our ongoing and planned clinical trials
	for vonapanitase (formerly PRT-201);
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our estimates regarding the amount of funds we require to complete our two planned Phase 3 clinical trials for vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&middot;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	whether and when we may submit a Biologics License Application or a supplemental Biologics License Application;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&middot;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our search for additional product opportunities;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&middot;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the sufficiency of existing facilities to meet our needs;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&middot;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	whether we will need to conduct any additional studies after our Phase 3 trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our estimates regarding the amount of funds required to fund operations into the fourth quarter of 2017;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our plans to fund our chemistry, manufacturing and controls;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing and plans for additional financing;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our estimate of when we will require additional funding;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our plans to commercialize and bring vonapanitase to market;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the timing of, and our ability to, obtain and maintain regulatory approvals for our product candidates, including vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the timing of a clinical trial of vonapanitase in Europe, results and submission of a Marketing Authorization Application;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our interpretation of the data from our completed Phase 2 trial for vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the rate and degree of market acceptance and clinical utility of any approved product candidate and the general market for the prevention of vascular access failure;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnership arrangements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to quickly and efficiently identify and develop additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our commercialization, marketing, distribution and manufacturing capabilities, strategy and expenses;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	timing to recruit and expand our employee base and sales force, both in and outside the United States;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	plans to initiate Phase 1 or Phase 1/2 trials in symptomatic peripheral artery disease or other indications;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the reimbursement of vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our research and development costs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our general and administrative costs and salary and personnel costs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the costs associated with preparation for commercial operations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the costs associated with being a public company;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our intellectual property position;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our plans to seek patent protection in available countries;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our expectations that vonapanitase will qualify for a 12-year period of exclusivity;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our reliance on third parties as suppliers and manufactures;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our plans to build out compliance, financial and operating infrastructure after Phase 3 completion;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our plans to improve existing, and implement new, systems to manage our business;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	future payment of dividends;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the impact of accounting policies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the impact of changes in interest rates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 80PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX; TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	exposure to foreign currency exchange risks;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our purchase of forward foreign currency contracts in the future; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the continued adoption of stock trading plans by employees, including executive officers.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	All forward-looking statements in this Annual
	Report on Form 10-K involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance
	or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
	statements. Factors that may cause actual results to differ materially from current expectations include, among other things, the
	risk factors set forth below in Part II, Item 1A, Risk Factors, and elsewhere in this Annual Report on Form 10-K. These factors
	should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included
	in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
	Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if
	new information becomes available in the future.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	This Annual Report on Form 10-K also contains
	estimates, projections and other information concerning our industry, our business, and the markets for certain medical conditions,
	including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information
	that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties
	and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise
	expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar
	data prepared by market research firms and other third parties, industry, medical and general publications, government data and
	similar sources.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	NOTE REGARDING STOCK SPLIT
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Unless otherwise indicated, all information in
	this Annual Report on Form 10-K and in our condensed consolidated financial statements gives retrospective effect to 1-for-15.87
	reverse stock split of our common stock that was effected on October 6, 2014. All share, share equivalent and per share amounts
	presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of preferred stock were converted
	into shares of common stock upon consummation of our initial public offering have been adjusted to reflect the effects of the reverse
	stock split.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
<B>
	PART I
</B>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<A NAME="F10K_031416P_HTM_A_001">
</A>
	Item 1. Business
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
<I>
	Unless the context requires
	otherwise, references in this Annual Report on Form 10-K to &#8220;Proteon&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221;
	refer to Proteon Therapeutics, Inc.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We are a late-stage biopharmaceutical company focused
	on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. Our
	product candidate, vonapanitase (formerly PRT-201), is a recombinant human elastase that we are developing to reduce vascular access
	failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be
	conducted without a functioning vascular access. We believe the data from our completed Phase&nbsp;2 trial of vonapanitase in patients
	undergoing creation of an arteriovenous fistula, or AVF, support that a one-time, local application of vonapanitase during AVF
	surgical creation reduces AVF failure, thereby improving patient outcomes and reducing the burden on patients and the healthcare
	system. We are not aware of any approved preventative treatments to reduce the failure rate of AVFs. We began enrolling patients
	in our first Phase 3 clinical trial of vonapanitase, PATENCY-1, during the third quarter of 2014 for patients undergoing creation
	of a radiocephalic AVF, completed patient enrollment in October 2015 and expect to release top-line data in December 2016. We enrolled
	the first patient in our second Phase 3 trial, PATENCY-2, in August 2015 and expect to complete enrollment in the first quarter
	of 2017.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The need to improve vascular access outcomes is
	well established in the hemodialysis community. A 2014 publication estimated the total cost of managing hemodialysis vascular access
	dysfunction in the United States to be approximately $2.9&nbsp;billion annually. AVFs are the gold standard of vascular access
	for hemodialysis, given they are associated with fewer complications and reduced rates of hospitalization as compared to other
	forms of vascular access. We estimate there are approximately 130,000 AVFs created in the United States annually, a procedure in
	which a surgeon transects a vein and sutures it to the side of a nearby artery, typically in the arm. However, AVFs have a greater
	than 50% failure rate in their first year after creation, resulting in frequent surgical or interventional procedures and a high
	rate of abandonment, leading to increased morbidity, mortality and costs of care. Function can usually be restored via additional
	procedures, either an intervention such as angioplasty, which is dilation of a blood vessel with a balloon, or a surgical revision.
	These procedures, however, are costly, invasive, painful, associated with a number of complications and often need to be repeated.
	AVF patients in the United States on average require greater than 1.5 procedures per year, each of which typically costs Medicare
	between $5,000 and $13,000.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We have demonstrated that vonapanitase generates
	fragments of elastin, a protein present in blood vessels, and we believe the fragments of elastin inhibit formation of neointimal
	hyperplasia, which is the growth of tissue inside vessels that narrows AVFs and reduces blood flow. During AVF creation surgery,
	a surgeon would administer drops of vonapanitase onto the surface of the artery and vein of an AVF for 10 minutes followed by a
	saline irrigation. We believe that a one-time, local application of vonapanitase to the external surface of the vessels during
	AVF surgical creation can modify the injury response, or scarring, resulting from surgery and thereby reduce the severity of neointimal
	hyperplasia and AVF failure following surgery.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In 2012, we completed a multicenter, randomized
	double-blind, placebo-controlled Phase&nbsp;2 trial of vonapanitase in 151 patients undergoing surgical creation of an AVF in the
	wrist, known as radiocephalic AVFs, or upper arm, known as brachiocephalic AVFs. The primary efficacy endpoint was primary unassisted
	patency, defined as the time from surgical creation of the AVF to occurrence of a thrombosis or an intervention such as angioplasty,
	to restore or maintain patency, or functionality. Both the 10 microgram and 30 microgram doses of vonapanitase showed a trend toward
	efficacy on the primary endpoint, although neither dose met the primary endpoint with statistical significance. For all AVFs, median
	patency, the time at which 50% of patients in a group lost primary unassisted patency, was 224&nbsp;days in the placebo group and
	greater than 365&nbsp;days in each of the vonapanitase treatment groups, indicating that vonapanitase prolonged primary unassisted
	patency. In the trial, patients treated with vonapanitase reported adverse events comparable to placebo. These events were consistent
	with the medical events experienced by chronic kidney disease patients undergoing AVF creation surgery.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	An analysis of the primary endpoint data revealed
	an uneven distribution in patency loss events in patients with a brachiocephalic AVF due to central stenosis in the shoulder and
	chest, remote from the site of an AVF. Central stenoses commonly exist prior to AVF creation and are unmasked following creation
	of brachiocephalic AVFs, which have higher blood flow than radiocephalic AVFs. These stenoses are unrelated to treatment with vonapanitase.
	To correct for this uneven distribution, we conducted a non-prespecified analysis of the primary endpoint that excluded patency
	loss events due to central stenoses. This analysis demonstrated a significant reduction in the risk of primary unassisted patency
	loss in the 30 microgram vonapanitase dose group (p=0.04) compared to placebo.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The benefit of vonapanitase on primary unassisted patency was most pronounced in the subset of patients undergoing
	creation of a radiocephalic AVF. The subset analysis of this endpoint for radiocephalic AVF patients receiving the 30 microgram
	dose, which was not prespecified, showed a significant increase in median primary unassisted patency of &gt;365&nbsp;days as compared
	to 125&nbsp;days in the placebo group. In addition, we observed beneficial drug effects on additional efficacy endpoints, including
	unassisted maturation, defined as increased vessel diameter and blood flow without the need for an intervention such as angioplasty;
	rate of procedures to restore or maintain AVF patency; secondary patency, defined as abandonment of the AVF and the need for creation
	of a new vascular access; use for hemodialysis; and hemodynamically significant stenosis, or narrowing of blood vessels.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In April 2013, we held an end of Phase&nbsp;2 meeting
	with the United States Food and Drug Administration, or FDA, during which we confirmed elements of our Phase&nbsp;3 development
	plan, including the primary endpoint. We are conducting two 300-patient Phase&nbsp;3 trials of vonapanitase using a 30 microgram
	dose, enrolling only patients undergoing a surgical procedure to create a radiocephalic AVF. We began enrolling patients in our
	first Phase 3 clinical trial of vonapanitase, PATENCY-1, during the third quarter of 2014 for patients undergoing creation of radiocephalic
	AVFs, completed patient enrollment in October 2015 and expect to release top-line data in December 2016. We enrolled the first
	patient in our second Phase 3 trial, PATENCY-2, in August 2015 and expect to complete enrollment in the first quarter of 2017.
	While the FDA offered no assurances that it will not require us to conduct any additional clinical studies, we believe we will
	not need to conduct any additional clinical studies after our Phase&nbsp;3&nbsp;trials. Further, if the results of the first Phase&nbsp;3
	trial are sufficiently compelling, we intend to meet with the FDA to discuss the possibility of submitting a Biologics License
	Application, or BLA, supported by the single Phase&nbsp;3 trial and may decide to submit a BLA to the FDA prior to completing the
	second Phase&nbsp;3 trial. Vonapanitase has received fast track designation from the FDA which is designed to facilitate the development
	and expedite the review of drugs and biologics to treat serious conditions and fill an unmet medical need, and orphan drug designation
	in the United States and European Union, for hemodialysis vascular access indications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We believe that if our Phase&nbsp;3 clinical program is successful vonapanitase will potentially become the
	standard of care for patients with chronic kidney disease, or CKD, who are undergoing surgical creation of a radiocephalic AVF.
	We retain worldwide commercial rights to vonapanitase. If approved by regulatory authorities, we intend to commercialize this product
	in the United States ourselves with a specialty hospital sales force, focused primarily on vascular surgeons, and intend to seek
	one or more collaborators to commercialize the product in additional markets. Our patents include claims covering formulations,
	methods of manufacturing and use of elastases, providing protection in the United States through mid-2029 and European Union through
	2028, with potential extension through 2032 in the United States and in the European Union.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Our Strengths
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We believe our company and vonapanitase possess
	the following attributes that increase the likelihood that we will be successful in developing and commercializing vonapanitase:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Entering Phase 3 trials for radiocephalic AVF creation.
</I>
	&nbsp;&nbsp;We are conducting two Phase&nbsp;3 clinical trials in radiocephalic AVF creation using a 30 microgram dose of vonapanitase, the population and dose in which, in a non-prespecified analysis, we observed an improvement in primary unassisted patency with vonapanitase in our Phase&nbsp;2 trial.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; WIDTH: 96PX">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Phase&nbsp;3 endpoints same as our Phase&nbsp;2 trial.
</I>
	&nbsp;&nbsp;The primary endpoint in our Phase&nbsp;3 trials, primary unassisted patency, is the same as we used in our Phase&nbsp;2 trial. In addition, our secondary endpoint (secondary patency) and tertiary endpoints (unassisted maturation, use for hemodialysis and average procedure rates) in our Phase&nbsp;3 trials were all endpoints in our Phase&nbsp;2 trial. In April 2013, we held an end of Phase&nbsp;2 meeting with the FDA during which we confirmed elements of our Phase&nbsp;3 development plan, including the primary endpoint.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Safety profile supports approval.
</I>
	&nbsp;&nbsp;Based on results from our clinical trials and preclinical studies, we believe vonapanitase, which is administered once and only acts locally, has demonstrated a favorable safety profile. Because vonapanitase is administered in a one-time, local application and is inactivated by antiproteases, substances that inhibit the activity of a protease, in the blood, there is no systemic activity. In clinical trials assessing safety, there were no material increases in adverse events in the vonapanitase treatment groups as compared to placebo and no material findings related to physical examinations or clinical laboratory testing including chemistry, hematology and coagulation panels or antibodies to vonapanitase. At our end of Phase&nbsp;2 meeting with the FDA, we confirmed that we do not need to conduct any additional preclinical studies to support a BLA filing.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Unmet medical need.
</I>
	&nbsp;&nbsp;While AVFs are considered the most desirable form of vascular access by the medical community, they are
	also associated with high failure rates, a serious complication for hemodialysis patients that results in substantially higher
	healthcare costs. A 2014 publication estimated the total cost of managing hemodialysis vascular access dysfunction in the United
	States to be approximately $2.9&nbsp;billion annually. We are not aware of any approved preventative treatments to reduce AVF failure
	rate. Vonapanitase has received fast track designation from the FDA, which is designed to facilitate the development and possibly
	expedite the review of drugs and biologics to treat serious conditions and fill an unmet medical need. We believe vonapanitase
	reduces vascular access failure in patients with CKD undergoing hemodialysis and, if approved, could become the standard of care
	by reducing the cycle of interventions, improving patient outcomes and reducing the overall burden on patients and the healthcare
	system.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Substantial and readily-addressable market opportunity.
</I>
	&nbsp;&nbsp;If vonapanitase is approved, we intend to commercialize this product in the United States and potentially certain European countries ourselves with a specialty hospital sales force, focused primarily on vascular surgeons, and intend to seek one or more collaborators to commercialize the product in additional markets. We estimate a sales force of approximately 75-100 representatives will enable us to call on the approximately 1,300 hospitals that account for more than 90% of the AVF surgical creations performed in the United States annually.&nbsp;&nbsp;We believe vonapanitase will be supported by key stakeholders, including referring nephrologists, patient advocacy groups, large dialysis organizations and payors. We believe vonapanitase will be reimbursed adequately as costs related to AVF surgical creation, which is typically performed in the hospital outpatient setting, are not included in the End Stage Renal Disease, or ESRD bundle, the single bundled payment from Medicare for a number of the costs of hemodialysis treatments, medications, labs and supplies for patients with end-stage renal disease.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Experienced team.
</I>
	&nbsp;&nbsp;Our executive management team has extensive experience in the renal and vascular disease fields through their substantial involvement in companies such as Abbott, AMAG, GelTex, Genzyme, Glaxo and Merck. Our Chief Executive Officer and Chief Medical Officer were senior executives at GelTex, a biopharmaceutical company, where they played leading roles in the development and commercialization of Renagel, a treatment for hemodialysis patients that led to Genzyme's acquisition of GelTex for more than $1&nbsp;billion. Our Senior Vice President of Marketing was a senior executive at AMAG Pharmaceuticals, a biopharmaceutical company, where he played a leading role in the commercialization of Feraheme for iron-deficiency anemia in adults with chronic kidney disease.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Our Strategy
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our strategy is to develop and commercialize vonapanitase
	for patients suffering from renal and vascular diseases, beginning with patients with CKD undergoing surgical creation of a radiocephalic
	AVF. Key elements of our strategy include our plans to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Complete clinical development of vonapanitase and seek regulatory approval in the United States in its lead indication.
</I>
	&nbsp;&nbsp;We commenced our first Phase&nbsp;3 clinical trial of vonapanitase for patients with CKD undergoing creation of a radiocephalic AVF in the third quarter of 2014. Prior to completing enrollment in the first Phase&nbsp;3 trial, we enrolled the first patient in our second Phase&nbsp;3 trial in August 2015 and expect to complete enrollment in first quarter of 2017. If the results of the first Phase&nbsp;3 trial, data expected in December 2016, are sufficiently compelling, we intend to meet with the FDA to discuss the possibility of submitting a BLA supported by the single Phase&nbsp;3 trial and may decide to submit a BLA to the FDA prior to obtaining data from the second Phase&nbsp;3 trial.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Commercialize vonapanitase directly in the United States.
</I>
	&nbsp;&nbsp;If vonapanitase is approved by the FDA, we intend to commercialize it ourselves in the United States with a specialty hospital sales force focused primarily on vascular surgeons. There are approximately 2,800 vascular surgeons in the United States. In 2013, according to the U.S. Renal Data System 2015 Annual Data Report, there were approximately 421,000 hemodialysis patients in the United States at the end of the year. Based on various third-party sources, we estimate that approximately 130,000 AVFs are placed annually. We believe a specialty hospital sales force of approximately 75-100 representatives will enable us to call on the approximately 1,300 hospitals that account for more than 90% of the AVF surgical creations performed in the United States annually. We believe that vonapanitase's potential benefits to patients undergoing surgical creation of an AVF will result in its broad adoption.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Undertake clinical development of vonapanitase in Europe and establish partnerships for commercialization of vonapanitase in all or parts of Europe.
</I>
	&nbsp;&nbsp;We are currently evaluating our existing clinical program to support filing in Europe. We may, based on additional data including the data from our Phase&nbsp;3 clinical trials in the United States and if sufficient funds become available, choose to conduct a clinical trial of vonapanitase in Europe. We estimate that there are approximately 315,000 hemodialysis patients in Europe. Prior to enrolling our first patient in Europe, we plan to formally seek guidance from the European Medicines Agency, or EMA, regarding its requirements for regulatory approval. We expect results from this trial to be available two to three years after the first patient is enrolled. If this European trial successfully meets its primary endpoint and depending on the guidance obtained from the EMA, we would expect to submit a Marketing Authorization Application, or MAA. If vonapanitase is approved by the EMA, we intend to commercialize it in European countries with our own specialty hospital sales force or with a commercial partner, or a combination thereof. Like in the United States, we intend to target both vascular surgeons who create AVFs as well as key referring nephrologists.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Pursue additional indications for vonapanitase.
</I>
	&nbsp;&nbsp;We believe that our Phase&nbsp;2 clinical data support further development of vonapanitase in brachiocephalic
	AVF creation. We may, based on additional data including the data from our Phase&nbsp;3 clinical trials and if sufficient funds
	become available, study the effects of a 30 microgram dose of vonapanitase versus placebo on brachiocephalic AVFs. If this trial
	were to successfully meet its primary endpoint, we would expect to submit a supplemental BLA, or sBLA, to the FDA and a supplemental
	MAA, or sMAA, to the EMA. Further, if sufficient funds become available and after reviewing the results from our Phase&nbsp;3 clinical
	trials, we may commence a clinical trial of vonapanitase in patients undergoing placement of an arteriovenous graft, or AVG. We
	believe vonapanitase's potential to reduce neointimal hyperplasia could offer a significant medical benefit in these patients.
	Further, we plan to commence three Phase 1 clinical trials of vonapanitase in patients with peripheral artery disease, or PAD.
	We believe vonapanitase's potential to reduce neointimal hyperplasia and/or dilate blood vessels could offer a significant medical
	benefit in these patients.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Establish partnerships for development and commercialization of vonapanitase in Japan and other Asian countries.
</I>
	&nbsp;&nbsp;We estimate that in 2013 there were approximately 315,000 patients on hemodialysis in Japan and more than 800,000 throughout all of Asia. Approximately 90% of Japanese hemodialysis patients receive AVFs. We may enter into collaborations for the development and commercialization of vonapanitase in Asia.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	In-license or acquire additional product opportunities.
</I>
	&nbsp;&nbsp;We plan to search for additional product opportunities that could be sold and marketed by the specialty hospital sales force required to successfully launch vonapanitase in the United States if it is approved for marketing.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Background on Hemodialysis
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Healthy kidneys serve many functions, including
	removing waste and excess water, helping to control blood pressure and keeping electrolytes, such as sodium and potassium, in balance.
	Patients with CKD have lost most or all kidney function, most commonly due to diabetes or hypertension. Kidney disease is progressive
	and once a patient has reached end-stage CKD, the kidneys are no longer able to remove waste and fluids from the body. At this
	point, some form of renal replacement therapy is required, such as hemodialysis, in which blood is processed by a hemodialysis
	machine, peritoneal dialysis, a process using a cavity in the abdomen called the peritoneum as a membrane across which fluids are
	exchanged from the blood, or kidney transplant.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	According to the U.S. Renal Data System 2015 Annual
	Data Report, in 2013 there were approximately 421,000 hemodialysis patients in the United States, and an incremental 103,000 patients
	initiated hemodialysis in the United States. As reported by Fresenius Medical, a major provider of hemodialysis services and renal
	care products, in 2013 there were approximately 315,000 hemodialysis patients in Europe, 315,000 hemodialysis patients in Japan
	and 2.2 million hemodialysis patients worldwide, with an annual worldwide growth rate of 6-7%.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Hemodialysis is the most common form of treatment
	for end-stage CKD. Hemodialysis is a chronic therapy performed by cannulating, or piercing, a vein with a large bore needle so
	that blood can be pumped through a hemodialysis machine, which removes waste and excess fluid normally excreted by the kidney.
	The cleansed blood is then returned to the same vein via a second needle. A hemodialysis session typically lasts three to four
	hours and is performed three times a week in an outpatient dialysis clinic.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	To enable sufficient blood to pass through the
	hemodialysis machine to complete treatment within four hours, a vein must have blood flow of at least 500 milliliters per minute.
	The arm is the most convenient location for accessing the blood stream on a recurring basis, but blood flow in the arm is approximately
	50 milliliters per minute. Therefore, most hemodialysis patients undergo a surgical procedure in which a surgeon establishes a
	direct connection between an artery and a vein to create a high flow circuit of sufficient diameter, most often in an arm. The
	direct artery-vein connection effectively bypasses the capillary circulation in the hand and leads to a process known as maturation,
	where the internal diameter, or lumen, of the vein and blood flow increase over a period of weeks, resulting in a lumen diameter
	greater than 4 millimeters and blood flow of 500-2,000 milliliters per minute in successful cases.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The gold standard for vascular access is an AVF,
	in which a surgeon transects a vein in the arm and sutures it to the side of a nearby artery. AVFs are preferred because they are
	less prone to patency loss than are AVGs; approximately 50% of AVFs and up to 75% of AVGs will lose primary patency and 20-30%
	of AVFs and 28-35% of AVGs will lose secondary patency in the first year after surgical placement. As compared to AVGs, AVFs require
	approximately 40% fewer interventional or surgical procedures and suffer from a rate of vascular access infection that is 54% lower.
	Patients dialyzing with an AVF have lower rates of thrombosis and hospitalization, longer survival, reduced mortality and lower
	cost of care. Beyond the substantial medical advantages of an AVF, available data from the U.S. Renal Data System show that patients
	who dialyze with an AVF cost Medicare approximately $15,000 less annually than patients who dialyze with an AVG and approximately
	$25,000 less annually than patients who dialyze with a catheter. According to published data, approximately 67% of hemodialysis
	patients in the United States dialyze with an AVF compared to 67-83% of patients in the major European countries and approximately
	90% of patients in Japan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Based on various third-party sources, we estimate
	there are approximately 130,000 AVFs created in the United States annually. There are a limited number of potential artery-vein
	combinations in the arm that can be used to create an AVF, principally the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	radiocephalic AVF at the wrist (radial artery sutured to cephalic vein), which we estimate is created in 40% of new AVF creations;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	brachiocephalic AVF at the elbow (brachial artery sutured to cephalic vein), which we estimate is created in 50% of new AVF creations; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	brachiobasilic AVF in the upper arm (brachial artery sutured to basilic vein), which we estimate is created in 10% of new AVF creations.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The medical community endorses radiocephalic AVFs
	as the optimal form of vascular access and the recommended first choice for new hemodialysis patients. Creating the vascular access
	site at the wrist preserves the potential future use of other access further up in the arm, is simpler to create, and is less likely
	to create heart failure or steal syndrome, where the diversion of flow through the AVF reduces blood to the hand. Radiocephalic
	AVFs are also less likely to suffer from central stenoses in the shoulder and chest, remote from the site of the AVF. The Kidney
	Disease Outcome Quality Initiative Guidelines, or KDOQI Guidelines, authored by the National Kidney Foundation, or NKF, specifically
	recommend starting with a radiocephalic AVF if possible, stating that "starting [closer to the hand] and moving [further up
	the arm] provides for the possibility of preserving as many potential sites as possible for future access creation." If a
	radiocephalic AVF must be abandoned, a surgeon can create a new vascular access higher up the arm, most likely a brachiocephalic
	AVF. However, if a brachiocephalic AVF is placed first, the surgeon cannot later move down that same arm to create a radiocephalic
	AVF because the cephalic vein has already been transected for use in the brachiocephalic AVF.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Radiocephalic (wrist) AVFs suffer from high
	rates of patency loss and maturation failure, with up to 70% being subject to primary unassisted patency loss and up to 35%
	being abandoned within 12 months after their surgical creation. Patency loss in radiocephalic AVFs occurs due to stenosis
	formation at or near the AVF 75-95% of the time. Some patients never receive a radiocephalic AVF because the surgeon believes
	the risk of failure is too high for those patients. These patients will typically undergo creation of an AVF higher up on the
	arm and permanently lose at least one of their access sites. We believe that the number of radiocephalic AVFs created
	annually may rise if vonapanitase improves outcomes and allows vascular surgeons to create radiocephalic AVFs in sites that
	they previously considered to pose an unacceptably high risk of failure.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The second choice for vascular access after AVF
	is an AVG in which a surgeon connects an artery and vein using a synthetic tube. Based on reported data, approximately 19% of hemodialysis
	patients in the United States dialyze with an AVG, compared to approximately 5-12% of patients in the major European countries
	and approximately 7% of patients in Japan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The least desirable type of vascular access is
	a catheter, a plastic tube that is placed directly through the skin into a vein, typically via an incision in the neck enabling
	placement of the catheter into a large vein that leads directly to the heart. The catheter connects the patient's vasculature to
	the hemodialysis machine. Because the catheter penetrates the skin continuously, it is subject to a high risk of infection and
	increased mortality. One of the primary goals of hemodialysis care is to keep patients off catheters. However, patients most often
	initiate hemodialysis through a catheter until an AVG or AVF is ready to be used, and are dialyzed temporarily through a catheter
	when the AVF or AVG they have been using fails and a new one has to be created. Approximately 14% of hemodialysis patients in the
	United States dialyze with a catheter, compared to 10-28% of patients in the major European countries and 2% of patients in Japan,
	based on published data.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Established Medical Need
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The need to improve vascular access outcomes is
	well established in the hemodialysis community. The health-related and economic cost of creating and maintaining vascular access
	for hemodialysis has led to a global effort to address the problem. Over the last 10 years, the NKF has established guidelines
	in an effort to increase the use of AVFs while reducing the rate of complications, mostly through the identification and promulgation
	of best practices. The National Institutes of Health, or NIH, joined the effort in 2000 with the creation of a multi-center consortium
	of medical centers, the Dialysis Access Clinical Trials Consortium to coordinate the testing of new treatments designed to improve
	AVF and AVG outcomes. The intensity of these efforts increased markedly in 2004, when the Centers for Medicare and Medicaid Services,
	or CMS, reacting to health and economic data, announced the "Fistula First" initiative to increase the use of AVFs while
	reducing complications. According to Fistula First, AVFs should be considered for every patient needing hemodialysis because AVFs
	last longer than AVGs, require fewer surgical and endovascular interventions, are associated with lower rates of infection, hospitalization
	and death, and are less costly. As a result of these efforts, AVF use has approximately doubled since 2004 to 67% of United States
	hemodialysis patients.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	A major problem with AVFs and AVGs is patency loss,
	in which the access experiences either a significant or complete reduction in blood flow, precluding hemodialysis and placing the
	access at risk of abandonment. However, the increased use of AVFs has led to a concurrent increase in AVF patency loss as AVFs
	are placed in patients with higher risks of AVF failure, such as the elderly, diabetics or patients with smaller blood vessels.
	Additionally, physicians have become more aggressive in monitoring and intervening earlier upon AVFs in an attempt to treat patency
	loss before it results in abandonment of that access site. These factors have resulted in an approximate doubling in the rate of
	AVF interventions in less than a decade.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We are not aware of any approved preventative measures
	to reduce the rate of vascular access patency loss, and the clinical implications of patency loss are severe. An episode of patency
	loss must be addressed urgently to restore blood flow, enable the patient to resume hemodialysis and avoid access abandonment.
	Treatment of patency loss typically involves an outpatient procedure, either an endovascular intervention, such as balloon angioplasty,
	stenting or thrombectomy, or a surgical revision.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Procedures to address patency loss are invasive,
	painful, and associated with a number of complications, and there are a number of problems associated with them, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	The procedures are not always successful in restoring patency.&nbsp;&nbsp;
</I>
	Procedures to address AVF patency loss are unsuccessful up to 27% of the time. When these procedures are unsuccessful or the physician determines that a procedure to restore patency is futile, the access site must be abandoned, resulting in the urgent need for catheter placement to enable hemodialysis. Recent data indicate that hemodialysis patients who switch from a permanent vascular access to a catheter have a mortality rate that is double those who remain on a permanent access. Access abandonment also results in surgical creation of a new AVF or placement of a new AVG, reducing the number of future access sites available to the patient.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	The procedures often fail to provide a durable benefit, resulting in a cycle of interventions for the patient.
</I>
	&nbsp;&nbsp;Recent data indicate that 50% of AVFs that undergo angioplasty to treat patency loss experience another episode of patency loss within 12&nbsp;months, resulting in the need for additional procedures to restore patency. AVF patients in the United States on average require greater than 1.5 procedures per year, each of which typically costs Medicare between $5,000 and $13,000. A United States hospital recently published data indicating that maintaining a radiocephalic AVF can cost on average more than $17,000 in the first year after surgical creation and in excess of $40,000 for the first and second year after surgical creation. A 2014 publication estimated the total cost of managing vascular access dysfunction in the United States to be approximately $2.9&nbsp;billion annually.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	AVFs and AVGs are also prone to secondary patency
	loss, in which the access must be abandoned. Patients on hemodialysis must dialyze with a catheter until a new permanent access
	can be surgically placed and becomes usable for hemodialysis, a process that typically requires a minimum of three months for AVFs.
	During this time, patients are at a heightened risk of serious infection, hospitalization and death. According to the U.S. Renal
	Data System, in 2011 hemodialysis patients averaged approximately 11 hospital days per year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Vonapanitase is a recombinant human elastase under development as a treatment to prevent AVF and AVG patency loss.
	We enrolled the first patient in the first of two Phase&nbsp;3 trials, PATENCY-1, for vonapanitase in radiocephalic AVF, our lead
	indication, in the third quarter of 2014, completed patient enrollment in October 2015, and expect to release top-line data in
	December 2016. In addition, we enrolled the first patient in the second Phase&nbsp;3 trial, PATENCY-2, in August 2015 and expect
	to complete enrollment in the first quarter of 2017.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Mechanism of Action
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	AVF patency loss occurs most commonly due to progressive
	scarring in the wall of the outflow vein near the lumen, resulting in stenosis of the lumen of the vein and obstruction of blood
	flow in the AVF. This form of vascular scarring is commonly known as neointimal hyperplasia. When surgeons create an AVF they handle
	and manipulate blood vessels resulting in mechanical vessel injury. Furthermore, after AVF creation the rapid flow of blood from
	the artery into the outflow vein results in unnatural physiologic changes and mechanical stresses in the vein wall. The response
	of the vein to this injury and stress results in activation and recruitment of scar forming cells, which multiply and migrate from
	the outside wall to the inside wall of the blood vessel and produce a thick layer of tissue, creating a narrowing in the vein lumen
	and a reduction in AVF blood flow. This blood vessel response to injury occurs during the first two to three weeks following vascular
	surgery and is shown in the following figure:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Vessel Injury During AVF and AVG Surgical Placement
	Results in Stenosis Formation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
</B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE1.JPG" ALT="">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We demonstrated through pre-clinical trials that
	vonapanitase fragments elastin, a protein present in blood vessel walls. The fragmentation of elastin in the outside wall of the
	blood vessel is thought to inhibit formation of neointimal hyperplasia thereby reducing the risk of patency loss. Elastase causes
	localized fragmentation of elastin protein fibers present in blood vessel walls. The elastin fragments generated by elastase are
	chemoattractants for scar forming cells, meaning that the fragments attract these scar forming cells, inhibiting their migration
	to the lumen. The cells recognize the elastin fragments via receptors present on the cell surface that bind to specific elastin
	fragment sub-types. The importance of elastin fragments in vascular biology, including the response to vascular injury has been
	established in the scientific literature over three decades. Published academic studies conducted in animals provide evidence that
	fragmentation of elastin in the outer wall of the blood vessels from administration of elastase after vascular injury resulted
	in a 38-42% reduction in neointimal hyperplasia at 28&nbsp;days following the surgical procedure. Based on our preclinical
<I>
	in
	vivo
</I>
	and
<I>
	ex vivo
</I>
	studies in human vessels, applying vonapanitase to the external surface of the blood vessels generates
	localized elastin fragments in the outside wall of injured blood vessels. We have established this effect in the doses we plan
	to advance in our clinical trials. We believe that a one-time, local application of a 30 microgram dose of vonapanitase to the
	external surface of the vessels during AVF surgical creation can reduce the vascular scarring on the inside of the vessel wall
	resulting from surgery and thereby reduce the severity of neointimal hyperplasia and the risk of AVF failure. During the AVF creation
	surgery, the surgeon administers drops of vonapanitase onto the surface of the artery and vein at the AVF for 10 minutes followed
	by a saline irrigation. We believe the elastin fragments that are generated by vonapanitase attract scar forming cells to the outside
	wall of the injured vessel, reducing their movement to the inside wall of the vessel, thereby inhibiting lumen stenosis. This mechanism
	is portrayed in the following figure:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	We Believe Vonapanitase Treatment Inhibits Stenosis
	Formation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE2.JPG" ALT="">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	This injury response and the role of elastase-generated
	fragments are operative in other cardiovascular surgeries, such as bypass, and interventional procedures, such as angioplasty.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Clinical Development of Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Our Phase&nbsp;2 AVF Clinical Trial
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In 2012, we completed a multicenter, randomized,
	double-blind, placebo-controlled Phase&nbsp;2 trial of vonapanitase in AVF that treated 151 patients with CKD undergoing creation
	of a radiocephalic AVF (n=67) or brachiocephalic AVF (n=84). Patients were treated with vonapanitase at doses of 10 or 30 micrograms
	or placebo at the time of AVF creation and were followed for up to 12&nbsp;months.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Primary endpoint
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The primary efficacy endpoint was primary unassisted
	patency over 12&nbsp;months. Primary unassisted patency was defined as the time from access creation until the first occurrence
	of either AVF thrombosis or a procedure, such as balloon angioplasty, to restore or maintain patency.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Both doses of vonapanitase showed a trend toward
	efficacy, although neither dose met the primary endpoint with statistical significance. Median patency, the time at which 50% of
	patients in a group lost primary unassisted patency, was 224&nbsp;days in the placebo group and greater than 365&nbsp;days in each
	of the vonapanitase treatment groups indicating patency in the vonapanitase treatment groups was prolonged by vonapanitase. Treatment
	with vonapanitase at 10 and 30 microgram doses was associated with a reduction of 31% and 33%, respectively, in the risk of primary
	unassisted patency loss. After adjusting for differences in baseline characteristics associated with the risk of primary unassisted
	patency loss, treatment with vonapanitase at 10 and 30 microgram doses was associated with a reduction of 24% and 41%, respectively,
	in the risk of primary unassisted patency loss. The following Kaplan-Meier curves and table display primary unassisted patency
	for all AVFs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Primary Unassisted Patency&#8212;All AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE3.JPG" ALT="">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The table below shows the primary unassisted patency
	data in the placebo and vonapanitase treatment groups.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Reduction in Risk of Primary Unassisted Patency
	Loss vs. Placebo&#8212;All AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	10 microgram
</B>
<B>
	dose
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	30 microgram
</B>
<B>
	dose
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=51
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=49
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Unadjusted Risk vs. Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-31% (p=0.19)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-33% (p=0.17)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Adjusted Risk(1) vs. Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-24% (p=0.35)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-41% (p=0.10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Note:&nbsp;&nbsp;Prespecified analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(1) Adjusted for differences in baseline characteristics
	associated with the risk of primary unassisted patency loss between treatment groups using a prespecified Cox regression analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Ninety-two patients with a patent AVF who completed
	12&nbsp;months of follow-up in the initial trial were followed in a registry to obtain additional data related to the efficacy
	endpoints. In this follow-up, the vonapanitase 30 mcg benefit on primary unassisted patency persisted out over a median of three
	years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	Radiocephalic AVFs.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;The
	benefit of vonapanitase on primary unassisted patency was more pronounced in the subset of patients undergoing creation of a radiocephalic
	AVF than in the subset of patients undergoing creation of a brachiocephalic AVF or all patients undergoing creation of an AVF.
	The subset analysis of this endpoint was not prespecified. The following Kaplan-Meier curves and table summarize the reduction
	in risk of primary unassisted patency loss in the subset of patients with radiocephalic AVFs. Treatment with vonapanitase at doses
	of 10 and 30 micrograms was associated with a reduction of 41% and 63%, respectively, in the risk of primary unassisted patency
	loss. Median patency was 125&nbsp;days in the placebo group and 377&nbsp;days in the 30 microgram group (in some cases the 12&nbsp;month
	follow up occurred after day 365 due to patient schedules), indicating a significant improvement in primary unassisted patency.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Primary Unassisted Patency&#8212;Radiocephalic
	AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE4.JPG" ALT="">
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Reduction in Risk of Primary Unassisted Patency
	Loss vs. Placebo&#8212;Radiocephalic AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	10 micrograms
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	30 micrograms
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=23
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=20
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Unadjusted Risk vs. Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-41% (p=0.18)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-63% (p=0.02)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Adjusted Risk(1) vs. Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-40% (p=0.20)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-61% (p=0.04)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Note:&nbsp;&nbsp;Non-prespecified analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(1) Adjusted for differences in baseline characteristics
	associated with the risk of primary unassisted patency loss between treatment groups using a prespecified Cox regression analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	Brachiocephalic AVFs.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;The
	benefit of vonapanitase on primary unassisted patency was less pronounced in the subset of patients undergoing creation of a brachiocephalic
	AVF. The subset analysis of this endpoint was not prespecified. The less pronounced benefit in brachiocephalic AVFs was in part
	due to an uneven distribution between brachiocephalic AVF groups in the number of patency loss events occurring in the central
	veins and cephalic arch, also known as central stenosis, which are remote from the site of the AVF. Patency loss in brachiocephalic
	AVFs occurs due to central stenosis 50% of the time. Central stenoses commonly exist prior to surgery due to the venous anatomy
	or scarring from a prior hemodialysis catheter, but are typically unmasked following creation of the higher blood flow brachiocephalic
	AVFs. Since vonapanitase is active locally at the site where it is applied on the AVF, and because we have demonstrated that vonapanitase
	is not active remotely, we believe that central stenoses are unrelated to vonapanitase. Therefore, to correct for this uneven distribution,
	we conducted a non-prespecified analysis of the primary endpoint in brachiocephalic AVFs which excluded patency loss events due
	to central stenoses. The following table summarizes the risk of primary unassisted patency loss in brachiocephalic AVFs including
	and then excluding patency loss events related to central stenoses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Reduction in Risk of Primary Unassisted Patency
	Loss vs. Placebo&#8212;Brachiocephalic AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	10 micrograms
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	30 micrograms
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=28
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=29
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Unadjusted Risk vs. Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-14% (p=0.72)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	+10% (p=0.82)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Unadjusted Risk vs. Placebo Excluding Central Stenoses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-12% (p=0.76)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-26% (p=0.46)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Note:&nbsp;&nbsp;Non-prespecified analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We also conducted a non-prespecified analysis across
	all patients of the primary endpoint correcting for this uneven distribution in central stenoses. The following Kaplan-Meier curves
	for primary unassisted patency for all AVFs (excluding central stenoses) and table demonstrate a significant reduction in the risk
	of primary unassisted patency loss for the 30 microgram dose (p=0.04, for the 30 microgram dose) versus placebo. Treatment with
	vonapanitase at doses of 10 and 30 micrograms was associated with a reduction of 31% and 48%, respectively, in the risk of primary
	unassisted patency loss. After adjusting for differences in baseline characteristics associated with the risk of primary unassisted
	patency loss, treatment with vonapanitase at doses of 10 and 30 micrograms was associated with a reduction of 25% and 52%, respectively,
	in the risk of primary unassisted patency loss.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Primary Unassisted Patency&#8212;All AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	(Excluding Central Stenoses)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE5.JPG" ALT="">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Reduction in Risk of Primary Unassisted Patency
	Loss vs. Placebo&#8212;All AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	(Excluding Central Stenoses)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	10 micrograms
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	30 micrograms
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=51
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=49
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Unadjusted Risk vs. Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-31% (p=0.20)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-48% (p=0.04)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Adjusted Risk vs. Placebo(1)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-25% (p=0.33)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-52% (p=0.02)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Note:&nbsp;&nbsp;Non-prespecified analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(1) Adjusted for differences in baseline characteristics
	associated with the risk of primary unassisted patency loss between treatment groups using a prespecified Cox regression analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In a larger trial of brachiocephalic AVFs, we expect
	that the occurrence of patency loss due to central stenosis would be evenly distributed between treatment groups. In the ongoing
	Phase&nbsp;3 clinical trials, we expect that patency loss due to central stenosis will be rare since we intend to enroll radiocephalic
	AVF patients exclusively, and radiocephalic AVFs rarely suffer from patency loss due to central stenosis because of lower blood
	flow. In our Phase&nbsp;2 trial, no radiocephalic AVF in any group lost primary patency due to central stenosis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Secondary and other endpoints
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Vonapanitase showed results consistent with a beneficial
	effect on multiple secondary efficacy endpoints. The prespecified efficacy endpoints were unassisted maturation, secondary patency,
	use for hemodialysis and hemodynamically significant lumen stenosis. In addition, we performed a prespecified efficacy analysis
	of average rate of procedures to restore or maintain AVF patency, a component of our primary endpoint. As with the primary efficacy
	analyses, we performed a number of prespecified and exploratory analyses of the data from this Phase&nbsp;2 trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Unassisted maturation
</I>
	.&nbsp;&nbsp;Maturation is necessary for use of an AVF for hemodialysis. Unassisted maturation was defined as achieving maturation at three months without an intervention. Maturation was assessed using ultrasound measuring blood flow and lumen vein diameter. All ultrasounds were reviewed by a central reader masked to treatment assignment and AVF outcome. Two well-accepted criteria for measuring maturation were used, as shown in the footnotes in the table below. The 30 microgram dose, which we have included in our Phase&nbsp;3 trials, showed improvement in maturation at Month 3, with statistically significant benefit seen in all AVFs combined and patients receiving radiocephalic AVFs (figure below). In the subset of patients with brachiocephalic AVFs, there was a trend toward improvement in unassisted maturation at both the 10 and 30 microgram doses.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Unassisted Maturation at Three Months&#8212;%
	of Patients (p-Value vs. Placebo)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Vonapanitase
<BR>
	10 micrograms
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Vonapanitase
<BR>
	30 micrograms
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	All AVFs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=39
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=39
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=37
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 55%">
	Percentage Mature NKF-KDOQI(1)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	46%
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	64% (p=0.11)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	70% (p=0.03)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Percentage Mature Robbin(2)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	67%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	87% (p=0.03)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	92% (p&lt;0.01)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Radiocephalic AVFs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=17
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=19
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Percentage Mature NKF-KDOQI(1)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	24%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	37% (p=0.48)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	57% (p=0.08)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Percentage Mature Robbin(2)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	47%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	74% (p=0.17)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	93% (p&lt;0.01)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Brachiocephalic AVFs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=22
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Percentage Mature NKF-KDOQI(1)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	64%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	90% (p=0.07)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	78% (p=0.34)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Percentage Mature Robbin(2)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	82%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	100% (p=0.11)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	91% (p=0.41)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Note:&nbsp;&nbsp;Prespecified analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(1) National Kidney Foundation Kidney Disease Outcomes
	Quality Initiative (NKF-KDOQI) maturation is defined as average vein lumen diameter
<U>
	&gt;
</U>
	6 millimeters and an outflow vein
	blood flow rate
<U>
	&gt;
</U>
	600 milliliters/minute.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(2) Robbin maturation is defined as average vein
	lumen diameter
<U>
	&gt;
</U>
	4 millimeters and an outflow vein blood flow rate
<U>
	&gt;
</U>
	500 milliliters/minute.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Unassisted Maturation&#8212;Radiocephalic AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE6.JPG" ALT="">
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(1) p-value=0.08 vs. placebo
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(2) p-value&lt;0.01 vs. placebo
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	The average rate of procedures to restore or maintain patency per patient year at risk.
</I>
	&nbsp;&nbsp;Patients undergoing a procedure often require repeated procedures over time because procedures such as balloon angioplasty can restore blood flow acutely but also damage the blood vessel. These data can be expressed as a procedure rate calculated as the number of days in which a procedure to restore or maintain patency was performed per patient divided by the patient's time on the trial. Procedures included thrombectomy, angioplasty, stent deployment and surgical revision. In a prespecified analysis, there was a 56% reduction in the rate of procedures in the 30 microgram group versus the placebo group. In the radiocephalic non-prespecified subset there was a 69% reduction in the average rate of procedures in the 30 microgram group versus the placebo group. In the brachiocephalic non-prespecified subset there was a 43% reduction in the average rate of procedure in the 30 microgram group versus the placebo group. Excluding procedures to treat central stenosis, through a non-prespecified analysis, in the brachiocephalic subset there was an 86% reduction in the average rate of procedures in the 30 microgram group versus the placebo group.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Average Procedure Rate to Restore/Maintain Patency
	(p-Value vs. Placebo)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Vonapanitase
<BR>
	10 micrograms
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Vonapanitase
<BR>
	30 micrograms
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	All AVFs (Prespecified)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=51
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 55%">
	Procedures per Year
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.9
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.8 (p=0.53)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.4 (p=0.07)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	All AVFs Excluding Central Stenoses (Non-prespecified)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=51
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Procedures per Year
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.8
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.7 (p=0.44)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.2 (p&lt;0.01)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Radiocephalic AVFs (Non-prespecified)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=24
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Procedures per Year
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	1.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.8 (p=0.63)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.3 (p=0.06)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Brachiocephalic AVFs (Non-prespecified)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Procedures per Year
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.7
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.7 (p=0.72)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.4 (p=0.50)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Brachiocephalic AVFs Excluding Central Stenoses (Non-prespecified)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Procedures per Year
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.7
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.7 (p=0.54)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.1 (p=0.07)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Ninety-two patients with a patent AVF completed
	12 months of follow-up in the initial trial were followed in a registry to obtain additional data related to the efficacy endpoints.
	In this follow up, the vonapanitase 30 mcg benefit on procedure rates persisted out over a median of 3 years in all AVF types as
	set out in the following table.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Average Procedure Rate to Restore/Maintain Patency
	Including Registry Data (p-Value vs. Placebo)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Vonapanitase
<BR>
	10 micrograms
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Vonapanitase
<BR>
	30 micrograms
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	All AVFs (Prespecified analysis)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=51
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; WIDTH: 55%">
	Procedures per Year
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.7
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.7 (p=0.93)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.2 (p=0.03)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Radiocephalic AVFs (Non-prespecified analysis)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=24
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Procedures per Year
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.9
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.6 (p=0.60)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.2 (p=0.05)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Brachiocephalic AVFs (Non-prespecified analysis)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Procedures per Year
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.8 (p=0.69)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.3 (p=0.29)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
	Secondary&nbsp;patency.
</I>
	&nbsp;&nbsp;Secondary patency loss was defined as abandonment of the AVF, which typically occurs following loss of primary unassisted patency due to thrombosis or failure of a procedure to restore patency and leads to additional surgery to create a new vascular access. We observed no significant differences in the risk of secondary patency loss in the overall AVF population or the non-prespecified subset of patients receiving brachiocephalic AVFs. However, as seen in the Kaplan-Meier curves and table below, a trend toward prolonged secondary patency was seen in patients receiving radiocephalic AVFs. In this non-prespecified subset analysis, treatment with vonapanitase at doses of 10 and 30 micrograms was associated with reductions of 55% and 73%, respectively, in the risk of secondary patency loss.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Secondary Patency&#8212;Radiocephalic AVFs
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE7.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0; COLOR: RED">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	10&nbsp;microgram dose
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	30&nbsp;microgram dose
</B>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Number of Patients
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=23
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	N=20
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Unadjusted Risk&nbsp;vs. Placebo
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-55%&nbsp;(p=0.19)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-73%&nbsp;(p=0.08)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Note:&nbsp;&nbsp;Non-prespecified analysis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Ninety-two patients with a patent AVF completed
	12&nbsp;months of follow-up in the initial trial were followed in a registry to obtain additional data related to the efficacy
	endpoints. In this follow-up, the vonapanitase 30 mcg benefit on secondary patency in radiocephalic AVFs persisted over a median
	of three years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&nbsp;&#8226;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
<U>
	Use for hemodialysis
</U>
	.
</I>
	&nbsp;&nbsp;Use
	was defined as use of the AVF for hemodialysis at any time without a previous intervention. Although the results were not
	statistically significant, there was a trend to more patients using the AVF for hemodialysis in the 30 microgram group (69%)
	compared with the placebo group (53%).
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<I>
<U>
	Hemodynamically significant lumen stenosis
</U>
	.
</I>
	&nbsp;&nbsp;Hemodynamically significant lumen stenosis, or narrowing of blood vessels, impairs AVF maturation and contributes to AVF patency loss. Hemodynamically significant lumen stenosis was defined as a 50% or greater stenosis and a significant elevation in peak blood flow velocity across the stenosis detected by ultrasound. Ultrasounds were performed using a standard protocol and reviewed by a central reader masked to treatment assignment and AVF outcome. Although the results were not statistically significant, there was a trend to fewer patients with a hemodynamically significant lumen stenosis in the patients receiving 10 micrograms (30%) and 30 micrograms (39%) of vonapanitase compared with the placebo group (51%) at six&nbsp;weeks. Detecting hemodynamically significant lumen stenosis is technically challenging and often confounded by the performance of procedures, such as angioplasty to treat stenosis prior to the ultrasound examination.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Safety and tolerability
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Vonapanitase is administered topically at the vascular
	access and only acts locally. We have not observed systemic activity or systemic toxicity in our preclinical animal studies, even
	following single-dose intravenous administration at very high multiples of the Phase&nbsp;2 clinical trial doses. Safety evaluations
	in Phase&nbsp;2 included ascertainment of adverse events, physical examinations, ultrasounds of the AVFs and nearby vessels, vital
	signs and laboratory studies. No significant safety signals were identified. In the trial, most patients treated with vonapanitase
	reported adverse events, the most common of which are summarized in the following table, as compared to placebo. These events were
	generally consistent with the medical events experienced by CKD patients undergoing AVF creation surgery. The most frequent adverse
	events were AVF incision pain, venous stenosis, procedural pain, AVF thrombosis, steal syndrome and hypoesthesia. Serious adverse
	events, or SAEs, reported by the investigator as possibly drug-related occurred in two 10 microgram vonapanitase patients (both
	AVF thrombosis), and two 30 microgram vonapanitase patients (one chest pain and one swelling at the surgical incision). There were
	no SAEs reported by the investigator as possibly drug-related in the placebo group. There was one SAE reported by the investigator
	as drug-related in the 10 microgram vonapanitase group (AVF maturation failure), and there were none in the other treatment groups.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Number and Proportion (%) of Patients with
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	Very Common Adverse Events
</B>
	(1)
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 0IN; BORDER-BOTTOM: BLACK 1PT SOLID">
	N (%)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Placebo
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	N=51
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	10&nbsp;micrograms
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	N=51
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Vonapanitase
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	30&nbsp;micrograms
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	N=49
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Any adverse event
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	42 (82)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	39 (77)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	43 (88)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	AVF thrombosis
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	13 (26)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	8 (16)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	7 (14)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Venous stenosis
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	10 (20)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	7 (14)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	8 (16)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Steal syndrome
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	7 (14)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	2 (4)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	6 (12)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Hypoesthesia
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	7 (14)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	6 (12)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	6 (12)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Procedural pain
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	6 (12)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	11 (22)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	11 (22)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	AVF incisional pain
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5 (10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	9 (18)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	9 (18)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	AVF site complication
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5 (10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	4 (8)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	4 (8)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Nausea
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5 (10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	1 (2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	2 (4)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Peripheral edema
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5 (10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0 (0)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	2 (4)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Arterial stenosis
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	4 (8)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5 (10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0 (0)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Paresthesia
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	1 (2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	1 (2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5 (10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Pain in extremity(2)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0 (0)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	1 (2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5 (10)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Note:&nbsp;&nbsp;None of the differences between
	groups were statistically significant.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(1) Adverse events occurring in at least 10% of
	placebo or either vonapanitase treatment groups.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	(2) All but one unrelated to limb used in AVF surgery.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Phase 1/2 AVF Clinical Trial
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We submitted an investigational new drug application,
	or IND, for vonapanitase as a treatment for patients undergoing AVF creation on April&nbsp;30, 2008. Our initial clinical trial
	of vonapanitase was a Phase&nbsp;1/2, randomized, double-blind, placebo-controlled, dose-escalation safety and exploratory efficacy
	trial in 66 patients undergoing creation of a radiocephalic or brachiocephalic AVF. Patients were treated with vonapanitase at
	nine dose levels ranging from 3.3&nbsp;micrograms to 9&nbsp;milligrams or placebo at the time of AVF creation and were followed
	for up to one year. This trial did not meet its primary endpoint, an endpoint we did not pursue in our Phase&nbsp;2 trial. However,
	consistent with our mechanism of action that involves partial fragmentation of elastin, doses of vonapanitase at 3.3, 10 and 33&nbsp;micrograms
	were associated with a trend toward prolonged primary unassisted patency (secondary endpoint p=0.66 in the All Treated population
	and p=0.15 in the All Treated Minus&nbsp;3 population), fewer procedures to restore or maintain patency (collected as supportive
	data) and less hemodynamically significant lumen stenosis (collected as supportive data) compared with placebo treated patients
	or patients treated with higher vonapanitase doses. Higher doses showed results similar to placebo and no dose met the primary
	efficacy endpoint with statistical significance. No dose-related increases in adverse events were observed in the trial. Based
	on the results of this trial, we selected 10&nbsp;microgram and 30&nbsp;microgram doses for further study in the Phase&nbsp;2 trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Our Phase&nbsp;3 Program
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We are conducting two randomized, double-blind Phase&nbsp;3 trials, with staggered start dates, comparing
	a 30 microgram dose of vonapanitase to placebo. We began enrolling patients in our first Phase&nbsp;3 pivotal trial, PATENCY-1,
	for vonapanitase in patients with CKD undergoing creation of a radiocephalic AVF in the third quarter of 2014 and began enrolling
	patients in the second Phase 3 trial, PATENCY-2, in August 2015. Each of the trials will enroll patients undergoing a surgical
	procedure to create a radiocephalic AVF. Each Phase&nbsp;3 trial will enroll approximately 300 patients, for a total of approximately
	600 patients, who will be randomized such that twice as many patients will receive vonapanitase as compared to placebo.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	In April 2013, we
	held an end of Phase&nbsp;2 meeting with the FDA, during which we confirmed the following key elements of our Phase 3 development
	plan: (i)&nbsp;the primary efficacy endpoint in our Phase&nbsp;3 trials, primary unassisted patency, which is the same as our primary
	endpoint in our Phase&nbsp;2 trial, is suitable for approval of vonapanitase in the United States; (ii)&nbsp;the secondary efficacy
	endpoint in our Phase&nbsp;3 trials, secondary patency, which was a secondary endpoint in our Phase&nbsp;2 trial, could be acceptable
	for inclusion in the approved product labeling in the United States if we hit statistical significance on both the primary endpoint
	and the secondary endpoint, and possibly even if we do not hit statistical significance on the secondary endpoint; (iii)&nbsp;the
	total number of patients expected to be treated through our Phase&nbsp;3 trial will provide a sufficient safety database to support
	a BLA filing; (iv)&nbsp;we do not need to conduct additional preclinical studies prior to conducting our Phase&nbsp;3 clinical
	trials or to support a BLA filing; and (v)&nbsp;we have Phase&nbsp;3-ready active pharmaceutical ingredient, or API, and finished
	product.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We began enrolling patients in our first Phase&nbsp;3
	trial, PATENCY-1, in the third quarter of 2014. Each patient will be followed for 12&nbsp;months. We expect that results will be
	available in December 2016. We began enrolling patients in our second Phase 3 trial, PATENCY-2, in August 2015 and expect to complete
	full enrollment in the first quarter of 2017.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our Phase&nbsp;3 trials will be conducted at sites
	in the United States with the second trial also including Canadian sites. In addition to collecting data on the primary and secondary
	endpoints, the Phase&nbsp;3 clinical trials will collect information related to the endpoints of maturation, use for hemodialysis
	and the rate of procedures to restore or maintain patency. Patients who consent will be enrolled in a patient registry to obtain
	long-term follow-up efficacy information.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We have designed each Phase&nbsp;3 trial to have
	over 95% power,
<I>
	i.e.
</I>
	, there is more than a 95% probability that the study will detect observed clinical effects of vonapanitase
	if the observed effects are true. In the first Phase&nbsp;3 trial, 311 patients were randomly allocated by the sites in a 2:1 ratio
	to either vonapanitase, at 30&nbsp;micrograms, or to placebo. With a 300 patient sample size (200 vonapanitase and 100 placebo),
	the study is powered to approximately 96% power to detect an increase in median primary unassisted patency from 5&nbsp;months to
	10&nbsp;months and 97% power to detect an increase in the proportion of patients with secondary patency at 12&nbsp;months from
	65% to 85%. A 10% drop out rate has been assumed in all of the calculations. The study will follow each patient for a maximum of
	12&nbsp;months. If the results of the first Phase&nbsp;3 trial are sufficiently compelling, we intend to meet with the FDA to discuss
	the possibility of submitting a BLA, supported by the single Phase&nbsp;3 trial in which the single Phase&nbsp;3 trial would form
	the primary basis of the demonstration of safety and efficacy, and the Phase&nbsp;2 trial, including non-prespecified analyses,
	would provide supportive information. We may decide to submit a BLA to the FDA prior to completing the second Phase&nbsp;3 trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Preclinical Development
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We have conducted an extensive preclinical program to evaluate the safety and tolerability of single doses
	of vonapanitase administered locally in animal models of AVF and AVG placement, by percutaneous and endovascular injection in animal
	models of peripheral artery disease, or PAD, as well as intravenously. We have conducted preclinical studies in multiple species
	at doses up to 50 milligrams of vonapanitase, which is over 1,500 times higher than the dose we intend to study in our planned
	Phase&nbsp;3 clinical trials. We observed no systemic activity or systemic toxicity for vonapanitase in any of our preclinical
	studies. We observed no toxicity in any of the doses that we subsequently studied or plan to study in Phase 3 clinical trials in
	humans. Only local toxicity was observed at surgical sites at high doses (10 and 50 milligrams, which is over 300-1500 times higher
	than the dose we intend to study in our planned Phase&nbsp;3 clinical trials). These changes were reversible, with normal wound
	healing observed at 14&nbsp;days except at the highest (50 milligrams) dose, in which there were some mild persistent changes in
	the jugular vein and subcutaneous tissue. Normal wound healing was observed in all the AVF studies in rabbits at doses up to 10
	milligrams and in all the AVG studies in dogs and pigs at doses up to 20 milligrams (the highest doses tested).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In our preclinical studies, we observed dose-dependent
	activity of vonapanitase on elastin removal.&nbsp;&nbsp;Studies have established a correlation with elastin removal and a reduction
	in neointimal hyperplasia.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Other Programs, Indications and Trials
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Other AVF Trials
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	European clinical program
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We are currently evaluating our clinical program
	to support filing in Europe. We may, based on additional data including the data from our Phase&nbsp;3 clinical trials in the
	United States and if sufficient funds become available, choose to conduct a clinical trial of vonapanitase in Europe. Prior to
	initiating a European clinical trial, we plan to formally seek guidance from the EMA regarding their requirements for regulatory
	approval.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Brachiocephalic AVF
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We believe that our Phase&nbsp;2 clinical data
	supports further development of vonapanitase in brachiocephalic AVF creation. We may, based on additional data, including the data
	from our Phase&nbsp;3 clinical trials, and if sufficient funds become available, study the effects of a 30 microgram dose of vonapanitase
	versus placebo on brachiocephalic AVFs. Prior to initiation of this trial, we expect to seek guidance from the FDA regarding trial
	design.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Arteriovenous Grafts
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	An arteriovenous graft, or AVG, is a surgical procedure
	in which a surgeon places a synthetic tube to connect a vein and an artery. We submitted an IND for vonapanitase as a treatment
	for patients undergoing AVG placement on April&nbsp;30, 2008. We conducted a Phase 1/2 randomized, double-blind, placebo-controlled,
	dose-escalation trial in 89 patients undergoing placement of an AVG. Patients were treated with placebo or eight different doses
	of vonapanitase ranging from 10 micrograms to 9 milligrams at the time of AVG placement and were followed for up to one year. Those
	patients who had not lost secondary patency were subsequently enrolled in a registry to obtain additional follow-up information
	on the AVG.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The primary outcome measure was safety. Adverse
	events were consistent with the medical conditions experienced by patients with CKD undergoing AVG surgery and showed no significant
	differences between groups. Some of the data showed indications of efficacy, especially in secondary patency, which is an approvable
	endpoint for hemodialysis access, for the groups treated with vonapanitase at doses of 10 micrograms and 30 micrograms.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	After reviewing the results from our first Phase&nbsp;3
	clinical trial, and if sufficient funds become available, we may commence a clinical trial of vonapanitase in patients undergoing
	placement of an AVG.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Peripheral Artery Disease
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In addition to vascular access indications, we
	are investigating vonapanitase as a treatment for patients with symptomatic peripheral artery disease, or PAD. Patients with lower
	extremity PAD suffer from stenosis formation in the arteries providing blood to the legs. These patients typically present with
	exercise-induced leg pain, a condition known as intermittent claudication. Patients with claudication are unable to adequately
	maintain their activities of daily living because they quickly experience pain that can be resolved only through rest. Severe cases
	result in critical limb ischemia, or lack of oxygen, and the possibility of amputation. PAD is a global problem affecting a large
	number of people throughout the industrialized world. Approximately 8&nbsp;million Americans suffer from PAD.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Patients with early stage PAD typically undergo
	lifestyle management such as smoking cessation, weight reduction and/or diabetes management, and treatment with oral medications.
	Approximately 800,000 patients in the United States who do not respond to lifestyle management and have worsening symptoms, undergo
	an endovascular procedure, typically balloon angioplasty with or without stenting or vein bypass surgery. While these procedures
	work acutely to restore blood flow, they suffer from poor long-term durability, resulting in the need for repeat procedures.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We believe that vonapanitase may improve the outcomes
	associated with angioplasty procedures, resulting in prolonged intervention-free patency while reducing the need for implantation
	of a permanent stent. We submitted an IND for vonapanitase as a treatment for PAD patients on April&nbsp;9, 2012. Our initial PAD
	clinical trial was a Phase&nbsp;1, open-label, dose-escalation safety/technical feasibility trial in 14 patients undergoing balloon
	angioplasty of the superficial femoral or popliteal artery in the leg. Following successful angioplasty, patients were treated
	with vonapanitase via an FDA-cleared, drug-delivery catheter that allows vonapanitase to be administered locally in the outer layer
	of the vessel wall. Patients were followed for up to 12&nbsp;months.
<FONT STYLE="COLOR: #333333">
	The study met its stated objectives,
	as data indicated that catheter-based treatment with vonapanitase was generally well-tolerated and technically feasible.
</FONT>
	We
	expect to initiate another Phase 1 study of vonapanitase delivered via a drug-delivery catheter in 2016 in up to 40 symptomatic
	PAD patients undergoing angioplasty of an infrapopliteal artery below the knee. We expect to follow these patients for 12 months.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We believe that vonapanitase may be an alternative
	to traditional endovascular procedures such as angioplasty, reducing clinical symptoms without the need for an interventional procedure.
	Vonapanitase may be delivered via a percutaneous approach, in which a physician inserts an image-guided needle through the skin
	to inject vonapanitase to the artery around the area of blockage. We believe that vonapanitase may dilate the artery, resulting
	in increased lumen artery diameter, higher blood flow, and an improvement in clinical symptoms. We anticipate initiating in 2016
	a Phase 1 study of vonapanitase delivered via a percutaneous approach enrolling up to 30 patients with symptomatic PAD as an alternative
	to angioplasty.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We believe that vonapanitase may improve the outcomes
	associated with vein bypass surgery, resulting in prolonged intervention-free patency. During vein bypass surgery, a surgeon places
	a vein, typically obtained from the patient&#8217;s leg, as an alternative conduit for blood to flow around the area of blockage
	restoring direct flow to the lower leg and foot. We believe that vonapanitase, administered to the outside of the vein concurrently
	with the surgery, may improve the outcomes associated with vein bypass surgery, resulting in prolonged intervention-free patency.
	We would anticipate initiating in 2017 a Phase 1 trial enrolling approximately 10-20 patients undergoing vein bypass surgery.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Manufacturing and Supply
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	We depend on third-party
	contract manufacturers for the production of vonapanitase. Our API is produced at our contract manufacturer, Lonza LTD, or Lonza,
	which is required to comply with the FDA's Current Good Manufacturing Practice, or cGMP, regulations. Vonapanitase finished product
	is produced at our contract fill/finisher providers, Jubilant HollisterStier and Patheon Manufacturing Services, LLC (formerly
	DSM Pharmaceuticals, Inc.), which is required to comply with cGMP regulations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We used API manufactured at Lonza to create finished
	product that was used in our Phase&nbsp;2 AVF clinical trial and is currently being used for our Phase&nbsp;3 AVF clinical trials.
	We also plan to manufacture API at Lonza for our commercial launch and future trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We modified our finished product at Jubilant HollisterStier
	for our Phase&nbsp;3 trials and potential commercial launch in order to facilitate ease of administration and fill and finish at
	the 30 microgram doses. The modified finished product is reconstituted with sterile water to create a dosing solution containing
	30 micrograms of vonapanitase. We demonstrated that the modified finished product had the same elastase activity and the same elastin
	removal from blood vessels following ex vivo treatments as the previous finished product using synthetic and natural elastin substrates.
	The modified finished product formulation was similar to the previous finished product formulation in maintaining the health and
	viability of live cells in culture. These data suggest the modified finished product will have the same efficacy and safety in
	clinical trials as the previous finished product.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Release and stability testing for API and finished
	product are performed at PPD,&nbsp;Inc. The tests indicate stability of at least five&nbsp;years for our API and at least two years
	for our finished product.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In our Phase 1 AVF study, Phase 1 AVG study, and
	Phase 1 PAD study, vonapanitase finished product at the 5 milligram per vial formulation was used. We plan to use this same 5 milligram
	formulation of vonapanitase, manufactured at Patheon, in two of our Phase 1 PAD studies. The finished product at Jubilant HollisterStier
	will be used for a third PAD study.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	At our end of Phase&nbsp;2 meeting, the FDA confirmed
	that our API and modified finished product are acceptable for Phase&nbsp;3 clinical trials. We have already manufactured finished
	product for the AVF Phase&nbsp;3 clinical trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In anticipation of a potential BLA filing, we plan
	to manufacture a minimum of three batches of API and of finished product as part of process validation and to test these batches
	for stability with a goal of establishing a commercial shelf-life of at least two years for finished product and a longer expiry
	for API.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Sales and Marketing
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our commercialization strategy is to develop vonapanitase
	into a leading therapy worldwide for the treatment of AVFs and in other renal and vascular diseases.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We have not yet established a sales and marketing
	organization. Our Chief Executive Officer has significant commercial experience in the industry, including commercial launch experience
	in the renal market. We intend to recruit an in-house specialty hospital sales force in the United States focused on promoting
	vonapanitase. We plan to target our marketing and sales efforts at those vascular surgeons who create AVFs. There are approximately
	2,800 vascular surgeons in the United States. We believe a specialty hospital sales force of approximately 75-100 representatives,
	supported by reimbursement specialists and a medical affairs team, will enable us to call on the approximately 1,300 hospitals
	that account for more than 90% of the AVF creations performed in the United States annually.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We believe that vonapanitase will be reimbursed
	appropriately as costs related to AVF surgical creation, which is typically performed in the hospital outpatient setting, are not
	included in the ESRD bundle.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	If vonapanitase is approved by the EMA, we may
	commercialize it in European countries with our own specialty hospital sales force or with a commercial partner, or a combination
	thereof. We believe that the market for vonapanitase in the five largest countries in the European Union represents the bulk of
	the potential European market and that a launch using a direct sales force may be achievable in these markets. We hope to enter
	into collaborations for the development and commercialization of vonapanitase in Japan and other Asian countries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Intellectual Property
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We strive to protect and enhance the proprietary
	technology, inventions and improvements that are commercially important to our business, including seeking, maintaining and defending
	patent rights. We also rely on know-how that may be important to the development of our business. We additionally expect to rely
	on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions where available.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our commercial success may depend in part on our
	ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how
	related to our business, as well as our ability to defend and enforce our patents and to operate without infringing the valid enforceable
	patents and proprietary rights of third parties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our ability to prevent third parties from making,
	using, selling, offering to sell or importing competing products to ours, including a competitor to vonapanitase, depends on the
	scope of our patents. We have several patents and patent applications relating to the vonapanitase formulation and its therapeutic
	uses, and we possess substantial know-how relating to the development and commercialization of vonapanitase. We cannot be sure
	that any of our pending patent applications or future patent filings will lead to the issuance of new patents, nor can we be sure
	that any of our existing patents or any patents that may be granted to us in the future will be adequate to protect our market.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We plan on pursuing in-licensing opportunities
	to develop, strengthen and maintain our proprietary position in our field. We expect to use trademark protection for our products
	as they are marketed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Patents
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We own 21 issued patents and 26 pending patent
	applications. The patents and applications primarily fall into two families, a first relating to the vonapanitase formulation and
	its manufacture and use, as well as other formulations of elastases (the "formulation family"), and the second relating
	to certain therapeutic uses of vonapanitase, and associated systems and kits that include a catheter and are suitable for a subset
	of those therapeutic uses (the "therapy family"). The formulation family includes two issued United States patent, one
	issued European patent, additional patents issued in Australia, China, Hong Kong, Japan, Israel, Mexico, and New Zealand, and patent
	applications pending in several major jurisdictions worldwide, including Japan, China, South Korea, Brazil, Mexico, Russia, India,
	Europe and the United States. The expected expiration date for any patents that have issued or may issue from the formulation family
	is December 4, 2028, exclusive of possible patent term extension available for one patent covering vonapanitase under the Hatch-Waxman
	Amendments or comparable provisions in other jurisdictions, except in the United States where we were awarded a patent term adjustment
	of 199 days due to United States Patent and Trademark Office, or USPTO delays, taking the expiration date to June 20, 2029. The
	therapy family includes seven issued United States patents and two issued European patents, and applications pending in the United
	States, Europe, Canada and Japan. The expected expiration date for any patents that have issued or may issue from the therapy family
	patents is September 24, 2020, except in the United States where several patents were awarded a patent term adjustment and the
	expected expiration date of two therapy family patents related to systems and kits including elastase and a catheter is June 30,
	2021, exclusive of possible patent term extension.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Patent Term
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The base term of a U.S. patent is 20 years from
	the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S.
	patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the
	USPTO. In some cases, the term of a U.S. patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring
	patent.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The term of a U.S. patent may be eligible for patent
	term extension under the Hatch-Waxman Amendment, to account for at least some of the time a product is under development and regulatory
	review after the patent is granted. With regard to a product for which FDA approval is the first permitted marketing of the active
	ingredient, the Hatch-Waxman Act allows for extension of protection of one U.S. patent that includes at least one claim covering
	the composition of matter of an FDA-approved product, an FDA-approved method of treatment using the product, and/or a method of
	manufacturing the FDA-approved product. The extended protection cannot exceed the shorter of five years beyond the non-extended
	expiration of the patent or 14 years from the date of the FDA approval of the product. Some foreign jurisdictions, including Europe,
	have analogous patent extension provisions, which allow for extension of the protection of a patent that covers a drug approved
	by the applicable foreign regulatory agency. In the future, if and when vonapanitase receives FDA approval, we expect to apply
	for patent extension to extend the protection of one of our patents covering vonapanitase or its use.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Assignment of Rights and License Agreement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	As successor to Proteon Therapeutics,&nbsp;LLC
	by merger, we acquired all of the assets of the&nbsp;LLC, including all of the intellectual property rights in a patent family
	entitled "Local, Transcatheter Delivery of Proteases to Reopen Obstructed Biological Conduits" (the "JHU patent
	family"). This patent family was originally developed by our founder, Dr. F.&nbsp;Nicholas Franano, at The Johns Hopkins University,
	or Johns Hopkins, and includes United States patent Nos.&nbsp;7,063,838; 7,153,505; 7,361,335; 7,632,494; 7,883,699; 8,524,226;
	8,562,983; and 8,568,716. Johns Hopkins assigned all of the intellectual property rights to Dr.&nbsp;Franano who in turn assigned
	the rights to the&nbsp;LLC. Under the terms of the assignment of rights and license agreement with Johns Hopkins, Dr.&nbsp;Franano
	reimbursed certain costs of Johns Hopkins and agreed to pay the future costs and expenses of patent prosecution and maintenance,
	as well as any costs related to infringement. In addition, under the agreement, Dr.&nbsp;Franano granted to Johns Hopkins rights
	to practice under the intellectual property rights for non-profit purposes. Our rights are further subject to any rights the United
	States Government may have in inventions that are the subject matter of the acquired patents under the Bayh Dole Act due to its
	sponsorship of research that led to certain of such inventions. The agreement does not specify a term and does not include any
	termination provisions. Dr.&nbsp;Franano agreed that upon commercialization of the assigned invention, he would remit to Johns
	Hopkins 2.5% of any revenues or fees received from certain net sales of any product covered by the JHU patent family. We assumed,
	and are the successor to, all of Dr.&nbsp;Franano's payment and other obligations to Johns Hopkins. Seven U.S. patents in the JHU
	patent family, and their foreign counterparts, described above as the therapy family, relate to certain therapeutic uses of vonapanitase,
	and the associated systems and kits that include a catheter and are suitable for a subset of those therapeutic uses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The biotechnology and pharmaceutical industries
	are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face
	potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies,
	academic institutions and governmental agencies and public and private research institutions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Some of our potential competitors have significantly
	greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical
	trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early stage companies may also prove
	to be significant competitors, particularly through collaborative arrangements with large and established companies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The key competitive factors that will differentiate
	vonapanitase, if approved, are likely to be its efficacy, safety, convenience, price, and the availability of reimbursement from
	government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors develop and
	commercialize products that are safer, more effective, more convenient or less expensive than products that we may develop. Our
	competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We are not aware of any therapeutic products approved
	in the United States or Europe for the prevention of vascular access failure. We are aware of other therapies in development by
	companies including Vascular Therapies and Symic Biomedical. vonapanitase could face competition from companies developing vascular
	access technologies, including BioConnect Systems, Avenu Medical, Phraxis, CreatiVasc , Laminate Medical Technologies, Stent Tek
	and TVA Medical. Other potentially competitive products include new synthetic grafts, including those that may be developed by
	companies that currently compete in the graft market, such as W.L. Gore, C.R. Bard and Maquet, as well as tissue engineered grafts,
	including those in development by Cytograft and Humacyte. Finally, vonapanitase's commercial success could be adversely affected
	by the development of technologies to improve the outcomes of interventions to restore patency, including stents, stent grafts
	and drug-coated balloons.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Government Regulation and Approval
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	United States&#8212;FDA process
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal
	Food, Drug, and Cosmetic Act, or FDCA, and other federal and state statutes and regulations, govern, among other things, the research,
	development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval
	monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention,
	treatment, or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the
	FDCA which governs the approval of new drug applications, or NDAs. Biological products, such as vonapanitase, are approved for
	marketing under provisions of the Public Health Service Act, or PHSA, via a BLA. The application process and requirements for approval
	of BLAs are very similar to those for NDAs, and biologics are associated with similar approval risks as drugs. Failure to comply
	with applicable United States requirements may subject a company to a variety of administrative or judicial sanctions, such as
	FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, clinical holds, product recalls, product seizures, total
	or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Approval process
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	FDA approval is required before any new unapproved
	product or a product with certain changes to a previously approved product may be marketed in the United States. FDA approval is
	required before any new unapproved drug, which includes biologics, or dosage form, including a new use of previously approved products,
	can be marketed in the United States. The steps required to be completed before a drug or biologic may be marketed in the United
	States include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="WIDTH: 90%; TEXT-ALIGN: JUSTIFY">
	preclinical laboratory tests, animal studies, and formulation studies, all performed in accordance with the FDA's Good Laboratory Practice, or GLP, regulations;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin and must be updated annually;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug or biologic for each indication to FDA's satisfaction;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	submission to the FDA of a BLA;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biologic is produced to assess compliance with cGMP regulations;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	satisfactory completion of FDA clinical site data audits; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	FDA review and approval of the BLA.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Satisfaction of FDA pre-market approval requirements
	typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of
	the product or disease.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Preclinical tests include laboratory evaluation
	of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and
	efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including
	GLP. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information
	about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical tests, such
	as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	A 30-day waiting period after the submission of
	each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned
	the IND within this 30-day period, the clinical trial proposed in the IND may begin. However, the FDA may within the 30-day time
	period raise concerns or questions relating to one or more proposed clinical trials and place the clinical trial on a clinical
	hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Accordingly,
	submission of an IND may or may not result in the FDA allowing clinical trials to commence. A separate submission to an existing
	IND must also be made for each successive clinical trial conducted during product development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Clinical trials involve the administration of the
	investigational new drug or biologic to healthy volunteers or patients under the supervision of a qualified investigator. Clinical
	trials must be conducted:&nbsp;&nbsp;(i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical
	practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical
	trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the
	parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on
	United States patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The FDA may order the temporary, or permanent,
	discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not
	being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The trial
	protocol and informed consent information for patients in clinical trials, including any changes to the protocols and informed
	consent forms, must also be submitted to an institutional review board, or IRB, for approval. An IRB may also require the clinical
	trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements or if the
	trial poses an unexpected serious harm to subjects, or may impose other conditions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Clinical trials to support NDAs or BLAs for marketing
	approval are typically conducted in three sequential phases, but the phases may overlap. In Phase&nbsp;1, the initial introduction
	of the drug or biologic into a limited population of healthy human subjects or patients, the product is tested to assess metabolism,
	pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence on effectiveness.
	Phase&nbsp;2 usually involves trials in a limited patient population to evaluate preliminarily the effectiveness of the drug or
	biologic for a particular indication, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks.
	If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase&nbsp;2 evaluations, Phase&nbsp;3
	trials are undertaken in a larger number of patients, typically at geographically dispersed clinical trial sites, to provide substantial
	evidence of clinical efficacy, to further test for safety in an expanded and diverse patient population, to permit the FDA to evaluate
	the overall benefit-risk relationship of the drug or biologic and to provide adequate information for the labeling of the product.
	In reviewing an NDA or a BLA, the FDA will consider all information submitted in the NDA or BLA, including the results of all clinical
	trials conducted. In most cases, the FDA requires two adequate and well-controlled Phase&nbsp;3 clinical trials to demonstrate
	the efficacy of the drug or biologic. A single Phase&nbsp;3 trial with other confirmatory evidence such as supportive results from
	Phase 1 and Phase 2 trials, including non-prespecified analyses, may be sufficient in rare instances where the trial is a large
	multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect
	on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result
	in a second trial would be practically or ethically impossible.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Progress reports detailing the status of the clinical
	trials must be submitted at least annually to the FDA, and safety reports must be submitted to the FDA and the investigators for
	serious, related and unexpected side effects.&nbsp;&nbsp;Progress and safety reporting must also be submitted to the applicable
	IRBs.&nbsp;&nbsp;Marketing application applicants must also report certain investigator financial interests to FDA.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The manufacture of investigational drugs and biologics for the conduct of human clinical trials is subject
	to cGMP requirements.&nbsp;&nbsp;Investigational drugs, biologics, and active pharmaceutical ingredients imported into the United
	States are also subject to regulation by the FDA relating to their labeling and distribution.&nbsp;&nbsp;Further, the export of
	investigational drug products and biologics outside of the United States is subject to regulatory requirements of the receiving
	country as well as U.S. export requirements under the FDCA.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Sponsors must also develop additional information
	about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial
	quantities in accordance with cGMP requirements.&nbsp;&nbsp;The manufacturing process must be capable of consistently producing
	quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity,
	strength, quality, purity, and potency of the final product.&nbsp;&nbsp;Additionally, appropriate packaging must be selected and
	tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration
	over its shelf life.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	After completion of the required clinical testing,
	an NDA or BLA is prepared and submitted to the FDA. FDA approval of the NDA or BLA is required before marketing of the product
	may begin in the United States. The NDA or BLA must include, among other things, the results of all trials and preclinical testing,
	and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls, including
	negative or ambiguous results as well as positive findings. The cost of preparing and submitting an NDA or BLA is substantial.
	The submission of most NDAs and BLAs is additionally subject to a substantial application user fee, currently $2,374,200, and the
	manufacturer and/or sponsor under an approved new drug or biologic application are also subject to annual product and establishment
	user fees, currently $114,450 per product and $585,200 per establishment. These fees are typically increased annually.&nbsp;&nbsp;A
	waiver or reduction of the application, establishment, and/or product fees may be obtained under certain limited circumstances.&nbsp;&nbsp;For
	instance, one basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees
	of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered
	for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application
	or the case of orphan designation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The FDA has 60&nbsp;days from its receipt of an
	NDA or BLA to determine whether the application will be accepted for filing based on the agency's threshold determination that
	it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept a BLA for
	filing.&nbsp;&nbsp;In this event, the BLA must be re-submitted with the additional information.&nbsp;&nbsp;The re-submitted application
	also is subject to review before the FDA accepts it for filing.&nbsp;&nbsp;Once the submission is accepted for filing, the FDA
	begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs and BLAs. Under the Prescription
	Drug User Fee Act, the FDA has a goal of responding to 90% of standard review original BLAs within ten months after the 60-day
	filing review period, but this timeframe is only a goal and, thus, the review time may be longer or extended. Priority review can
	be applied to drugs and biologics that the FDA determines are for a serious condition and, if approved, would provide a significant
	improvement in safety or effectiveness. FDA has the review goal of completing review of 90% of original BLA priority review applications
	within six months of the 60-day filing review period.&nbsp;&nbsp;The review process for both standard and priority review may be
	extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify
	information already provided in the submission.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The FDA may also refer applications for novel drug
	or biologic products, or drug or biologic products that present difficult questions of safety or efficacy, to an advisory committee&#8212;typically
	a panel that includes clinicians and other experts&#8212;for review, evaluation, and a recommendation as to whether the application
	should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.&nbsp;&nbsp;Before
	approving a drug or biologic for which no active ingredient (including any ester or salt of active ingredients) has previously
	been approved by the FDA, the FDA must either refer that drug or biologic to an external advisory committee or provide in an action
	letter, a summary of the reasons why the FDA did not refer the product candidate to an advisory committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The FDA reviews a BLA to determine, among other
	things, whether a product is safe, pure, and potent for its intended use and whether the facility in which it is manufactured,
	processed, packaged or held, as well as the manufacturing processes and controls, meet standards designed to ensure the product's
	continued identity, strength, safety, quality, purity, and potency Before approving an NDA or BLA, the FDA will typically inspect
	one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at
	which the drug or biologic is manufactured. FDA will not approve the product unless compliance with cGMP is satisfactory and the
	NDA or BLA contains data that provide evidence that the drug or biologic is safe and effective in the indication studied.&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	After the FDA evaluates the NDA or BLA and the
	manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter indicates
	that the review cycle of the application is complete and the application is not ready for approval. A complete response letter
	generally outlines the deficiencies in the submission and may require substantial additional clinical data and/or other significant,
	expensive, and time-consuming requirements related to clinical trials, preclinical studies and/or manufacturing. The FDA has committed
	to reviewing resubmissions of the NDA or BLA addressing such deficiencies in two or six months depending on the type of information
	included. Even if such data are submitted, however, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria
	for approval.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	An approval letter authorizes commercial marketing
	of the drug or biologic with specific prescribing information for specific indications. If a product receives regulatory approval,
	the approval may be significantly limited to specific diseases and dosages, or the indications for use may otherwise be limited,
	for example to specific patient populations or age groups.&nbsp;&nbsp;Each of these types of limitations could restrict the commercial
	value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product
	labeling, including black box warnings, or may not approve label statements that are necessary for successful commercialization
	and marketing.&nbsp;&nbsp;As a condition of NDA or BLA approval or following approval, the FDA may require a risk evaluation and
	mitigation strategy, or REMS, to help ensure that the benefits of the drug or biologic outweigh the potential risks. REMS can include
	medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include,
	but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
	special monitoring, and the use of patient registries. The requirement for REMS can materially affect the potential market and
	profitability of the product. Moreover, product approval may also be conditioned on substantial post-approval testing and surveillance
	to monitor the product's safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards
	is not maintained or problems are identified following initial marketing.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Changes to some of the conditions established in
	an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission
	and FDA approval of a new NDA or BLA or NDA or BLA supplement before the change can be implemented. An NDA or BLA supplement for
	a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures
	and actions in reviewing NDA or BLA supplements as it does in reviewing NDAs or BLAs, including user fee requirements for certain
	submissions.. As with new NDAs, the review process is often significantly extended by the FDA requests for additional information
	or clarification.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	U.S. Patent Term Restoration
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Depending upon the timing, duration and specifics
	of the FDA approval of vonapanitase and any future product candidates, some of our U.S. patents may be eligible for limited patent
	term extension. The Hatch-Waxman Amendments permit a patent restoration term, often referred to as patent term extension, of up
	to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent
	term restoration cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the product's approval date.
	The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date
	of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application. The period of
	the patent term restoration may also be reduced to account for time that an applicant did not act with due diligence.0020Only one
	patent applicable to an approved drug or biologic is eligible for the extension and the application for the extension must be submitted
	prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves or denies the application
	for any patent term extension or restoration. In the future, we intend to apply for extension of patent term for one of our patents
	covering vonapanitase to add patent life beyond its current expected expiration date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Post-approval requirements
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Once an NDA or BLA is approved, a product will
	be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion
	of drugs and biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored
	scientific and educational activities and promotional activities involving the internet. Drugs and biologics may be marketed only
	for the approved indications and in accordance with the provisions of the approved labeling. Failure to comply with these requirements
	can result in adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In addition, the distribution of prescription pharmaceutical
	products, including samples, is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs,
	biologics and drug and biologic samples at the federal level, and sets minimum standards for the registration and regulation of
	drug and biologic distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical
	product samples and impose requirements to ensure accountability in distribution.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 46 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Adverse event reports, deviation reports, and other
	annual reports are required following FDA approval of an NDA or BLA. The FDA also may require post-marketing testing, known as
	Phase&nbsp;4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on
	an approval that could restrict the distribution or use of the product. In addition, quality control, drug and biologic manufacture,
	packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug and biologic manufacturers and certain
	of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with
	the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities
	to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production
	and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product
	recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously
	unrecognized problems are subsequently discovered.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Moreover, the Drug Quality and Security Act imposes
	obligations on manufacturers of pharmaceutical products related to product tracking and tracing.&nbsp;&nbsp;Among the requirements
	of this legislation, manufacturers are required to provide certain information regarding the product to individuals and entities
	to which product ownership is transferred, will be required to label products with a product identifier and are required to keep
	certain records regarding the product.&nbsp;&nbsp;The transfer of information to subsequent product owners by manufacturers will
	eventually be required to be done electronically.&nbsp;&nbsp;Manufacturers are also required to verify that purchasers of the manufacturers'
	products are appropriately licensed.&nbsp;&nbsp;Further, under this legislation, manufacturers have investigation, quarantine,
	disposition, and FDA and trading partner notification responsibilities related to counterfeit, diverted, stolen and intentionally
	adulterated products that would result in serious adverse health consequences or death to humans, as well as products that are
	the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely
	to result in serious health consequences or death.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Orphan drug designation
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Under the Orphan Drug Act, the FDA may grant orphan
	drug designation to drugs or biologics intended to treat a rare disease or condition&#8212;generally a disease or condition that
	affects fewer than 200,000 individuals annually in the United States.&nbsp;&nbsp;Additionally, sponsors must present a plausible
	hypothesis for clinical superiority to obtain orphan drug designation if there is a product already approved by the FDA that is
	intended for the same indication and that is considered by the FDA to be the same drug or biologic as the already approved drug
	or biologic. This hypothesis must be demonstrated to obtain orphan drug exclusivity. Orphan drug designation must be requested
	before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the drug or biologic and
	its potential orphan use are disclosed publicly by the FDA. Orphan drug designation entitles a party to financial incentives such
	as opportunities for grant funding towards clinical study costs, tax advantages, and user-fee waivers. The first NDA or BLA applicant
	to receive FDA approval for a particular drug or biologic to treat a particular disease with FDA orphan drug designation is entitled
	to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity
	period, the FDA may not approve any other applications to market the same drug or biologic for the same disease, except in limited
	circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity, that the request for designation
	was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients
	with the rare disease or condition. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic
	for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits
	of orphan drug designation are tax credits for certain research, waiver of the NDA or BLA application user fee, and exclusion from
	price limitations imposed by the 340B drug discount program on sales of covered outpatient drugs to certain categories of hospitals
	added to the program by the Affordable Care Act.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 47 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Fast track designation and accelerated approval
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The FDA is required to facilitate the development,
	and expedite the review, of drugs or biologics that are intended for the treatment of a serious or life-threatening disease or
	condition and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the
	sponsor of a new drug or biologic candidate may request that the FDA designate the candidate for a specific indication as a fast
	track drug or biologic concurrent with, or after, the filing of the IND for the candidate. The FDA determines if the drug or biologic
	candidate qualifies for fast track designation within 60&nbsp;days of receipt of the sponsor's request. Under the fast track program,
	sponsors have more opportunities to interact with FDA, and fast track product candidates may be eligible for priority review, if
	they meet the priority review criteria.&nbsp;&nbsp;If FDA determines, after preliminary evaluation of clinical data submitted by
	a sponsor, that a fast track product may be effective, FDA may also permit the sponsor to submit a marketing application on a rolling
	basis before the full application is complete. This rolling review is available if the applicant provides, and the FDA approves,
	a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's time
	period goal for reviewing an application does not begin until the last section of the NDA or BLA is submitted. Additionally, the
	fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging
	in the clinical trial process.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Any product submitted to the FDA for marketing,
	including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review,
	such as accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening
	illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means
	the FDA may approve the product based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a
	clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an
	effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence
	of the condition and the availability or lack of alternative treatments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In clinical trials, a surrogate endpoint is a measurement
	of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions,
	or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug or biologic
	candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&nbsp;4
	or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies,
	or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug or biologic from the market
	on an expedited basis. All promotional materials for drug or biologic candidates approved under accelerated regulations are subject
	to prior review by the FDA.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Pediatric information
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Under the Pediatric Research Equity Act, or PREA,
	NDAs or BLAs or supplements to NDAs or BLAs for a new active ingredient, indication, dosage form, dosage regimen or route of administration
	must contain data to assess the safety and effectiveness of the drug or biologic for the claimed indications in all relevant pediatric
	subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug or biologic is safe
	and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation,
	PREA does not apply to any drug or biologic for an indication for which orphan designation has been granted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Pediatric exclusivity is another type of exclusivity
	in the United States. Pediatric exclusivity, if granted, provides an additional six months of exclusivity to be attached to any
	existing exclusivity or patent protection. This six month exclusivity, which runs from the end of other exclusivity protection
	or patent delay, may be granted based on the voluntary completion of a pediatric trial that fairly responds to an FDA-issued "Written
	Request" for such a trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Additional controls for biologics
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	To help reduce the increased risk of the introduction
	of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely
	defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger
	to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the
	creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and
	between states.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 49 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	After a BLA is approved, the product may also be
	subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required
	to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official
	release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing
	the results of all of the manufacturer's tests performed on the lot. The FDA may also perform certain confirmatory tests on lots
	of some products before releasing the lots for distribution by the manufacturer.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In addition, the FDA conducts laboratory research
	related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after
	approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing,
	and are subject to periodic inspection after approval.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Biosimilars
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Biologics Price Competition and Innovation
	Act of 2009, or BPCIA, creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable
	with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires
	a high similarity to the reference product notwithstanding minor differences in clinically inactive components, and no clinically
	meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity
	must be shown through analytical studies, animal studies, and at least one clinical trial, absent a waiver by the Secretary of
	Health and Human Services.&nbsp;&nbsp;There must be no difference between the reference product and a biosimilar in conditions
	of use, route of administration, dosage form, and strength.&nbsp;&nbsp;A biosimilar product may be deemed interchangeable with
	a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results
	as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched
	after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive
	use of the reference biologic. FDA approved the first biosimilar or interchangeable product under the BPCIA in 2015. Other biosimilar
	applications are currently under review. Complexities associated with the larger, and often more complex, structures of biological
	products, as well as the process by which such products are manufactured, pose significant hurdles to implementation which are
	still being evaluated by the FDA.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 50 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	A reference biologic is granted 12 years of exclusivity
	from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four years
	from the date of licensure of the reference product.&nbsp;&nbsp;However, certain changes and supplements to an approved BLA, and
	subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do
	not qualify for the twelve year exclusivity period.&nbsp;&nbsp;The PHSA also includes provisions to protect reference products
	that have patent protection. The biosimilar product sponsor and reference product sponsor must exchange certain patent and product
	information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome of negotiations
	surrounding the exchanged information, the reference product sponsor may bring a patent infringement suit and injunction proceedings
	against the biosimilar product sponsor.&nbsp;&nbsp;The first biologic product submitted under the abbreviated approval pathway
	that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for
	other biologics for the same condition of use for the lesser of (i)&nbsp;one year after first commercial marketing of the first
	interchangeable biosimilar, (ii)&nbsp;eighteen months after the first interchangeable biosimilar is approved if there is no patent
	challenge, (iii)&nbsp;eighteen months after resolution of a lawsuit over the patents of the reference biologic in favor of the
	first interchangeable biosimilar applicant, or (iv)&nbsp;42&nbsp;months after the first interchangeable biosimilar's application
	has been approved if a patent lawsuit is ongoing within the 42-month period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Disclosure of clinical trial information
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Sponsors of clinical trials of FDA-regulated products,
	including drugs and biologics, are required to register and disclose certain clinical trial information. Information related to
	the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial
	is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after
	completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has
	been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development
	programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	European Union&#8212;EMA process
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In the European Union, medicinal products are
	authorized following a similar demanding process as that required in the United States and applications are based on the ICH Common
	Technical Document, an agreed upon format to assemble all quality, safety and efficacy data for preparation of an application
	of a new drug. Prior to submitting a European Marketing Authorization Application, or MAA, it is necessary to gain approval of
	a detailed Pediatric Investigation Plan, or PIP, with the European Medicines Agency's Pediatric Committee, or PDCO. After gaining
	PIP approval, medicines can be authorized in the European Union by using either the centralized authorization procedure or national
	authorization procedures.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 51 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Centralized procedure
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Under the centralized procedure, after the EMA
	issues an opinion, the European Commission issues a single marketing authorization valid across the European Union, as well as
	Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human medicines that are:&nbsp;&nbsp;derived from
	biotechnology processes, such as genetic engineering; contain a new active substance indicated for the treatment of certain diseases,
	such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions; and officially
	designated orphan medicines. For medicines that do not fall within these categories, an applicant has the option of submitting
	an application for a centralized marketing authorization to the EMA, as long as the medicine concerned is a significant therapeutic,
	scientific or technical innovation, or if its authorization would be in the interest of public health.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	National authorization procedures
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	There are also two other possible routes to authorize
	medicinal products in several countries, which are available for products that fall outside the scope of the centralized procedure:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 96PX; TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Decentralized procedure.
</I>
	&nbsp;&nbsp;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of a medicinal product that has not yet been authorized in any European Union country and that does not fall within the mandatory scope of the centralized procedure.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Mutual recognition procedure.
</I>
	&nbsp;&nbsp;In the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures of that country. Thereafter, further marketing authorizations can be sought from other European Union countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	While we believe that our development program,
	our Phase&nbsp;3 trial design, and overall non-clinical and clinical data package could support future regulatory approval of vonapanitase
	in the European Union, we have not submitted such information to the European Union for their review.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 52 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Good manufacturing practices
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Like the FDA, the EMA, the competent authorities
	of the European Union Member States and other regulatory agencies regulate and inspect equipment, facilities and processes used
	in the manufacturing of pharmaceutical and biologic products prior to approving a product. If, after receiving clearance from regulatory
	agencies, a company makes a material change in manufacturing equipment, location, or process, additional regulatory review and
	approval may be required. Once we or our partners commercialize products, we will be required to comply with cGMP, and product-specific
	regulations enforced by, the European Commission, the EMA and the competent authorities of European Union Member States following
	product approval. Also like the FDA, the EMA, the competent authorities of the European Union Member States and other regulatory
	agencies also conduct regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval
	of a product. If, as a result of these inspections, it is determined that our or our partners' equipment, facilities, or processes
	do not comply with applicable regulations and conditions of product approval, regulatory agencies may seek civil, criminal or administrative
	sanctions and/or remedies against us, including the suspension of our manufacturing operations or the withdrawal of our product
	from the market.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
	Data and market exclusivity
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Similar to the United States, there is a process
	for authorization of generic versions of innovator drug products in the European Union. Abridged applications for the authorization
	of generic versions of drugs authorized by EMA can be submitted to the EMA through a centralized procedure referencing the innovator's
	data and demonstrating bioequivalence to the reference product, among other things.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	New medicinal products in the European Union can
	receive eight years of data exclusivity coupled with two years of market exclusivity, and a potential one year extension, if the
	marketing authorizations holder obtains an authorization for one or more new therapeutic indications that demonstrates "significant
	clinical benefit" in comparison with existing therapies; this system is usually referred to as "8+2+1". We expect
	to be eligible for at least 10 years of market exclusivity following any approval of vonapanitase.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Abridged applications cannot rely on an innovator's data until after expiry of the eight year data exclusivity
	term; applications for a generic product can be filed but the product cannot be marketed until the end of the market exclusivity
	term.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Other international markets&#8212;drug approval process
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In some international markets (
<I>
	e.g.
</I>
	, China
	or Japan), although data generated in United States or European Union trials may be submitted in support of a marketing authorization
	application, additional clinical trials conducted in the host territory, or studying people of the ethnicity of the host territory,
	may be required prior to the filing or approval of marketing applications within the country.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 53 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Pricing and reimbursement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In the United States and internationally, sales
	of products that we market in the future, and our ability to generate revenues on such sales, are dependent, in significant part,
	on the availability and level of reimbursement from third-party payors such as state and federal governments, managed care providers
	and private insurance plans. Substantial uncertainty exists as to the reimbursement status of newly approved healthcare products
	by third-party payors. In the United States no uniform policy of coverage and reimbursement for drug and biologic products exists.
	Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will
	be made on a payor by payor basis. As a result, the coverage determination process is often a time-consuming and costly process
	that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately,
	with no assurance that coverage and adequate reimbursement will be obtained.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Private insurers, such as health maintenance organizations
	and managed care providers, have implemented cost-cutting and reimbursement initiatives and likely will continue to do so in the
	future. These include establishing formularies that govern the drugs and biologics that will be offered and also the out-of-pocket
	obligations of member patients for such products. Several third-party payors are requiring that drug and biologic companies provide
	them with predetermined discounts from list prices, are using preferred drug lists (which include biologics) to leverage greater
	discounts in competitive classes, are disregarding therapeutic differentiators within classes, and are challenging the prices charged
	for drugs and biologics.&nbsp;&nbsp;It is possible that some third party payors may not consider our technology to be a significant
	benefit in a clinical and cost effectiveness comparison with other technologies or techniques intended to address the same conditions
	as our product candidates and reimbursement may not be available to our customers, or may not be sufficient to allow our products
	to be marketed on a competitive basis. Cost-control initiatives could cause us to discount or rebate a portion of the price we
	might establish for products, which could result in lower than anticipated product revenues. If the realized prices for our products,
	if any, decrease or if governmental and other third party payors do not provide adequate coverage or reimbursement, our prospects
	for revenue and profitability will suffer.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 54 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In addition, particularly in the United States
	and increasingly in other countries, we may be required to provide mandatory discounts and pay fixed rebates to state and federal
	governments and agencies in connection with purchases of our products that are used or reimbursed by such entities. Rebates also
	must be paid to the governments of U.S. territories on drugs that are reimbursed by Medicaid in the territories. It is possible
	that future legislation in the United States and other jurisdictions could be enacted which could potentially impact the reimbursement
	rates for the products we are developing and may develop in the future and also could further impact the levels of discounts and
	rebates paid to federal and state government entities. Any legislation that impacts these areas could impact, in a significant
	way, our ability to generate revenues from sales of products that, if successfully developed, we bring to market.&nbsp;&nbsp;Federal
	programs also impose penalties on manufacturers of drugs marketed under an NDA and biological products marketed under a BLA in
	the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price
	Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices.&nbsp;&nbsp;Government
	authorities and third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
	medications, which could affect our ability to sell our product candidates profitably.&nbsp;&nbsp;Biological products approved
	under BLAs and drugs approved under NDAs are subject to greater discounts and reporting obligations under federal programs than
	generic drugs approved under Abbreviated New Drug Applications, or ANDAs, although biosimilars are generally treated the same as
	the reference biologic. The inflation penalty applicable to these products can equal the selling price.&nbsp;&nbsp;It is also not
	uncommon for market conditions to warrant multiple discounts to different customers on the same unit, such as purchase discounts
	to institutional care providers and rebates to the health plans that pay them, which reduces the net realization on the original
	sale.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	There is no legislation at the European Union level
	governing the pricing and reimbursement of medicinal products in the European Union other than in relation to the transparency
	and timing of national decision making and the availability of appeal. As a result, the competent authorities of each of the 28&nbsp;European
	Union Member States have adopted individual strategies regulating the pricing and reimbursement of medicinal products in their
	territory. These strategies often vary widely in nature, scope and application. However, a major element that they have in common
	is an increased move towards reduction in the reimbursement price of medicinal products, a reduction in the number and type of
	products selected for reimbursement and an increased preference for generic products over innovative products. These efforts have
	mostly been executed through these countries' existing price control methodologies. It is increasingly common in many European
	Union Member States for Marketing Authorization Holders to be required to demonstrate through health technology assessment the
	pharmaco-economic superiority of their products as compared to products already subject to pricing and reimbursement in specific
	countries. In order for drugs to be evaluated positively under such criteria, pharmaceutical companies may need to re-examine,
	and consider altering, a number of traditional functions relating to the selection, study, and management of drugs, whether currently
	marketed, under development, or being evaluated as candidates for research and/or development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 55 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Sales and marketing, and other healthcare related activities
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Sales, promotion and other activities following
	product approval are subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United
	States, the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of the Department of Health and Human Services,
	the U.S. Department of Justice, and similar foreign, state, and local government authorities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	As described above, the FDA regulates all advertising
	and promotion activities for products under its jurisdiction both prior to and after approval. A company can make only those claims
	relating to safety and efficacy that are approved by the FDA in labeling. Physicians may prescribe legally available drugs and
	biologics for uses that are not described in the product's labeling and that differ from those tested by us and approved by the
	FDA. These off-label uses are common across medical specialties, and often reflect a physician's belief that the off-label use
	is the best treatment for the patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but
	FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Failure to comply with
	applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising,
	consent decrees and the full range of civil and criminal penalties available to the FDA.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In the United States sales, marketing and scientific/educational
	programs must also comply with various federal and state laws pertaining to healthcare "fraud and abuse," including anti-kickback
	laws and false claims laws. Anti-kickback laws make it illegal for a prescription manufacturer to solicit, offer, receive, or pay
	any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of a particular
	drug or biologic. The term &#8216;&#8216;remuneration&#8217;&#8217; has been broadly interpreted to include anything of value.
	The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers,
	purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory
	safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are narrowly drawn. Practices
	that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject
	to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Several courts have interpreted
	the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals
	of federal healthcare covered business, the statute has been violated.&nbsp;Due to the breadth of the statutory provisions and
	the absence of guidance in the form of regulations and very few court decisions addressing industry practices, it is possible that
	our practices might be challenged under anti-kickback or similar laws. Moreover, recent healthcare reform legislation has strengthened
	these laws. For example, the recently enacted Patient Protection and Affordable Care Act, or ACA, among other things, amends the
	intent requirement of the federal anti-kickback and criminal healthcare fraud statutes to clarify that a person or entity does
	not need to have actual knowledge of this statute or specific intent to violate it. In addition, ACA clarifies that the government
	may assert that a claim that includes items or services resulting from a violation of the federal anti-kickback statute constitutes
	a false or fraudulent claim for purposes of the civil False Claims Act.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 56 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The civil False Claims Act prohibits anyone from
	knowingly presenting, or causing to be presented for payment, to third-party payors (including Medicare and Medicaid) claims for
	reimbursed drugs (including biologics) or services that are false or fraudulent, claims for items or services not provided as claimed,
	or claims for medically unnecessary items or services. A claim includes &#8216;&#8216;any request or demand&#8217;&#8217; for money
	or property presented to the United States government, and may be predicated on false certification of compliance with a statute
	or regulation that is a condition of payment. The False Claims Act also applies to false submissions that cause the government
	to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability
	under the civil False Claims Act. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for
	allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product.
	Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products
	for unapproved, and thus non-covered, uses, and for underpaying rebates by concealing their best price. In addition, federal health
	care programs require drug and biologic manufacturers to report pricing information, which is used to quantify discounts and establish
	reimbursement rates.&nbsp;&nbsp;&nbsp;Civil False Claims Act actions may be brought by the government or may be brought by private
	individuals on behalf of the government, called "qui tam" actions. The False Claims Act provides for trebling of actual
	damages and a penalty for each false claim the manufacturer submitted or caused to be submitted, which, when aggregated, can yield
	substantial liability,
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In addition to the Anti-Kickback Statute and the
	civil False Claims Act, there are a number of other laws that we may be subject to due to the nature of our business.&nbsp;&nbsp;The
	criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious,
	or fraudulent and, unlike the civil False Claims Act, requires proof of intent to submit a false claim. The federal Health Insurance
	Portability and Accountability Act of 1996, or HIPAA, prohibits, among other actions, knowingly and willfully executing, or attempting
	to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling
	or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense, and knowingly
	and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement
	in connection with the delivery of or payment for healthcare benefits, items or services. As discussed above, ACA amended the intent
	standard for HIPAA&#8217;s healthcare fraud provision such that a person or entity no longer needs to have actual knowledge of
	the statute or specific intent to violate it in order to have committed a violation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 57 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The civil monetary penalties statute further imposes
	penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim
	to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or
	is false or fraudulent.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Section 1927 of the Social Security Act&nbsp;requires
	that manufacturers of drugs and biological products covered by Medicaid report pricing information to the Centers for Medicare
	&amp; Medicaid Services, or CMS, on a monthly and quarterly basis, including the best price available to any customer of the manufacturer,
	with certain exceptions for government programs, and pay prescription rebates to state Medicaid programs based on a statutory formula
	and derived from reported pricing information.&nbsp;&nbsp;In addition, many states authorize their Medicaid programs to establish
	Preferred Drug Lists (which include biologics) to leverage supplemental Medicaid rebates.&nbsp;&nbsp;Reporting false pricing information
	may cause underpayment of rebates or overpayment of pharmacies that are reimbursed by Medicaid on the basis of reported prices
	and has been the basis of numerous civil, as well as criminal False Claims Act cases against manufacturers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Veterans Health Care Act, or VHCA, requires
	manufacturers of covered drugs and biologics participating in the Medicaid program to report certain non-federal pricing information
	from which a mandatory purchase discount is derived and to enter into Federal Supply Schedule contracts with the Department of
	Veterans Affairs through which their covered drugs and biologics must be sold to certain federal agencies at the statutory price.&nbsp;&nbsp;This
	necessitates compliance with applicable federal procurement laws and regulations and subjects us to contractual remedies as well
	as administrative, civil, and criminal sanctions.&nbsp;&nbsp;In addition, the VHCA requires manufacturers participating in Medicaid
	to agree to provide different mandatory discounts to certain Public Health Service grantees and other safety net hospitals and
	clinics.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The federal and state governments further regulate
	the payments made to physicians and other health care providers. The ACA created new federal requirements for reporting, by applicable
	manufacturers of covered drugs and biologics, payments and other transfers of value to physicians and teaching hospitals, and ownership
	and investment interests held by physicians and other healthcare providers and their immediate family members.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We may also be subject to data privacy and security
	regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information
	Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes specified requirements relating
	to the privacy, security and transmission of individually identifiable health information. Penalties for violating HIPAA include
	civil penalties, criminal penalties, and imprisonment. Among other things, HITECH, through its implementing regulations, makes
	HIPAA&#8217;s privacy and security standards directly applicable to &#8216;&#8216;business associates,&#8217;&#8217; defined as
	a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains or transmits
	protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. HITECH also strengthened
	the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons,
	and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the
	federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state
	laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant
	ways and may not have the same requirements, thus complicating compliance efforts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 58 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	There further may be state law equivalents of each
	of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party
	payor, including commercial insurers, and state laws governing transparency, the privacy and security of health information in
	certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus
	complicating compliance efforts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our activities relating to our products may be
	subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal and civil sanctions, including
	fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid)
	and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies.
	Similar sanctions and penalties also can be imposed upon executive officers and employees, including criminal sanctions against
	executive officers under the so-called "responsible corporate officer" doctrine, even in situations where the executive
	officer did not intend to violate the law and was unaware of any wrongdoing.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Given the significant penalties and fines that
	can be imposed on companies and individuals if convicted, allegations of such violations often result in settlements even if the
	company or individual being investigated admits no wrongdoing. Settlements often include significant civil sanctions, including
	fines and civil monetary penalties, and corporate integrity agreements. If the government were to allege or convict us or our executive
	officers of violating these laws, our business could be harmed. In addition, private individuals have the ability to bring similar
	actions. Our activities could be subject to challenge for the reasons discussed above and due to the broad scope of these laws
	and the increasing attention being given to them by law enforcement authorities. Further, there are an increasing number of state
	laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities
	as to what is required to comply with the laws. Given the lack of clarity in laws and their implementation, our reporting actions
	could be subject to the penalty provisions of the pertinent state authorities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 59 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Depending on the circumstances, failure to comply
	with these laws can also result in penalties, including criminal, civil and/or administrative criminal penalties, damages, fines,
	disgorgement, debarment from government contracts and future orders under existing contracts, refusal to allow us to enter into
	supply contracts, including government contracts, reputational harm, diminished profits and future earnings and the curtailment
	or restructuring of our operations, any of which could adversely affect our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Similar rigid restrictions are imposed on the promotion
	and marketing of medicinal products in the European Union and other countries. Laws (including those governing promotion, marketing,
	anti-kickback and personal data provisions), industry regulations and professional codes of conduct often are strictly enforced.
	Even in those countries where we are not directly responsible for the promotion and marketing of our products, inappropriate activity
	by our international distribution partners can have adverse implications for us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Other laws and regulatory processes
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We will become subject to a variety of financial
	disclosure and securities trading regulations as a public company in the United States, including laws relating to the oversight
	activities of the Securities and Exchange Commission, or SEC and, following the listing of our capital stock on the NASDAQ Global
	Market, we will be subject to the regulations of the NASDAQ Global Market. In addition, the Financial Accounting Standards Board,
	or FASB, the SEC and other bodies that have jurisdiction over the form and content of our accounts, our financial statements and
	other public disclosure are constantly discussing and interpreting proposals and existing pronouncements designed to ensure that
	companies best display relevant and transparent information relating to their respective businesses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our international operations are subject to compliance
	with the Foreign Corrupt Practices Act, or the FCPA, which prohibits corporations and individuals from paying, offering to pay,
	or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or
	political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity.
	The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring
	the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international
	subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. We also
	may be implicated under the FCPA for activities by our partners, collaborators, CROs, vendors or other agents. Activities that
	violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement,
	oversight, and debarment from government contracts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 60 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our present and future business has been and will
	continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to safe working
	conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import and export and use
	and disposal of hazardous or potentially hazardous substances used in connection with our research work are or may be applicable
	to our activities. Certain agreements entered into by us involving exclusive license rights or acquisitions may be subject to national
	or supranational antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which
	might result from future legislation or administrative action, cannot accurately be predicted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Employees
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	As of March 10, 2016, we had 17 full-time employees and one part-time employee, of whom 11 are in research
	and development and six are in general and administrative functions. None of our employees is subject to a collective bargaining
	agreement or represented by a labor or trade union. We believe that our relations with our employees are good.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Corporate Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We were incorporated under the laws of the State of Delaware in March 2006, and at that time, acquired Proteon
	Therapeutics,&nbsp;LLC, our predecessor, which was formed in June 2001. Our executive offices are located at 200 West Street, Waltham,
	Massachusetts 02451, and our telephone number is (781)&nbsp;890-0102. Our website address is
<U>
	http://www.proteontherapeutics.com
</U>
	.
	The information on our website, or any website referred to in this Form 10-K, is not incorporated by reference in this Annual Report
	on Form&nbsp;10-K or in any other filings we make with the SEC.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Where to Find More Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We make our public filings with the SEC, including
	our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all exhibits and amendments to
	these reports, available free of charge at our website,
<U>
	http://www.proteontherapeutics.com
</U>
	, as soon as reasonably practicable
	after we file or furnish such materials with the SEC. Our SEC filings are also at the Public Reference Room of the SEC at 100 F
	Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling 1-800-SEC-0330.
	In addition, the SEC also maintains an internet site at
<U>
	www.sec.gov
</U>
	that contains reports, proxy statements and other information
	regarding registrants that file electronically, including Proteon.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 61 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<A NAME="F10K_031416P_HTM_A_002">
</A>
	Item 1A. Risk Factors
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<B>
<I>
	Any investment in our Common Stock involves
	a high degree of risk. The following risk factors and other information included in this Annual Report on Form 10-K should be carefully
	considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently
	known to us or that we currently believe to be immaterial may also adversely affect our business. We refer you to our &#8220;Cautionary
	Note Regarding Forward-Looking Statements,&#8221; which identifies certain forward-looking statements contained in this report
	that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations
	and future growth prospects could be materially and adversely affected.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Risks Related to Our Financial Condition and Need for Additional Capital
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We have a limited operating history and have incurred significant
	losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	We are a late-stage biotechnology company,
	and we have not commercialized any products or generated any revenues from the sale of products. We have incurred losses from operations
	in each year since our inception, and our net losses were $21.4 million and $3.3 million for the years ended December 31, 2015
	and 2014, respectively. As of December 31, 2015, we had an accumulated deficit of $131.3 million. We do not expect to generate
	any product revenues in the foreseeable future. We do not know whether or when we will generate revenue or become profitable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0">
	We have devoted most of our financial resources to
	research and development, including our clinical and preclinical development activities. To date, we have financed our operations
	primarily through the sale of equity securities and, prior to our initial public offering, the sale of convertible debt. Our current
	product candidate, vonapanitase, is in clinical trials and we have no commercial sales, which, together with our limited operating
	history, make it difficult to assess our future viability. The amount of our future net losses will depend, in part, on the rate
	of our future expenditures and our ability to obtain funding through equity or debt financings or strategic collaborations. We
	have not completed pivotal clinical trials for any product candidate and it will be several years, if ever, before we have vonapanitase
	or any future product candidates ready for commercialization. Even if we obtain regulatory approval to market vonapanitase or any
	additional product candidates, our future revenues will depend upon the size of any markets in which vonapanitase or any additional
	product candidates have received approval, our ability to achieve sufficient market acceptance, reimbursement from third-party
	payors and other factors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 35PT 0 5.95PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 35PT 0 5.95PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 35PT 0 5.95PT">
	We expect to continue to incur significant
	expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially
	if and as we:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	continue our clinical development and seek regulatory approval of vonapanitase, particularly with respect to its lead indication for radiocephalic arteriovenous fistula, or AVFs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	commercialize vonapanitase directly in the United States;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	undertake clinical development of vonapanitase in Europe and establish partnerships for commercialization of vonapanitase in all or parts of Europe;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	pursue additional indications for vonapanitase including clinical development of vonapanitase for brachiocephalic
	AVFs, patients requiring placement of an arteriovenous graft, or AVG, and symptomatic peripheral artery disease, or PAD;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	in-license or acquire additional product opportunities and make milestone or other payments under any in-license agreements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	contracting for the manufacture of commercial quantities of vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	maintain, protect and expand our intellectual property portfolio;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	attract and retain skilled personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	create additional infrastructure to support our operations as a public company and our product development; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	experience any delays or encounter issues with any of the above.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.3PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The net losses we incur may fluctuate significantly
	from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good
	indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations
	of securities analysts or investors, which could cause our stock price to decline.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We will require substantial additional financing to achieve our
	goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit,
	reduce or terminate our product development, any commercialization efforts or other operations.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 63 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	Our operations have consumed substantial
	amounts of cash since inception. As of December 31, 2015, our cash, cash equivalents and available-for-sale investments were $65.3
	million. Our research and development expenses were $12.4 million and $6.4 million for the years ended December 31, 2015 and 2014,
	respectively. We believe that we will continue to expend substantial resources for the foreseeable future developing vonapanitase
	and any additional product candidates. These expenditures will include costs associated with research and development, potentially
	acquiring new technologies, potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling
	products approved for sale, if any. In addition, other unanticipated costs may arise. Because the outcome of our planned and anticipated
	clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to fund and successfully complete
	the development and commercialization of vonapanitase or any additional product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0.5PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0">
	We began enrolling patients in our first Phase 3
	clinical trial of vonapanitase during the third quarter of 2014 for patients undergoing creation of radiocephalic AVFs, completed
	patient enrollment in October 2015 and expect to release top-line data in December 2016. We enrolled the first patient in our second
	Phase 3 AVF trial in August 2015 and expect to complete enrollment in the first quarter of 2017. Based on our current operating
	plan, and absent any future financings or strategic partnerships, we believe that our existing cash and cash equivalents and available-for-sale
	investments will be sufficient to fund our projected operating expenses and capital expenditure requirements into the fourth quarter
	of 2017, allowing us to obtain results from our first Phase 3 clinical trial of vonapanitase in radiocephalic AVFs. This period
	could be shortened if there are any significant and unexpected increases in spending on development programs or more rapid progress
	of development programs than anticipated. We do not expect our existing capital resources to be sufficient to enable us to complete
	our second Phase 3 trial. In addition, we plan to initiate other small Phase 1 or Phase 1/2 trials in additional indications, which
	would further reduce our capital resources. However, we do not expect to initiate any other Phase 2 or Phase 3 trials prior to
	receiving and reviewing data from our first Phase 3 AVF clinical trial. Furthermore, our operating plan may change as a result
	of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private
	equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations,
	strategic alliances and licensing arrangements, or a combination of these approaches. Even if we believe we have sufficient funds
	for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific
	strategic considerations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0.5PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	Additional fundraising efforts may divert
	our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize vonapanitase
	or any additional product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts
	or on terms acceptable to us, or at all. We could also be required to seek funds through arrangements with collaborative partners
	or otherwise at an earlier stage than would otherwise be ideal and we may be required to relinquish rights to vonapanitase or any
	additional product candidates, or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on
	our business, operating results and prospects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 0.5PT 0 5.95PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 64 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	If we are unable to obtain funding on a
	timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs
	or the commercialization of any approved products or be unable to expand our operations or otherwise capitalize on our business
	opportunities, as desired, which could materially adversely affect our business, financial condition and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0.5PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We have never generated any revenue from product sales and may
	never be profitable.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As a company, we have never obtained regulatory
	approval for, or commercialized, any product candidate. Our ability to generate substantial revenue and achieve profitability depends
	on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory
	approvals necessary to commercialize, vonapanitase or any additional product candidates. We do not anticipate generating revenues
	from product sales for at least the next several years, if ever. If vonapanitase or any additional product candidates fail in clinical
	trials or do not gain regulatory approval, or if vonapanitase or any additional product candidates, if approved, fail to achieve
	market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain
	profitability in subsequent periods. Our ability to generate future revenues from product sales depends heavily on our success
	in:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	completing clinical development of vonapanitase for one or more indications and research and preclinical and clinical development of additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	seeking and obtaining regulatory and marketing approvals for vonapanitase if and when we complete clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support clinical development and the market demand for vonapanitase, if approved;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	launching and commercializing vonapanitase if we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing our own sales, marketing and distribution infrastructure;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	obtaining and maintaining adequate timely coverage and reimbursement from third-party payors for vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	obtaining market acceptance of vonapanitase as a viable treatment option;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	addressing any competing technological and market developments;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	implementing additional internal systems and infrastructure, as needed;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	identifying and validating new product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	maintaining, protecting and expanding our portfolio of intellectual property rights, including patents and know-how;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	developing vonapanitase such that, if approved, it can be commercialized without infringing the intellectual property rights of third parties; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	attracting, hiring and retaining qualified personnel.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.3PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 65 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Even if vonapanitase or any additional product candidates that we may develop is approved for commercial sale,
	we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase
	beyond expectations if we are required by the United States Food and Drug Administration, or the FDA, the European Medicines Agency,
	or EMA, or other regulatory agencies, domestic or foreign, to perform clinical trials and other studies in addition to those that
	we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable
	and may need to obtain additional funding to continue operations. Our failure to become and remain profitable would depress the
	market price of our Common Stock and could impair our ability to raise capital, expand our business, diversify our product offerings
	or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Risks Related to Clinical Development, Regulatory Review and Approval
	of Our Product
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We are substantially dependent on the success of our current product
	candidate, vonapanitase, and cannot guarantee that this product candidate will successfully complete Phase 3 clinical trials, receive
	regulatory approval or be successfully commercialized.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We currently have no products approved for commercial
	distribution. We have invested substantially all of our efforts and financial resources in the development of our current product
	candidate, vonapanitase. Our business depends entirely on the successful development and commercialization of vonapanitase, in
	vascular access or additional indications, which may never occur. Our ability to generate revenues in the near term is substantially
	dependent on our ability to develop, obtain regulatory approval for, and then successfully commercialize vonapanitase. We currently
	generate no revenues from sales of any products, and we may never be able to develop or commercialize a marketable product.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Vonapanitase will require additional clinical
	development, regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant
	marketing efforts and further investment before we generate any revenues from product sales. We are not permitted to market or
	promote vonapanitase for any indication before we receive regulatory approval from the FDA or comparable foreign regulatory authorities,
	and we may never receive this regulatory approval for any of our product candidates. If we do not receive FDA approval and successfully
	commercialize vonapanitase, we will not be able to generate revenue from vonapanitase in the United States in the foreseeable future,
	or at all. Moreover, any significant delays in obtaining approval for and commercializing vonapanitase will have a substantial
	adverse impact on our business and financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 66 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We have not previously submitted a Biologics License Application, or BLA, to the FDA, or similar drug or
	biologic approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that vonapanitase
	or any additional product candidates will be successful in clinical trials or receive regulatory approval. In our Phase 2 clinical
	trial, our primary efficacy endpoint of primary unassisted patency did not show statistically significant benefit for the 30 microgram
	dose versus placebo. While statistical analyses of the subset of patients with radiocephalic AVFs suggested a clinically significant
	benefit over placebo for that patient subset, those analyses were not prespecified, and we cannot assure you that these non- prespecified
	results will be repeated in our Phase 3 trials. Following completion of the Phase 2 clinical trial of vonapanitase, we analyzed
	the data in a number of ways in addition to the analysis specified in the protocol. For example, we analyzed the data from the
	subset of patients undergoing creation of a radiocephalic AVF. Analysis of data in a manner or from subsets that were not prespecified
	in the protocol is typically not sufficient to serve as the basis for regulatory approval and is generally not considered as reliable
	as analyses which were prespecified in the protocol. Even though our Phase 3 trials will enroll patients undergoing a surgical
	procedure to create a radiocephalic AVF (
<I>
	i.e.
</I>
	, that subset of patients in which vonapanitase showed a greater benefit in
	our Phase 2 clinical trial), there are risks of failure inherent at any stage of product development, and we may not demonstrate
	efficacy with regard to the primary endpoint of our ongoing and planned Phase 3 clinical trials, or unexpected adverse events may
	appear. Further, vonapanitase or any additional product candidates, may not receive regulatory approval even if they are successful
	in clinical trials. If approved for marketing by applicable regulatory authorities, our ability to generate revenues from vonapanitase
	will depend on our ability to, among other things:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	launch commercial sales of vonapanitase, whether alone or in collaboration with others;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	create market demand for vonapanitase through our own marketing and sales organization, and through any other promotional arrangements that we may otherwise establish;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	hire, train and deploy a specialty sales force, focused primarily on vascular surgeons, to commercialize vonapanitase in the United States;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	manufacture vonapanitase in sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter and establish and maintain agreements with wholesalers, distributors and group purchasing organizations on commercially reasonable terms;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	create partnerships with third parties to promote and sell vonapanitase in any foreign markets where we receive marketing approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	obtain and maintain patent protection and regulatory exclusivity for vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	achieve appropriate reimbursement for vonapanitase;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	effectively compete with other products; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	maintain a continued acceptable safety profile of vonapanitase following launch.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 67 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As we continue to develop vonapanitase for other
	indications, including AVG, brachiocephalic AVF and symptomatic PAD, or develop additional product candidates, we will face similar
	risks and challenges.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Clinical development is a lengthy and expensive process with an
	uncertain outcome due to many factors. Because the results of early clinical trials are not necessarily predictive of future results,
	vonapanitase may not have favorable results in later clinical trials or receive regulatory approval.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Clinical development is expensive, difficult to
	design and implement, takes many years to complete and its outcome is inherently uncertain. Failure can occur at any time during
	the clinical trial process and vonapanitase is subject to the risks of failure inherent in drug and biological development, including
	failure to demonstrate efficacy in a pivotal clinical trial or in the patient population we intend to enroll, the occurrence of
	severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements
	and determination by the FDA or any comparable foreign regulatory authority that a drug and biological product is not approvable.
	Trends and results observed in earlier stage clinical trials, particularly trends and results observed through non-prespecified
	analysis of the data, may not be replicated in later stage clinical trials. For example, as is common with Phase 2 trials, we explored
	a number of endpoints. We also analyzed the data from our Phase 2 clinical trial of vonapanitase in a number of ways, some of which
	were not prespecified. Product candidates such as vonapanitase in Phase 3 clinical trials may fail to demonstrate sufficient efficacy
	despite having progressed through initial clinical trials, even if certain non-prespecified analyses of primary or secondary endpoints
	in those early trials showed trends toward efficacy or, in some analyses, statistical significance. Companies frequently suffer
	significant setbacks in late-stage clinical trials due to lack of efficacy, manufacturing or formulation changes or adverse safety
	profiles, even after earlier clinical trials have shown promising results. During the course of our clinical development, we modified
	our vonapanitase finished product formulation for our Phase 3 trials and commercial launch in order to facilitate ease of administration
	and fill and finish of vials at our 30 microgram dose. Our formulation changes could adversely affect results in our clinical trials,
	requiring us to make further formulation changes. Additional changes could cause us to delay or repeat clinical trials, or could
	cause FDA to request additional studies or data, and we could incur unexpected costs that would have an adverse effect on our business,
	operating results and prospects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 68 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The design of a clinical trial can determine whether
	its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical
	trial is well advanced or completed. Proteon has limited experience in designing clinical trials and may be unable to design and
	execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying
	interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies
	and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the
	results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities
	may disagree and may not grant marketing approval of vonapanitase or any additional product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In some instances, there can be significant variability
	in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including
	changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and
	adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Any Phase 3 or other clinical
	trial that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market vonapanitase
	or any additional product candidate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Any delay or failure in our clinical trials would
	delay our obtaining, or make us unable to obtain, applicable regulatory approvals, which would prevent us from commercializing
	vonapanitase or any additional product candidates, generating revenues and achieving and sustaining profitability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If clinical trials of vonapanitase or any additional product candidates
	fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable foreign regulators, we may incur additional
	costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of vonapanitase
	or any additional product candidates.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We are not permitted to commercialize, market,
	promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable foreign
	regulatory authorities, such as the EMA, impose similar restrictions. We may never receive these regulatory approvals. We must
	have completed extensive preclinical development and clinical trials to demonstrate the safety and efficacy of the product candidate
	in humans before we will be able to obtain these approvals. Clinical testing is expensive, is difficult to design and implement,
	can take many years to complete and is inherently uncertain as to outcome.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 69 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Any inability to successfully complete clinical
	development could result in additional costs to us and impair our ability to generate revenues from product sales, regulatory and
	commercialization milestones and royalties. If, following submission, our BLA is not accepted for substantive review or approved,
	the FDA may require that we conduct additional clinical or preclinical trials, manufacture additional validation batches or develop
	additional analytical test methods before it will reconsider our application. If the FDA requires additional studies or data, we
	would incur increased costs and delays in the marketing approval process, which may require us to expend more resources than we
	have available. In addition, the FDA may not consider any additional required trials that we perform and complete to be sufficient.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition, if (1) we are required to conduct
	additional clinical trials or other testing of or generate data pertaining to vonapanitase beyond the trials and testing that we
	contemplate, (2) we are unable to successfully complete clinical trials or other testing of vonapanitase or any additional product
	candidates, (3) the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (4) there are
	unacceptable safety concerns associated with vonapanitase or any additional product candidates, we, in addition to incurring additional
	costs, may:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	be delayed in obtaining marketing approval for vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	not obtain marketing approval at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	obtain approval for indications or patient populations that are not as broad as we intended or desired;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	be subject to additional post-marketing testing or other requirements; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	be required to remove the product from the market after obtaining marketing approval.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In general, the FDA requires two adequate and
	well-controlled clinical trials to demonstrate the effectiveness of a product candidate. If the results of our first Phase 3 clinical
	trial are sufficiently compelling, we intend to meet with the FDA to discuss the possibility of submitting a BLA supported by the
	single Phase 3 trial and may decide to submit a BLA to the FDA prior to completing the second Phase 3 trial. If we attempt to rely
	on a single Phase 3 trial to demonstrate the effectiveness of vonapanitase, the usual demonstration of the statistical significance
	in the primary efficacy endpoint (p=0.05) is unlikely to be sufficient to obtain approval of vonapanitase, and we would likely
	be required to demonstrate more robust statistical significance. Even with a robust p-value, the FDA may not consider the results
	of the single Phase 3 trial to be sufficient for BLA filing or approval, and may require that we complete our second Phase 3 trial
	or that we even conduct additional trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 70 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may be unable to obtain regulatory approval for vonapanitase
	or any additional product candidates under applicable regulatory requirements. The denial or delay of any approvals would prevent
	or delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results
	of operations.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Vonapanitase and any additional product candidates are subject to extensive governmental regulations relating to, among
	other things, research, clinical trials, approval, manufacturing, recordkeeping, labeling, storage, advertising, promotion, distribution,
	import, export and commercialization. In order to obtain regulatory approval for the commercial sale of any product candidate,
	we must demonstrate through extensive preclinical studies and clinical trials that the product candidate is safe and effective
	for use in each target indication. Failure to obtain marketing approval for a product candidate will prevent us from commercializing
	the product candidate. Vonapanitase is still in development and is subject to the risks of failure inherent in drug or biologic
	development. We have not received approval to market any product candidate from regulatory authorities in any jurisdiction. We
	have only limited experience in conducting and managing the clinical trials, and in submitting and supporting the applications
	necessary to gain marketing approvals, and we expect to rely on third-parties, including clinical research organizations, or CROs,
	to assist us in this process. Securing marketing approval also requires the submission of information about the product manufacturing
	process to, and inspection of manufacturing facilities and clinical trial sites by, the regulatory authorities. Vonapanitase may
	not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other
	characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. We may gain regulatory approval
	for vonapanitase or any additional product candidates in some but not all of the territories available or some but not all of the
	target indications, resulting in limited commercial opportunity for the product, or we may never obtain regulatory approval for
	vonapanitase or any additional product candidates in any jurisdiction.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The process of obtaining marketing approvals,
	both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval
	is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the
	product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment
	of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays
	in the approval or rejection of an application. The FDA and foreign regulatory authorities also have substantial discretion in
	the drug and biologics approval process. The number and types of preclinical studies and clinical trials that will be required
	for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed
	to address, and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and
	amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development
	and may vary among jurisdictions, and there may be varying interpretations of data obtained from preclinical studies or clinical
	trials, either of which may cause delays or limitations in the approval or the decision not to approve an application. Regulatory
	agencies can delay, limit or deny approval of a product candidate for many reasons, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	IRBs, the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indications;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	FDA Advisory Committee or other regulatory authority may recommend non-approval or restrictions on approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the results of later-stage clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign regulatory authorities for approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the results of later-stage clinical trials may not confirm the positive results from earlier preclinical studies or clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the data collected from clinical trials of vonapanitase or any additional product candidate may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA, or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our manufacturing processes or facilities may not be adequate to support approval of our product candidates; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	regulatory agencies may change their approval policies or adopt new regulations in a manner rendering our clinical data insufficient for approval.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	It is possible that neither vonapanitase nor any
	product candidates we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us
	or any future collaborators to commence product sales. We do not know whether any clinical trials will begin as planned, or will
	be revised prior to or during the conduct of the study, completed on time or conducted at all. Any delay in obtaining, or failure
	to obtain, required approvals would materially adversely affect our ability to generate revenue from the particular product candidate,
	which likely would result in significant harm to our financial position and adversely impact our stock price.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 72 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may face difficulty in enrolling patients for clinical trials.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We may find it difficult to enroll patients in
	our clinical trials, which could delay or prevent completion of clinical trials of vonapanitase or any additional product candidates.
	We have never previously limited a trial to patients undergoing a surgical procedure to create a radiocephalic AVF, as we are doing
	in our ongoing and planned Phase 3 trials. Identifying and qualifying patients to participate in clinical trials of vonapanitase
	or any additional product candidates are critical to our success. The timing of our clinical trials depends on the speed at which
	we can recruit patients to participate in testing product candidates. The enrollment timeline for radiocephalic AVF patients is
	lengthy and there are a limited number of sites from which we can enroll pre-hemodialysis or hemodialysis patients. If patients
	are unwilling to participate in our trials because of negative publicity from adverse events or for other reasons, including competitive
	clinical trials for similar patient populations, the timeline for recruiting patients, conducting trials and obtaining regulatory
	approval of potential products may be delayed or prevented. These delays could result in increased costs, delays in advancing our
	product development, delays in testing the effectiveness of our technology or termination of the clinical trials altogether. We
	may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics
	to achieve diversity in a trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by numerous
	factors including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	severity of the disease under investigation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	design of the trial protocol;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	size and nature of the patient population;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	eligibility criteria for the trial in question;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	perceived risks and benefits of the product candidate under study;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	proximity and availability of clinical trial sites for prospective patients;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	availability of competing therapies and clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	efforts to facilitate timely enrollment in clinical trials;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to obtain and maintain subject consents and the risk that enrolled subjects will drop out or be withdrawn from our studies;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	patient referral practices of physicians; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	ability to monitor patients adequately during and after treatment and the ability of subjects to comply with the clinical trial procedures.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We may not be able to initiate or continue clinical
	trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by regulatory
	agencies. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need
	to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 73 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If we experience any of a number of possible unforeseen events
	in connection with clinical trials of vonapanitase or any additional product candidates, potential marketing approval or commercialization
	of vonapanitase or any additional product candidates could be delayed or prevented.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If we experience delays in clinical testing, we
	will be delayed in obtaining regulatory approvals and commercializing our product candidates, our costs may increase and our business
	may be harmed. We do not know whether any future clinical trials that have not started will begin as planned, whether the design
	will be revised prior to or during conduct of the study, completed on schedule or conducted at all. Our product development costs
	will increase if we experience delays in clinical testing. Significant clinical trial delays also could shorten any periods during
	which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market
	before we do, which would impair our ability to successfully commercialize our product candidates and may harm our business, results
	of operations and prospects. We may experience numerous unforeseen events during, or as a result of, clinical trials that could
	delay or prevent marketing approval of vonapanitase or any additional product candidates, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	trials of vonapanitase or any additional product candidates may produce unfavorable or inconclusive results;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our third-party contractors, including those manufacturing vonapanitase or any additional product candidates or components or ingredients for commercial use or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	regulators or institutional review boards may not authorize us or our investigators to commence or continue to conduct a clinical trial at a prospective trial site;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may have to suspend or terminate clinical trials of vonapanitase or any additional product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of a product candidate;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their respective standards of conduct, a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar biologic or biologic candidate;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 74 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may experience delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and/or Contract Research Organizations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may experience withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to participate in our clinical trials, and may further be delayed in trying to add clinical trial sites to our studies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may experience delays in the importation and manufacture of clinical supply;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	patient enrollment in these clinical trials may be slower than we anticipate and is limited to a select number of sites, which could cause significant delays given the prolonged enrollment period;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	participants may drop out of clinical trials of vonapanitase at a higher rate than we anticipate and we may not be able to obtain the follow up data for the 12 month period planned in our Phase 3 trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	patients who enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the clinical trial or increase the needed enrollment size for the clinical trial beyond the 300 proposed for each Phase 3 trial, all of which may extend the clinical trial&#8217;s duration;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design, implementation, or our interpretation of data from preclinical studies and clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	FDA or comparable foreign regulatory authorities may find that our clinical trials were not conducted in accordance with Good Clinical Practices, or GCPs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial supplies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our finished product that has been manufactured for the vonapanitase Phase 3 trials may be inadequate, or the materials or manufactured product candidates necessary to conduct future clinical trials of vonapanitase or any additional product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may lack adequate funding to continue the clinical trials or to pay FDA&#8217;s substantial user fees; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Product development costs for us will increase
	if we experience delays in testing or pursuing marketing approvals, and we may be required to obtain additional funds to complete
	clinical trials and prepare for possible commercialization of vonapanitase or any additional product candidates. We do not know
	whether any future clinical trials that have not yet started will begin as planned, will need to be restructured or will be completed
	on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive
	right to commercialize vonapanitase or any additional product candidates or allow our competitors to bring products to market before
	we do and impair our ability to successfully commercialize vonapanitase or any additional product candidates and may harm our business
	and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to
	the denial of marketing approval of vonapanitase or any additional product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Any product for which we obtain FDA approval will be subject to
	extensive ongoing regulatory requirements, and we may be subject to penalties if we fail to comply with regulatory requirements
	or if we experience unanticipated problems with our products, when and if any of them are approved.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Any product for which we obtain marketing approval,
	along with the manufacturing processes, post-approval clinical research, labeling, advertising and promotional activities for the
	product, will be subject to continual requirements of, and review by, the FDA and comparable regulatory authorities. These requirements
	include submissions of safety and other post-marketing information and reports, tracking, tracing, and investigation, notification,
	disposition obligations under the Drug Quality and Security Act, registration and listing requirements, current good manufacturing
	practices, or cGMPs, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of
	records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. The FDA and comparable
	foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA
	or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates,
	they may withdraw approval, require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions
	on a product&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or
	post-market surveillance.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Even if regulatory approval of a product is granted,
	the approval will be subject to limitations on the indicated uses for which the product may be marketed and may be subject to other
	conditions of approval. We and our contract manufacturers will be subject to periodic unannounced inspections by the FDA to monitor
	and ensure compliance with cGMPs and other regulatory requirements. In addition, approval may contain requirements for costly post-marketing
	testing and surveillance to monitor the safety or efficacy of the product. Discovery after approval of previously unknown problems
	with any such products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result
	in actions such as:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	restrictions on a product&#8217;s manufacturing processes;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	restrictions on the marketing of a product;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	restrictions on product distribution;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	requirements to conduct post-marketing clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Untitled, Cyber, or Warning Letters from the FDA or similar correspondence from comparable regulatory authorities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	withdrawal of the products from the market;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	refusal to approve pending applications or supplements to approved applications that we submit;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	recall of products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	mandated modifications to promotional materials or require us to provide corrective information to healthcare practitioners;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	requirements to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	debarring us pursuant to the FDCA, excluding us from participation in federal healthcare programs, requiring a corporate integrity agreement or debarring us from government contracts;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the imposition of costly new manufacturing requirements or use of alternative suppliers, requiring additional warnings on the label;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	FDA or other regulatory bodies issuing safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	fines, restitution or disgorgement of profits or revenue;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	suspension or withdrawal of regulatory approvals or refusal to approve future or pending applications or supplements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	refusal to permit the import or export of our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	product seizure;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	injunctions; and/or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	imposition of civil or criminal penalties.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.3PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Accordingly, assuming we receive marketing approval
	for vonapanitase or any additional product candidates, we and our contract manufacturers will continue to expend time, money and
	effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies
	and quality control.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Vonapanitase may cause undesirable side effects or have other
	properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling, or result
	in significant negative consequences following any potential marketing approval.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As with many pharmaceutical and biological products,
	treatment with vonapanitase or any additional product candidates may produce undesirable side effects or adverse reactions or events.
	These adverse events may occur despite our belief, based on our preclinical and clinical trials to date, that vonapanitase has
	a favorable safety profile. For instance, vonapanitase shows a high degree of structural similarity with other human serine proteases,
	which are proteins that cut other proteins to activate, inactivate or degrade these other proteins, and it is theoretically possible
	that if anti-vonapanitase antibodies are developed that they could cross-react with one or more of those other proteases because
	of the structural similarity, and prompt an adverse reaction. However, we have not seen any evidence of such cross-reactivity in
	our preclinical or clinical trials to date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Based on our Phase 2 trial, adverse side effects
	that could occur with treatment with vonapanitase include AVF surgical incision pain, venous stenosis, procedural pain, AVF thrombosis,
	steal syndrome and hypoesthesia. If any of these adverse events occur in rates or severity exceeding placebo and unacceptable to
	regulatory authorities or IRBs, if anti-vonapanitase antibodies develop and are associated with cross-reactivity to other proteases,
	or unknown serious events emerge, our clinical trials could be suspended or terminated by us, IRBs, or the applicable regulatory
	authorities, and the FDA, the EMA or other foreign regulatory authorities could order us to cease further development of, or deny
	approval of, vonapanitase or any additional product candidates for any or all targeted indications. The product-related side effects
	could affect patient recruitment or the ability of enrolled patients to complete the trial. If we elect or are required to delay,
	suspend or terminate any clinical trial of vonapanitase or any additional product candidates, the commercial prospects of these
	product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed
	or eliminated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition, even if we were to obtain approval,
	regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including
	more limited patient populations, may require that contraindications, warnings or precautions be included in the product labeling,
	including a black-box warning, may grant approval contingent on the performance of costly post-marketing clinical trials or other
	post-market requirements, or may approve a product candidate with a label that does not include the labeling claims necessary or
	desirable for the successful commercialization of that product candidate. Any of these occurrences may harm our business, financial
	condition and prospects significantly.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 78 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	78
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may not be able to maintain orphan drug designation or obtain
	or maintain orphan drug exclusivity for vonapanitase.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We have obtained orphan drug designation from
	the FDA for vonapanitase. In the United States, under the Orphan Drug Act, the FDA may designate a product as an orphan drug if
	it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals
	in the United States. The first NDA or BLA applicant to receive FDA approval for a particular drug or biologic to treat a particular
	disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product,
	for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same
	drug or biologic for the same disease, except in limited circumstances. Orphan drug exclusivity may be lost if the FDA determines,
	among other reasons, that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
	quantity of the product to meet the needs of patients with the rare disease or condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Even if we obtain orphan drug exclusivity for
	vonapanitase, that exclusivity may not effectively protect the product from competition because different products can be approved
	for the same condition. Even after an orphan product is approved, the FDA can subsequently approve a product containing the same
	principal molecular features for the same condition if the FDA concludes that the later product is clinically superior in that
	it is shown to be safer, more effective or makes a major contribution to patient care.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In response to a recent court decision regarding
	the plain meaning of the exclusivity provision of the Orphan Drug Act, the FDA may undertake a reevaluation of aspects of its orphan
	drug regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies, and
	it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations
	and policies, our business could be harmed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	79
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
<B>
<I>
	A fast track product, priority
	review, or other designation by the FDA for our product candidates may not lead to faster development or regulatory review or
	approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We have received a fast track product designation
	for vonapanitase for improving vascular access and decreasing the need for surgery in patients with CKD who are on hemodialysis
	or being prepared for hemodialysis. As applicable, we may seek fast track, priority review, or other designations for other uses
	of vonapanitase. A fast track product designation is designed to facilitate the clinical development and expedite the review of
	drugs and biologics intended to treat a serious condition which demonstrate the potential to address an unmet medical need. Priority
	review designation is intended to speed the FDA marketing application review timeframe for drugs and biologics that treat a serious
	condition and, if approved, would provide a significant improvement in safety or effectiveness. For drugs and biologics that have
	been designated as fast track products, interaction and communication between the FDA and the sponsor of the trial can help to
	identify the most efficient path for clinical development. Sponsors of drugs and biologics designated as fast track products therapies
	may also be able to submit marketing applications on a rolling basis, meaning that the FDA may review portions of a marketing application
	before the sponsor submits the complete application to the FDA, as long as the sponsor pays the user fee upon submission of the
	first portion of the marketing application. For products that receive a priority review designation, the FDA&#8217;s marketing
	application review goal is shortened to six months, as opposed to ten months under standard review. This review goal is based on
	the date the FDA accepts the marketing application for review, which typically adds two months to the timeline for review and decision
	from the date of submission.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Designation as a fast track product, priority
	review product, or under another program is within the discretion of the FDA. Accordingly, even if we believe one of our product
	candidates meets the criteria for designation as a fast track product, priority review product, or other designation, the FDA may
	disagree and instead determine not to make such designation. In any event, the receipt of either designation for a product candidate
	may not result in a faster development process, review or approval compared to drugs and biologics considered for approval under
	conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that
	the products no longer meet the conditions for qualification as a fast track product or under another designation program or decide
	that the time period for FDA review or approval will not be shortened.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may expend our limited resources to pursue a particular product
	candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there
	is a greater likelihood of success.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Because we have limited financial and managerial
	resources, we have focused on developing one product candidate, vonapanitase, and have focused on developing this product candidate
	for specific indications that we identify as most likely to succeed, in terms of both its regulatory approval and commercialization.
	As such, we are currently primarily focused on the development of vonapanitase for vascular access, and our Phase 3 trials will
	be limited to the application of vonapanitase in radiocephalic AVFs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	80
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In the future we intend to pursue additional indications
	such as the application of vonapanitase in brachiocephalic AVF creation and/or patients undergoing placement of an AVG and/or patients
	with symptomatic PAD. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications
	that may prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable
	commercial products or profitable market opportunities. Our spending on current and future research and development programs and
	product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the
	commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate
	through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to
	retain sole development and commercialization rights to such product candidate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Even if we obtain and maintain approval for vonapanitase or additional
	product candidates from the FDA, we may never obtain approval for vonapanitase or additional product candidates outside of the
	United States, which would limit our market opportunities and adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Even if we obtain approval of a product candidate
	in the United States from the FDA, such approval does not ensure approval of that product candidate by regulatory authorities in
	other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities
	in other foreign countries or by the FDA. Sales of vonapanitase or any additional product candidates outside of the United States
	will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing
	approval for a product candidate, comparable regulatory authorities of foreign countries must also approve the manufacturing and
	marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements
	and administrative review periods different from, and greater than, those in the United States, including additional preclinical
	studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement
	before it can be approved for sale in that country. In some cases, the price that we intend to charge for our products, if approved
	for sale, is also subject to approval. Moreover, the failure to obtain approval in one jurisdiction may negatively impact our ability
	to obtain approval in another jurisdiction.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Based on additional data including the data from
	our Phase 3 clinical trials and assuming sufficient funds become available, we plan to commence a clinical trial of vonapanitase
	in Europe for patients undergoing creation of radiocephalic AVFs. Prior to enrolling our first patient in Europe, we plan to formally
	seek guidance from the EMA regarding its requirements for regulatory approval. We expect results from this trial to be available
	two to three years after the first patient is enrolled. If results of this European trial successfully meet its primary endpoint
	and depending on the guidance obtained from the EMA, we would expect to submit a Marketing Authorization Application, or MAA, following
	our receipt of the trial results. Obtaining an approval is a lengthy and expensive process and the EMA has its own procedures for
	approval of product candidates. Even if a product candidate is approved, the EMA may limit the indications for which the product
	may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or
	reporting as conditions of approval. Regulatory authorities in countries outside of the United States and Europe also have requirements
	for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory
	approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us
	and could delay or prevent the introduction of vonapanitase or any additional product candidates in those countries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 81 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	81
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Advertising and promotion of any product candidate that obtains
	approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human
	Services&#8217; Office of Inspector General, state attorneys general, members of Congress and the public.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	While the FDA does not restrict physicians from
	prescribing approved drugs and biologics for uses outside of the products&#8217; approved labeling, known as off-label use, pharmaceutical
	manufacturers are prohibited from promoting and marketing their products for such uses. Violations, including promotion of our
	products for off-label uses, are subject to enforcement letters, inquiries, investigations, civil and criminal sanctions by the
	government, corporate integrity agreements, debarment from government contracts, debarment and exclusion from participation in
	federal healthcare programs. Additionally, comparable foreign regulatory authorities will heavily scrutinize advertising and promotion
	of any product candidate that obtains approval outside of the United States.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In the United States, engaging in the impermissible
	promotion of our products for off-label uses can also subject us to false claims litigation under federal and state statutes, which
	can lead to civil and criminal penalties and fines, debarment from government contracts, exclusion from participation in federal
	healthcare programs and corporate integrity agreements with governmental authorities that materially restrict the manner in which
	a company promotes or distributes drug and biologic products. These false claims statutes include the federal civil False Claims
	Act, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging
	submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program
	such as Medicare or Medicaid. If the government decides to intervene and prevails in the lawsuit, the individual will share in
	any fines or settlement funds. If the government does not intervene, the individual may proceed on his or her own. Since 2004,
	these False Claims Act lawsuits against pharmaceutical companies have increased significantly in volume and breadth, leading to
	several substantial civil and criminal settlements regarding certain sales practices promoting off-label product uses involving
	fines that are as much as $3.0 billion.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 82 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	82
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	This growth in litigation has increased the risk
	that a pharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with
	burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid and other federal and state healthcare
	programs. If we do not lawfully promote our approved products, we may become subject to such litigation and, if we do not successfully
	defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of
	operations and prospects. The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent,
	limit or delay marketing approval, and the sale and promotion of our product candidates. If we are slow or unable to adapt to changes
	in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance,
	we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability
	to achieve or sustain profitability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If we are found in violation of federal or state &#8220;fraud
	and abuse&#8221; laws or other healthcare laws and regulations, we may be required to pay a penalty and/or be suspended from participation
	in federal or state healthcare programs, which may adversely affect our business, financial condition and results of operation.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We may also be subject to various federal and
	state laws pertaining to healthcare "fraud and abuse," including anti-kickback laws and false claims laws. Anti-kickback
	laws make it illegal for a prescription drug or biologic manufacturer to solicit, offer, receive or pay any remuneration in exchange
	for, or to induce, the referral of business, including the purchase or prescription of a particular drug or biologic. Other laws
	that we may be subject to include the civil False Claims Act, criminal False Claims Act, the HIPAA fraud and abuse provisions,
	the Civil Monetary Penalties statute, Section 1927 of the Social Security Act, the Veterans Health Care Act, the Foreign Corrupt
	Practices Act, federal and state statutes and regulations pertaining to payments made to physicians and other health care providers,
	the HIPAA privacy and security provisions, and other analogous state laws. Due to the breadth of the statutory provisions, it is
	possible that our practices might be challenged under anti-kickback, healthcare, or other fraud and abuse laws. Moreover, recent
	healthcare reform legislation has strengthened these laws. For example, the recently enacted Patient Protection and Affordable
	Care Act, or ACA, among other things, amends the intent requirement of the federal anti-kickback and certain of the criminal healthcare
	fraud statutes to clarify that a person or entity does not need to have actual knowledge of this statute or specific intent to
	violate it. In addition, the ACA clarifies that the government may assert that a claim that includes items or services resulting
	from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the civil False Claims
	Act. False claims laws prohibit anyone from knowingly and presenting, or causing to be presented for payment, to government third-party
	payors (including Medicare and Medicaid) claims for reimbursed drugs, or biologics or services that are false or fraudulent, claims
	for items or services not provided as claimed, or claims for medically unnecessary items or services. Liability may also arise
	from false certification of compliance with laws and regulations that are conditions of payment. Our activities relating to the
	sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws, and other healthcare
	statutes are punishable by criminal and civil sanctions, including fines and civil monetary penalties, the possibility of exclusion
	from federal healthcare programs (including Medicare and Medicaid) and corporate integrity agreements, which impose, among other
	things, rigorous operational and monitoring requirements on companies. We may further be subject to such other actions as debarment
	from government contracts and future orders under existing contracts, refusal to allow us to enter into supply contracts, including
	government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations,
	any of which could adversely affect our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 83 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	83
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Given the significant penalties and fines that
	can be imposed on companies and individuals if convicted or found liable, allegations of violations under fraud and abuse laws
	often result in settlements even if the company or individual being investigated admits no wrongdoing. Settlements often include
	significant civil sanctions, including fines and civil monetary penalties, and corporate integrity agreements. If the government
	were to allege or convict us or our executive officers of violating these laws, our business could be harmed. In addition, private
	individuals have the ability to bring similar actions under the False Claims Act. Our activities could be subject to challenge
	for the reasons discussed above and due to the broad scope of these laws and the increasing attention being given to them by law
	enforcement authorities. Further, an increasing number of state laws require manufacturers to make reports to states on pricing
	and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. Given the lack
	of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent
	state authorities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Similar rigid restrictions are imposed on the
	promotion and marketing of medicinal products in the European Union and other countries. Laws (including those governing promotion,
	marketing and anti-kickback provisions), industry regulations and professional codes of conduct often are strictly enforced. Even
	in those countries where we are not directly responsible for the promotion and marketing of our products, inappropriate activity
	by our international distribution partners can have adverse implications for us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may not be able to comply with requirements of foreign jurisdictions
	in conducting trials outside of the United States.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	To date, we have not conducted any clinical trials
	outside of the United States. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country,
	should we attempt to do so, is subject to numerous risks unique to conducting business in foreign countries, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	difficulty in establishing or managing relationships with contract research organizations, or CROs, and physicians;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	different standards for the conduct of clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our inability to locate qualified local consultants, physicians and partners;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the acceptability of data obtained from trials conducted outside the United States to the FDA in support of a BLA.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
	Risks Related to Commercialization
	of Our Product
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If we are unable to establish effective marketing and sales capabilities
	or enter into agreements with third parties to market and sell our product candidates, if they are approved, we may be unable to
	generate product revenues.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We currently do not have a commercial infrastructure
	for the marketing, sale and distribution of biological products. If approved, in order to commercialize our products, we must build
	our marketing, sales and distribution capabilities or make arrangements with third parties to perform these services. We may not
	be successful in doing so. If vonapanitase is approved by the FDA, we plan to build a specialty sales force in the United States
	of approximately 75-100 representatives, supported by reimbursement specialists and a medical affairs team. We may seek to further
	penetrate the United States market in the future by expanding our sales force or through collaborations with other pharmaceutical
	or biotechnology companies or third party manufacturing and sales organizations. If approved for marketing outside the United States,
	we may commercialize outside the United States with our own specialty sales force and/or with a commercial partner.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 84 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	84
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As a company we have no prior experience in the
	marketing, sale and distribution of biological products, and there are significant risks involved in the building and managing
	of a commercial infrastructure. The establishment and development of our own sales force and related compliance plans to market
	any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to
	successfully develop this capability. We, or our future collaborators, will have to compete with other companies to recruit, hire,
	train, manage and retain marketing and sales personnel. In the event we are unable to develop a marketing and sales infrastructure,
	we may not be able to commercialize vonapanitase or any additional product candidates, which would limit our ability to generate
	product revenues. Our ability to generate product revenues would be impaired by:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our inability to recruit, train, manage and retain adequate numbers of effective sales and marketing personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the inability of sales personnel to obtain access to vascular surgeons or persuade adequate numbers of vascular surgeons to use vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our inability to effectively oversee a geographically dispersed sales and marketing team;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the costs associated with training sales personnel on legal compliance matters and monitoring their actions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	liability for sales personnel failing to comply with the applicable legal requirements; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Although our current plan is to hire most of our
	sales and marketing personnel only if vonapanitase is approved by the FDA, we will incur expenses prior to product launch in recruiting
	this sales force and developing a marketing and sales infrastructure. If the commercial launch of vonapanitase is delayed as a
	result of FDA requirements or other reasons, we would incur these expenses prior to being able to realize any revenue from sales
	of vonapanitase. Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales
	force and marketing teams may not be successful in commercializing vonapanitase or any additional product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In the event we are unable to hire a sales force
	or collaborate with a third-party marketing and sales organization to commercialize any approved product candidates outside the
	United States, our ability to generate product revenues may be limited. To the extent we rely on third parties to commercialize
	any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves.
	In addition, we would have less control over the sales efforts of any other third parties involved in our commercialization efforts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Even if vonapanitase or any additional product candidates receive
	regulatory approval, they may fail to achieve the broad degree of physician adoption and use necessary for commercial success.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 85 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	85
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The commercial success of vonapanitase and any
	product candidates that we may develop will depend upon the degree of market acceptance by physicians, patients, healthcare payors
	and others in the medical community. Even if the FDA approves vonapanitase or one or more of our future product candidates, physicians
	and patients may not accept and use them. Acceptance and use of any of our products will depend upon a number of factors including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products, and their advantages as compared to any competitive products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the timing of market introduction of the product candidate as well as competitive products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the clinical indications for which the product candidate is approved;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any restrictions on or warnings regarding the use of the products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	cost-effectiveness of our products relative to any competing products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	availability of timely coverage and reimbursement for our products from government or other third-party payors; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	effectiveness of marketing and distribution efforts by us and any our licensees and distributors.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Because we expect sales of vonapanitase, if approved,
	to generate substantially all of our product revenues for the foreseeable future, the failure of vonapanitase to gain market acceptance
	would harm our business and would require us to seek additional financing.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Vonapanitase or any additional product candidates, if approved,
	may face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration
	and expansion.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The biotechnology and pharmaceutical industries
	are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face
	potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, biotechnology and
	medical device companies, academic institutions, governmental agencies and public and private research institutions. While we believe
	that vonapanitase&#8217;s features, safety and efficacy will differentiate it from any competitive products that may become available
	in the future, we expect to face potential competition from many different sources, including larger and better-funded pharmaceutical,
	specialty pharmaceutical and biotechnology companies and medical device companies, as well as from academic institutions and governmental
	agencies and public and private research institutions that may develop potentially competitive products or technologies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 86 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	86
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Some of our competitors have significantly greater
	financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
	obtaining regulatory approvals, marketing and selling approved products than we do. Smaller or early stage companies may also prove
	to be significant competitors, particularly through collaborative arrangements with large and established companies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The key competitive factors affecting the success
	of vonapanitase, if approved, are likely to be its efficacy, safety, convenience, price, and the availability of reimbursement
	from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors develop
	and commercialize products that are safer, more effective, more convenient or less expensive than any products that we may develop.
	Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for
	ours.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We are not aware of any therapeutic products approved
	in the United States or Europe for the prevention of vascular access failure. We are aware of therapies in development with companies,
	including Vascular Therapies and Symic Biomedical. Vonapanitase could face competition from companies developing vascular access
	technologies, including BioConnect Systems, Avenu Medical, Phraxis, CreatiVasc, Laminate Medical Technologies, Stent Tek and TVA
	Medical. Other potentially competitive products include new synthetic grafts, including those that may be developed by companies
	that currently compete in the graft market, such as W.L. Gore, C.R. Bard and Maquet, as well as tissue engineered grafts, including
	those in development by Cytograft and Humacyte. Finally, vonapanitase&#8217;s commercial success could be affected by the development
	of technologies to improve the outcomes of interventions to restore patency, including stents, stent grafts and drug-coated balloons.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Vonapanitase, or any additional product candidates for which we
	seek approval as biologic products, may face competition sooner than anticipated.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The enactment of the Biologics Price Competition
	and Innovation Act of 2009, or BPCIA, as part of the ACA, created an abbreviated pathway for the approval of biosimilar and interchangeable
	biological products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar
	biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing
	brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the
	original branded product was approved under a BLA. Certain changes, however, and supplements to an approved BLA, and subsequent
	applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify
	for the 12-year exclusivity period. Moreover, President Obama's proposed budget for fiscal year 2017 proposes cutting this twelve
	year period of exclusivity down to seven years. President Obama also proposed to prohibit additional periods of exclusivity for
	brand biologic products due to minor changes in product formulation, a practice often referred to as &#8220;evergreening
<B>
	.&#8221;
</B>
	The Trans-Pacific Partnership international trade agreement further includes exclusivity provisions for biologics that would
	require member countries not to approve biosimilars before at least 8 years of exclusivity has expired for biologics or, alternatively,
	five years plus other measures to provide effective market protection. Future proposed budgets, international trade agreements
	and other arrangements or proposals may also affect periods of exclusivity in the future. .
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	87
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The law is complex and is still being interpreted
	and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it
	is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have
	a material adverse effect on the future commercial prospects for our biological products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We believe that vonapanitase, or any additional
	product candidates approved as a biological product under a BLA, should qualify for the BPCIA&#8217;s 12-year period of exclusivity.
	However, there is a risk that the FDA will not consider vonapanitase or any additional product candidates to be reference products
	for competing products, potentially creating the opportunity for generic competition sooner than anticipated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Additionally, this period of regulatory exclusivity
	does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway.
	Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that
	is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace
	and regulatory factors that are still developing. It is possible that payers will give reimbursement preference to biosimilars
	even over reference biologics absent a determination of interchangeability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If the government or other third-party payors fail to provide
	adequate timely coverage and payment rates for vonapanitase or any additional product candidates or if surgeons or hospitals choose
	not to use vonapanitase, our revenue and prospects for profitability will be limited.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In both domestic and foreign markets, sales of
	our future products will depend substantially upon the availability of timely coverage and reimbursement from government or other
	third-party payors. The majority of incident and prevalent hemodialysis patients have Medicare coverage, while other patients have
	other third-party payors, including other government health programs such as Medicaid, managed care providers, private health insurers
	and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new drug and biologic
	products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Vonapanitase
	or any additional product candidates, if approved, may face competition from other therapies, biologics, and drugs for limited
	financial resources. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future
	products to the satisfaction of outpatient clinics, hospitals, other target customers and their third-party payors. These post-marketing
	studies might require us to commit a significant amount of management time and financial and other resources. Our future products
	might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable
	us to maintain price levels sufficient to realize an appropriate return on investment in product development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 88 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	88
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Third-party payors, whether foreign or domestic,
	or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. Assuming coverage
	is approved, the resulting reimbursement payment rates might not be adequate to allow us to establish or maintain a market share
	sufficient to realize a sufficient return on our investments. If reimbursement is not available, or is available only to limited
	levels, our product candidates may be competitively disadvantaged, and we, or our collaborators, may not be able to successfully
	commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing
	and prevent us from realizing an adequate margin over cost. In addition, in the United States, no uniform policy of coverage and
	reimbursement for drug and biologic products exists among third-party payors. Therefore, coverage and reimbursement for drug and
	biologic products can differ significantly from payor to payor. Further, we believe that future coverage and reimbursement will
	likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement
	for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the
	United States or international markets, which could have a negative effect on our business, results of operations, financial condition
	and prospects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Government programs impose price controls on pharmaceutical
	and biological products and penalties for increasing commercial prices at rates that exceed the government inflation index, which
	may limit the commercial price we charge and our realization on sales. Further, the net reimbursement for drug and biologic products
	may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs and biologics from
	countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate
	payment rates from both government-funded and private payors for any our product candidates for which we obtain marketing approval
	could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and
	our overall financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 89 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	89
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
	Risks Related to Dependence
	on Third Parties
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We and our contract manufacturers are subject to significant regulation
	with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory
	requirements and have limited capacity.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We currently have a relationship with only one
	supplier, Lonza, for the manufacturing of the API for vonapanitase for clinical testing purposes, and intend to continue to use
	Lonza as our sole or primary supplier in the future. We have used two companies, Jubilant HollisterStier and Patheon Manufacturing
	Services Inc. (formerly DSM Pharmaceuticals), to vial and make our vonapanitase finished product. We also expect to rely upon third
	parties to produce materials required for the commercial production of vonapanitase or any additional product candidates if we
	succeed in obtaining the necessary regulatory approvals. This may increase the risk that we will not have sufficient quantities
	of our product candidates to conduct our clinical trials or such quantities at an acceptable cost, which could result in the delay,
	prevention, or impairment of clinical development and commercialization of our product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	All entities involved in the preparation of drugs
	or biologics for clinical trials or commercial sale, including our existing contract manufacturers, are subject to extensive regulation.
	Ingredients of a finished therapeutic biologic product approved for commercial sale or used in clinical trials must be manufactured
	in accordance with cGMPs and equivalent foreign standards. These regulations govern manufacturing processes and procedures (including
	record-keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products
	and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other
	contaminants, or to inadvertent changes in the properties or stability of product candidate that may not be detectable in final
	product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis
	and must adhere to the FDA&#8217;s cGMPs regulations enforced by the FDA through its facilities inspection program. Any failure
	by our third-party manufacturers to comply with cGMPs, or failure to scale-up manufacturing processes, including any failure to
	deliver sufficient quantities of product candidates in a timely manner for the process validation required in connection with a
	BLA filing, could lead to a delay in, or failure to obtain, regulatory approval of the manufacturing facility, vonapanitase or
	any additional product candidates. For example, on November 27, 2013, our third-party supplier of finished biological product,
	Jubilant HollisterStier, received a Warning Letter from the FDA alleging that the company was not complying with cGMPs. We received
	a letter from the FDA on February 13, 2014, stating that the Warning Letter does not impact the batch of finished product we intend
	to use for our Phase 3 clinical trials. However, this third party or other third parties could encounter similar difficulties that
	could impede our clinical trials or commercialization.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 90 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	90
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our facilities and quality systems and the facilities
	and quality systems of some or all of our third-party contractors must also pass a pre-approval inspection for compliance with
	the applicable regulations as a condition of regulatory approval of vonapanitase or any additional product candidates. In addition,
	the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product
	candidate or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If
	these facilities and quality systems do not pass a pre-approval plant inspection from the FDA or a comparable foreign authority,
	approval of our product candidate by the FDA or the equivalent approvals in other jurisdictions will not be granted until the regulatory
	authority is satisfied that the facility complies with applicable regulations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Regulatory authorities also may, at any time following
	approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection
	or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable
	regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures
	that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension
	of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed
	upon us or third parties with whom we contract could materially harm our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If we or any of our third-party manufacturers
	fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve
	a pending application for a new drug or biologic product or revocation of a pre-existing approval. If any such event occurs, our
	business, financial condition and results of operations may be materially harmed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Currency fluctuations in the Swiss Franc and changes in exchange
	rates could adversely affect our business by increasing our costs and cause our profitability to decline.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.1PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our contract with Lonza for the manufacturing
	of the API is denominated in Swiss Francs. Therefore, fluctuations in the exchange rate for Swiss Francs may affect our operating
	results. On January 15, 2015, the Swiss National Bank announced an edit to its policy of fixing the Swiss Franc and Euro exchange
	rate, which caused volatility in the currency markets for Swiss Francs and an immediate increase in their value, making our contractual
	payments to Lonza more expensive based on the current exchange rates. In the second quarter of 2015, we entered into forward foreign
	currency contracts to purchase Swiss Francs to reduce our foreign currency exposure under our contract with Lonza. In the future
	we may purchase additional forward foreign currency contracts to hedge certain forecasted transactions, including those with Lonza,
	and reduce exposures to foreign currency fluctuations. Any use of these derivative instruments would be intended to mitigate a
	portion of the exposure of these risks with the intent to reduce our risk or cost, but generally would not fully offset any change
	in operating results as a consequence of fluctuations in foreign currencies. Any significant foreign exchange rate fluctuations
	could adversely affect our financial condition and results of operations and any use of derivative instruments may not offset such
	fluctuations and could exacerbate their impact on our financial condition and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	91
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We rely on third parties to conduct some or all aspects of our
	product manufacturing, protocol development, research, and preclinical and clinical testing, and plan to continue to rely on such
	third parties if we receive marketing approvals. These third parties may not perform satisfactorily.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We do not currently, and do not expect in the
	future, to independently conduct all aspects of our product manufacturing, protocol development, research and monitoring and management
	of our clinical programs. Vonapanitase API is produced by our contract manufacturer, Lonza. Vonapanitase finished product is produced
	by our contract fill/finish provider, Jubilant HollisterStier. Release testing and stability for API and finished product is performed
	by PPD, Inc. We currently rely, and expect to continue to rely, on third parties with respect to these items for our continued
	and future clinical studies as well as for commercialization, if we receive regulatory marketing approval. While we will have agreements
	governing their activities, we will have limited influence over their actual day-to-day performance. Nevertheless, we will be responsible
	for ensuring that the manufacturing is conducted in accordance with regulatory requirements such as cGMPs. Our reliance on the
	third parties does not relieve us of our regulatory responsibilities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Any of these third parties may terminate their
	engagements with us under the terms of our agreements upon notice to us. If we need to enter into alternative arrangements, our
	product candidate development and eventual commercialization activities may be delayed. Our reliance on these third parties for
	research and development activities, and eventual commercial supply, reduces our day-to-day control over these activities but does
	not relieve us of our responsibility to ensure compliance with all required legal, regulatory and scientific standards and any
	applicable trial protocols. For example, for vonapanitase or any additional product candidates that we develop and commercialize
	on our own, we will remain responsible for ensuring that the product is manufactured in accordance with cGMPs, each of our clinical
	trials is conducted in accordance with GCPs and its protocol and is analyzed in accordance with its statistical analysis plan for
	the clinical trial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If these third parties do not successfully carry
	out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our
	protocols, we may be delayed in completing, or unable to complete, the clinical trials required to support future approval of vonapanitase
	or any additional product candidates, and, if ultimately approved for marketing, may not be able to produce a sufficient amount
	of commercial supply.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 13.05PT 0 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 92 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	92
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 13.05PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 13.05PT 0 0">
	We rely on our manufacturers to purchase
	from third-party suppliers the materials necessary to produce our product candidate, vonapanitase, for our clinical trials, and
	eventual commercial supply, if we receive regulatory approval. There are a small number of suppliers for certain raw materials
	that we use to manufacture vonapanitase. These suppliers may not sell these raw materials to our manufacturers at the times we
	need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of these
	raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw
	materials. Although the API and the finished product for each of our Phase 3 trials has already been manufactured and is held in
	storage, we will need supply of finished product as part of the process validation and for any stability or other tests in connection
	with a BLA application and also to conduct additional clinical trials, for example for additional vonapanitase indications. We
	will further require finished product for commercialization if we receive regulatory approval. Any significant delay in the supply
	of vonapanitase&#8217;s ingredients due to the need to replace a third-party manufacturer could considerably delay completion of
	our clinical trials, product testing and potential regulatory approval of vonapanitase or any additional product candidate, and
	commercialization as we believe that replacing Lonza as the manufacturer of our API would take one to two years and replacement
	of any of our other manufactures may take a substantial amount of time. If our manufacturers or we are unable to purchase these
	raw materials after regulatory approval has been obtained for our product candidate, our ability to commercially launch and/or
	generate revenues from the sale of any approved product would be impaired. Reliance on third-party manufacturers entails exposure
	to risks to which we would not be subject if we manufactured the product candidate ourselves, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reduced day-to-day control over the manufacturing process for our product candidates as a result of using third-party manufacturers for all aspects of manufacturing activities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reduced control over the protection of our trade secrets and know-how from misappropriation or inadvertent disclosure;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that may be costly or damaging to us or result in delays in the development or commercialization of our product candidates; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 93 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	93
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Any of these events could lead to delays in the
	development of vonapanitase or any additional product candidates, including delays in our clinical trials, or failure to obtain
	regulatory approval for our product candidates, or it could impact our ability to successfully commercialize vonapanitase or any
	additional product candidates. Some of these events could be the basis for FDA or other regulatory action, including Warning Letters,
	injunction, recall, seizure or total or partial suspension of production. Any of these events could have a material adverse effect
	on our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We rely on third parties to conduct, supervise and monitor our
	clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may
	not be able to obtain regulatory approval for, or commercialize, vonapanitase or any additional product candidates and our business
	could be substantially harmed.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We rely on CROs and clinical trial sites to ensure
	our clinical trials are conducted properly and on time. While we will have agreements governing their activities, we will have
	limited influence over their actual day-to-day performance. Nevertheless, we will be responsible for ensuring that each of our
	clinical trials is conducted in accordance with the applicable protocol, and legal, regulatory and scientific standards and recognize
	that our reliance on the CROs does not relieve us of our regulatory responsibilities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We and our CROs are required to comply with the
	FDA&#8217;s GCPs for conducting, recording and reporting the results of clinical trials to assure that the data and reported results
	are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The
	FDA and comparable foreign regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal
	investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our
	future clinical trials may be deemed unreliable and the FDA, the EMA, or other foreign regulatory authorities may require us to
	perform additional clinical trials before approving any marketing applications. In addition, we are required to report certain
	financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria.
	The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted
	by principal investigators who previously served or currently serve as scientific advisors or consultants to us from time to time
	and receive cash compensation in connection with such services.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Upon inspection, the FDA may determine that our
	clinical trials did not comply with GCPs. In addition, our future clinical trials will require a sufficient number of test subjects
	to evaluate the safety and efficacy of vonapanitase or any additional product candidates. Accordingly, if our CROs fail to comply
	with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which
	would delay the regulatory approval process.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 94 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	94
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our CROs are not our employees, and we are therefore
	unable to monitor on a day-to-day basis whether or not they devote sufficient time and resources to our clinical and nonclinical
	programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also
	be conducting clinical trials or other product development activities that could harm our competitive position. If our CROs do
	not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy
	of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements,
	or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
	approval for, or successfully commercialize, vonapanitase or any additional product candidates. If any such event were to occur,
	we may be subject to regulatory enforcement actions, our financial results and the commercial prospects for vonapanitase or any
	additional product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If any of our relationships with these third-party
	CROs terminates, we may not be able to enter into arrangements with alternate CROs or to do so on commercially reasonable terms.
	Further, switching or adding additional CROs involves additional costs and requires management time and focus. In addition, a transition
	period may be required when a new CRO commences work. As a result, delays may occur, which could materially impact our ability
	to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no
	assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material
	adverse impact on our business, financial condition and prospects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We also rely on other third parties to store and
	distribute our products for the clinical trials that we conduct. Any performance failure on the part of our distributors could
	delay clinical development or marketing approval of vonapanitase or any additional product candidates or commercialization of our
	product, if approved, producing additional losses and depriving us of potential product revenue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may seek to form partnerships in the future with respect to
	vonapanitase or any additional product candidates, and we may not realize the benefits of such partnerships.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 95 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	95
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We may form partnerships, create joint ventures
	or collaborations or enter into licensing arrangements with third parties for the development and commercialization of vonapanitase
	or any additional product candidates. We face significant competition in seeking appropriate strategic partners and the negotiation
	process is time-consuming and complex. Any delays in entering into new strategic partnership agreements related to our product
	candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if
	they reach the market. Moreover, we may not be successful in our efforts to establish a strategic partnership or other collaborative
	arrangement for any additional product candidates because the potential partner may consider that our research and development
	pipeline is insufficiently developed to justify a collaborative effort, or that vonapanitase or any additional product candidates
	and programs do not have the requisite potential to demonstrate safety and efficacy in the target population. Even if we are successful
	in establishing such a strategic partnership or collaboration, we cannot be certain that, following such a strategic transaction
	or license, we will be able to progress the development and commercialization of the applicable product candidates as envisioned,
	or that we will achieve the revenues that would justify such transaction.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
	Risks Related to Our Intellectual
	Property
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If our efforts to protect our intellectual property related to
	vonapanitase or any additional product candidates are not adequate, we may not be able to compete effectively in our market.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We rely upon a combination of patents, patent
	applications, know-how and confidentiality agreements to protect the intellectual property related to our only product candidate,
	vonapanitase, and will use a similar strategy to protect any additional product candidates. The patent position of biotechnology
	companies is generally uncertain because it involves complex legal and factual considerations. The standards applied by the United
	States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or
	predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable
	in biotechnology patents. The patent applications that we own may fail to result in issued patents with claims that cover vonapanitase
	or any additional product candidates in the United States or in other countries. There is no assurance that all potentially relevant
	prior art relating to our patents and patent applications has been found, and prior art that is not before the patent examiners,
	as well as prior art that is before the patent examiners, could be used by a third party to invalidate a patent or could be relied
	on to prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if these
	patents cover vonapanitase or any additional product candidates, third parties may challenge their validity, enforceability or
	scope, which may result in our patents being narrowed or invalidated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Furthermore, even if they are unchallenged, our
	patents and patent applications may not adequately provide exclusivity for vonapanitase or any additional product candidates, prevent
	others from designing around our patents with similar products that are outside the scope of our patents, or prevent others from
	operating in jurisdictions in which we did not pursue patent protection. Any of these outcomes could impair our ability to prevent
	competition from third parties, which may have an adverse impact on our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 96 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	96
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If patent applications we hold with respect to
	vonapanitase or any additional product candidates fail to issue, if their breadth or strength of protection is threatened, or if
	they fail to provide meaningful exclusivity for vonapanitase or any additional product candidates, it could dissuade companies
	from collaborating with us. As of December 31, 2015 we own 29 issued patents and own 20 pending patent applications, most of which
	cover aspects of vonapanitase or its use. We cannot offer any assurances about which, if any, of the pending patent applications
	will issue as patents, the breadth of any such patents or any of our currently issued patents, or whether any issued patents will
	be challenged by third parties or will be found invalid and unenforceable if challenged. Any successful challenge to these patent
	applications, or patents that may issue from them, or to currently issued patents owned by us, could deprive us of rights necessary
	for the successful commercialization of vonapanitase or any other product candidate that we may develop. Since patent applications
	in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued,
	we cannot be certain that we were the first to file a patent application relating to any particular aspect of a product candidate.
	Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated
	by these third parties, or by the USPTO itself, to determine who was the first to invent any of the subject matter covered by the
	patent claims of our patents and patent applications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In the United States, for patent applications
	filed prior to March 16, 2013, assuming the other requirements for patentability are met, the first to invent is entitled to the
	patent, while outside the United States, the first to file a patent application is entitled to the patent. Our currently pending
	patent applications are examined under the system in place before March 16, 2013. Third parties are allowed to submit prior art
	prior to the issuance of a patent by the USPTO, and may become involved in reexamination,
<I>
	inter partes
</I>
	review or interference
	proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce
	the scope of, or invalidate, our patent rights, which could adversely affect our competitive position with respect to third parties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition, patents have a limited lifespan.
	In most countries, the statutory term of a patent is 20 years from the earliest domestic priority date claimed. In the United States,
	for applications filed after June 7, 1995, the statutory term of a patent is 20 years from earliest non-provisional priority date
	claimed. Various extensions of patent protection may be available in particular countries; however, in all circumstances, the life
	of a patent, and the protection it affords, has a limited term. If we encounter delays in obtaining regulatory approvals, the period
	of time during which we could market a product under patent protection could be reduced. We expect to seek extensions of patent
	protection where these are available in any countries where we are prosecuting patents. Such possible extensions include those
	permitted under the Drug Price Competition and Patent Term Restoration Act of 1984 in the United States, which permits up to five
	years&#8217; extension of patent protection and no more than fourteen years following product approval for a single patent that
	covers an FDA-approved drug or biologic that contains an active ingredient or salt or ester of the active ingredient that has not
	previously been marketed. The scope of protection available during an extension of a patent claiming a product is limited to the
	approved product itself for approved uses, and the scope of protection available during an extension of a patent claiming a method
	of using a product is limited to the uses claimed in the patent and approved for the product. The actual length of the extension
	is calculated by adding one half of the time between the IND effective date and a company's initial submission of a marketing application,
	plus the entire time between the submission of the marketing application and the FDA's approval of the application. However, the
	applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other
	countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our
	patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of
	our investment in development and clinical trials by referencing our clinical and preclinical data, and then may be able to launch
	their product earlier than might otherwise be the case.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 97 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	97
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Any loss of, or failure to obtain, patent protection
	could have a material adverse impact on our business. We may be unable to prevent competitors from entering the market with a product
	that is similar to or the same as our products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Confidentiality agreements with employees and third parties may
	not prevent unauthorized disclosure of proprietary information.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We seek to protect our proprietary technology
	and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors.
	We also seek to preserve the integrity and confidentiality of our data and know-how by maintaining physical security of our premises
	and physical and electronic security of our information technology systems. Nonetheless, despite these precautions, agreements
	or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our know-how may otherwise
	become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use
	intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how
	and inventions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Enforcing a claim that a third party illegally
	obtained and is using any of our know-how is expensive and time consuming, and the outcome is unpredictable. In addition, courts
	outside the United States sometimes are less willing than United States courts to protect know-how. Misappropriation or unauthorized
	disclosure of our know-how could impair our competitive position and may have a material adverse effect on our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 98 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	98
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may become involved in lawsuits to protect or enforce our intellectual
	property, which could be expensive, time consuming and unsuccessful, and which may lead to a finding that our patents are invalid
	and/or unenforceable.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.1PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Competitors may infringe our patents or misappropriate
	or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, litigation may be necessary
	to enforce or defend our intellectual property rights, to protect our know-how and/or to determine the validity and scope of our
	own intellectual property rights. Intellectual property litigation can be expensive and time consuming. Many of our current and
	potential competitors have the ability to dedicate substantially greater resources to litigate intellectual property rights than
	we can. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing or misappropriating our intellectual
	property. Litigation could result in substantial costs and diversion of management resources, which could harm our business and
	financial results. In addition, in an infringement proceeding, a court may decide that our patents are invalid or unenforceable,
	and may refuse to stop the other party from using the technology at issue, including on the grounds that our patents are invalid
	or unenforceable or do not cover the technology in question. An adverse result in any litigation proceeding could put one or more
	of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial
	amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
	information could be compromised by disclosure during this type of litigation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Third-party claims of intellectual property infringement or misappropriation
	may prevent or delay our development and commercialization efforts.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.1PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our commercial success depends in part on our
	ability to develop, manufacture, market and sell vonapanitase or any additional product candidates, and to use proprietary technologies
	without infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and adversarial
	proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology
	and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination, and
<I>
	inter
	partes
</I>
	review proceedings before the USPTO and corresponding foreign patent offices. Third parties own patent rights both within
	and outside the United States in the fields in which we are developing and may develop vonapanitase or any additional product candidates.
	As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that vonapanitase or
	any additional product candidates may be subject to claims of infringement of the patent rights of third parties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 99 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	99
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Third parties may assert that we are employing
	their proprietary technology without authorization. There may be third-party patents or patent applications with claims that may
	cover vonapanitase or any additional product candidates and/or the use, manufacture, sale and/or offer for sale of vonapanitase
	or any additional product candidates. We are aware of European Patent No. EP 1 012 307 B1, or the '307 patent, which claims, among
	other things, autocatalytically cleavable zymogenic precursor of a serine protease wherein a naturally occurring non-autocatalytic
	cleavage site is replaced in the zymogenic precursor by an autocatalytic cleavage site. The '307 patent expires on August 12, 2018.
	We currently estimate that the soonest that we will market vonapanitase is after this date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In some cases, we may have failed to identify
	relevant third-party patents or patent applications. For example, applications filed before November 29, 2000, and certain applications
	filed after that date that will not be filed outside the United States remain confidential until patents issue. Except for the
	preceding exceptions, patent applications in the United States and elsewhere are generally published but, only after a waiting
	period of approximately 18 months after the earliest filing. Therefore, patent applications covering vonapanitase or future product
	candidates could have been filed by others without our knowledge. Additionally, pending patent applications which have been published
	can, subject to certain limitations, be later amended in a manner that could cover vonapanitase or any additional product candidates
	and/or the use, manufacture, sale and/or offer for sale of vonapanitase or any additional product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If any valid and enforceable third-party patents
	were held by a court of competent jurisdiction to cover vonapanitase or any additional product candidates and/or their use, manufacture,
	sale, and/or offer for sale, the holders of any of these patents may be able to block our ability to develop and commercialize
	the applicable product candidate until the patent expired or unless we obtain a license. Licenses may not be available on acceptable
	terms, if at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors
	gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced
	to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable
	to enter into licenses on acceptable terms.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Some of our early research of recombinant expression
	of vonapanitase, but not the corresponding development work, utilized some technology under license from a third party. The third
	party may contend that we use the licensed technology for our commercial recombinant expression of vonapanitase. Litigation may
	be necessary to defend against such a claim. Even if we are successful in defending against such a claim, litigation could result
	in substantial costs and be a distraction to management. If we are not successful in defending against such a claim, in addition
	to paying monetary damages, we may have to reconfigure the vonapanitase expression system, which would materially adversely affect
	our commercial development efforts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 100 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	100
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Parties making claims against us may obtain injunctive
	or other equitable relief, which could effectively block our ability to commercialize vonapanitase or any additional product candidates.
	We may face a claim of misappropriation if a third party believes that we inappropriately obtained and used trade secrets of that
	third party. If we are found to have misappropriated a third party&#8217;s trade secrets, we may be prevented from further using
	such trade secrets, limiting our ability to develop vonapanitase or any additional product candidates, and we may be required to
	pay damages.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Defending against claims of patent infringement
	or misappropriation of trade secrets could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately
	prevail, or to settle at an early stage, any litigation could burden us with substantial unanticipated costs. In addition, litigation
	or threatened litigation could result in significant demands on the time and attention of our management team, distracting them
	from the pursuit of other company business. In the event of a successful claim of infringement against us, we may have to pay substantial
	damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products
	or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	During the course of any patent or other intellectual
	property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings
	in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our products,
	programs, or intellectual property could be diminished. Accordingly, the market price of our Common Stock may decline.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If we are unable to adequately protect our proprietary technology,
	or obtain and maintain issued patents which are sufficient to protect our current product candidate, vonapanitase, or any additional
	product candidates, others could compete against us more directly, which would have a material adverse impact on our business,
	results of operations, financial condition and prospects.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.1PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We strive to protect and enhance the proprietary
	technologies that we believe are important to our business, including seeking patents intended to cover our products and compositions,
	their methods of use and any other inventions that are important to the development of our business. We also rely on know-how to
	protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 101 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	101
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our success will depend significantly on our ability
	to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related
	to our business, defend and enforce our current patents and any future patents that may issue, preserve the confidentiality of
	our know-how and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also
	rely on know-how and in-licensing opportunities to develop, strengthen and maintain the proprietary position of vonapanitase or
	any additional product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We cannot provide any assurances that any of our
	pending patent applications will mature into issued patents and, if they do, that such patents or our currently issued patents
	will include claims with a scope sufficient to protect vonapanitase or any additional product candidates or otherwise provide any
	competitive advantage. For example, one of our patents that may provide coverage for vonapanitase only covers particular formulations.
	As a result, this patent would not prevent third-party competitors from creating, making and marketing alternative formulations
	that fall outside the scope of our patent claims. There can be no assurance that any such alternative formulations will not be
	equally effective.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Moreover, other parties have developed technologies
	that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or
	may receive patents that may overlap or conflict with our patent applications, either by claiming the same methods or formulations
	or by claiming subject matter that could dominate our patent position. These third party patent positions may limit or even eliminate
	our ability to obtain patent protection for certain inventions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The patent positions of biotechnology and pharmaceutical
	companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity
	and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged,
	deemed unenforceable, invalidated, or circumvented. United States patents and patent applications may also be subject to interference
	proceedings,
<I>
	ex parte
</I>
	reexamination, or
<I>
	inter partes
</I>
	review proceedings, and challenges in district court. Patents
	may be subjected to opposition, revocation proceedings, or comparable proceedings lodged in various foreign, both national and
	regional, patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss
	or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be
	costly. Thus, any patents that we may own or exclusively license may not provide any protection against competitors. Furthermore,
	an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in
	turn could affect our ability to develop, market or otherwise commercialize vonapanitase or any additional product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 102 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	102
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Furthermore, though a patent is presumed valid
	and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate
	proprietary protection or competitive advantages against competitors with similar products. Even if a patent issues and is held
	to be valid and enforceable, competitors may be able to design around our patents, such as using pre-existing or newly developed
	technology. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. We may
	not be able to prevent the unauthorized disclosure or use of our technical knowledge or know-how by consultants, vendors, former
	employees and current employees. The laws of some foreign countries do not protect our proprietary rights to the same extent as
	the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries.
	If these developments were to occur, they could have a material adverse effect on our sales.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition, proceedings to enforce or defend
	our patents, if and when issued, could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly.
	These proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one
	or more of our patents are invalid or otherwise unenforceable. If any of our patents, if and when issued, covering vonapanitase
	or any additional product candidates, are invalidated or found unenforceable, our financial position and results of operations
	would be materially and adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties
	covered vonapanitase, or any additional product candidates, our financial position and results of operations would also be materially
	and adversely impacted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The degree of future protection for our proprietary
	rights is uncertain, and we cannot ensure that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.3PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any of our patents or pending patent applications, if issued, will include claims having a scope sufficient to protect vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any of our pending patent applications will issue as patents at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we will be able to successfully commercialize product candidates, if approved, before our relevant patents expire;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we were the first to make the inventions covered by each of our patents and pending patent applications;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we were the first to file patent applications for these inventions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	others will not develop similar or alternative technologies that do not infringe our patents;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	others will not use pre-existing technology to effectively compete against us;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any of our patents will be found ultimately to be valid and enforceable;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we will develop additional proprietary technologies or product candidates that are separately patentable; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	that our commercial activities or products will not infringe the patents or proprietary rights of others.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 103 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	103
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We rely upon unpatented know-how to maintain our
	competitive position, which we seek to protect, in part, by confidentiality agreements with our employees and our collaborators
	and consultants. It is possible that technology relevant to our business will be independently developed by a person that is not
	a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate
	the terms of these agreements, we may not have adequate remedies for any such breach or violation, and our confidential know-how
	could become known to others through such breaches or violations. Further, our know-how could otherwise become known or be independently
	discovered by our competitors. Further, the term of confidentiality requirements for current and terminated agreements with some
	of our consultants, contract manufacturing or research organizations and other third parties is finite.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may be subject to claims challenging the inventorship or ownership
	of our patents and other intellectual property.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We enter into confidentiality and intellectual
	property assignment agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other
	advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will
	be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights
	to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which the academic advisor
	is required to assign any inventions developed in connection with providing services to us, the academic advisor may not have the
	right to assign these inventions to us, as it may conflict with his or her obligations to assign all intellectual property to his
	or her employing institution.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Litigation may be necessary to defend against
	these and other claims challenging inventorship or ownership of inventions. If we are unsuccessful in defending against any of
	these claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
	of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even
	if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
	and other employees.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 104 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	104
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Obtaining and maintaining our patent protection depends on compliance
	with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our
	patent protection could be reduced or eliminated for non-compliance with these requirements.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The USPTO and various foreign governmental patent
	agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process.
	There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in
	partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the
	market earlier than would otherwise have been the case.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Issued patents covering vonapanitase or covering any additional
	product candidates could be found invalid or unenforceable if challenged in court.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If we initiated legal proceedings against a third
	party to enforce a patent, if and when issued, covering vonapanitase or any additional product candidate, the defendant could counterclaim
	that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant
	counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures
	to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability
	assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the USPTO,
	or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in
	the United States or abroad, even outside the context of litigation. These mechanisms include reexamination and
<I>
	inter partes
</I>
	review in the United States and equivalent proceedings in foreign jurisdictions,
<I>
	e.g.
</I>
	, opposition proceedings. These
	proceedings could result in revocation or amendment of our patents in such a way that they no longer cover, for example, vonapanitase
	or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
	to validity, for example, we cannot be certain that there is no invalidating prior art, including prior art of which we and the
	patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability,
	we would lose at least part, and perhaps all, of the patent protection on the applicable product candidate. A loss of patent protection
	would have a material adverse impact on our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 105 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	105
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We will not seek to protect our intellectual property rights in
	all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the
	jurisdictions where we seek protection.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Filing, prosecuting and defending patents on product
	candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property
	rights in some countries outside the United States could be less extensive than those in the United States, assuming that rights
	are obtained in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights
	to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from
	practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions
	in and into the United States or other jurisdictions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Competitors may use our technologies in jurisdictions
	where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing
	products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products
	may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent
	them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual
	property rights may not be effective or sufficient to prevent third parties from so competing.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The laws of some foreign countries do not protect
	intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems
	in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries,
	particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially
	those relating to biotechnology. This could make it difficult for us to stop the infringement of our patents, if obtained, or the
	misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws
	under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents
	against third parties, including government agencies or government contractors. In these countries, patents may provide limited
	or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming
	process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not
	have the benefit of patent protection in such countries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 106 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	106
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Many companies have encountered significant problems
	in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
	certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly
	those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing
	of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions
	could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents
	at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke
	third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies
	awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around
	the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Some of our intellectual property may have been discovered through
	government funded programs and thus may be subject to federal regulations such as government &#8220;march-in&#8221; rights, certain
	reporting requirements, and a preference for United States industry. Compliance with these regulations may limit our exclusive
	rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with foreign
	manufacturers.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Some of our intellectual property rights may have
	been generated through the use of United States government funding and therefore are subject to certain federal regulations. For
	example, our patents relating to some therapeutic uses of vonapanitase and associated systems and kits that include a catheter,
	which we refer to as the &#8220;therapy family,&#8221; arose from research funded by the United States government. As a result,
	the United States government has certain rights to this intellectual property pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole
	Act. These United States government rights in certain inventions developed under a government-funded program include a non-exclusive,
	non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States
	government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions
	to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government
	action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public
	use under federal regulations, also referred to as &#8220;march-in rights.&#8221; The United States government also has the right
	to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail
	to file an application to register the intellectual property within specified time limits. In addition, the United States government
	may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual
	property generated under a government funded program is also subject to certain reporting requirements, compliance with which may
	require us or the applicable licensor to expend substantial resources. In addition, the United States government requires that
	any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially
	in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show
	that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be
	likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially
	feasible. This preference for United States manufacturers may limit our ability to contract with foreign product manufacturers
	for products covered by the applicable intellectual property.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 107 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	107
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We currently do not plan to apply for additional
	United States government funding, but if we do, and we discover compounds or drug or biological candidates as a result of such
	funding, intellectual property rights to these discoveries may be subject to the applicable provisions of the Bayh-Dole Act.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If we do not obtain additional protection under the Hatch-Waxman
	Amendments and similar foreign legislation by extending the patent protection for vonapanitase, our business may be materially
	harmed.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Depending upon the timing, duration and specifics
	of the first FDA marketing approval of vonapanitase and, if applicable, any additional product candidates, a United States patent
	that we own or license may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration
	Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit extension of one patent that covers
	an FDA-approved drug or biologic that contains an active ingredient or salt or ester of the active ingredient that has not previously
	been marketed for up to five years and no more than fourteen years after product approval for patent term lost during product development
	and the FDA regulatory review process. The length of the extension is calculated by adding one half of the time between the IND
	effective date and a company's initial submission of a marketing application, plus the entire time between the submission of the
	marketing application and the FDA's approval of the application. During this period of extension, the scope of protection is limited
	to the approved product for approved uses (for patents claiming a product) and any use claimed by the patent and approved for the
	product (for patents claiming a method of using a product).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Although we plan on seeking patent term restoration
	for our products, it may not be granted if, for example, we fail to apply within applicable deadlines, fail to apply prior to expiration
	of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of
	patent protection afforded could be less than we request. If we are unable to obtain patent term restoration or the term of any
	such patent restoration is less than we request, our competitors may be able to enter the market and compete against us sooner
	than we anticipate, and our ability to generate revenues could be materially adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 108 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	108
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Changes in United States patent law could diminish the value of
	patents in general, thereby impairing our ability to protect our products.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As is the case with other biotechnology companies,
	our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology
	industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In
	addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation, the Leahy-Smith
	America Invents Act, or America Invents Act. The America Invents Act includes a number of significant changes to United States
	patent law. These include provisions that affect the way patent applications will be prosecuted, provides expanded opportunities
	for post-grant administrative review of patents before the USPTO, and may also affect patent litigation. It is not yet clear what,
	if any, impact the America Invents Act will have on the operation of our business. However, the America Invents Act and its implementation
	could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense
	of any patents that may issue from our patent applications, all of which could have a material adverse effect on our business and
	financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition, recent United States Supreme Court
	rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners
	in certain situations. The full impact of these decisions is not yet known. For example, on March 20, 2012 in
<I>
	Mayo Collaborative
	Services v. Prometheus Laboratories, Inc.
</I>
	, the Court held that several claims drawn to measuring drug metabolite levels from
	patient samples and correlating them to drug doses were not patent-eligible subject matter. The decision appears to impact diagnostics
	patents that merely apply a law of nature via a series of routine steps and it has created uncertainty around the ability to obtain
	patent protection for certain inventions. Additionally, on June 13, 2013 in
<I>
	Association for Molecular Pathology v. Myriad Genetics,
	Inc.,
</I>
	the Court held that claims to isolated genomic DNA are not patent-eligible, but claims to complementary DNA molecules
	are patent-eligible because they are not a natural product. The effect of the decision on patents for other isolated natural products
	is uncertain. However, on March 4, 2014, the USPTO issued a memorandum to patent examiners providing guidance for examining claims
	that recite laws of nature, natural phenomena or natural products under the
<I>
	Myriad
</I>
	and
<I>
	Prometheus
</I>
	decisions. This
	guidance did not limit the application of
<I>
	Myriad
</I>
	to DNA, but, rather, applied the decision to other natural products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition to increasing uncertainty with regard
	to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents,
	once obtained. Depending on these and other decisions by the United States Congress, the federal courts and the USPTO, the laws
	and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to
	enforce our current or future patents.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 109 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	109
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We may be subject to damages resulting from claims that we or
	our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.1PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our employees have been previously employed at
	other biotechnology or pharmaceutical companies, including our competitors or potential competitors, or at universities or academic
	medical centers. We also engage advisors and consultants who are concurrently employed at universities or who perform services
	for other entities. Although we are not aware of any claims currently pending against us, we may be subject to claims that we or
	our employees, advisors or consultants have inadvertently or otherwise used or disclosed intellectual property, including trade
	secrets or other proprietary information, of a former employer or other third party. We may in the future also be subject to claims
	that an employee, advisor or consultant performed work for us that conflicts with that person&#8217;s obligations to a third party,
	such as an employer, and thus, that the third party has an ownership interest in the intellectual property arising out of work
	performed for us. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these
	claims, litigation could result in substantial costs and be a distraction to management. If we are unsuccessful in defending against
	such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of
	key personnel or their work product could hamper or prevent our ability to commercialize vonapanitase or any additional product
	candidates, which would materially adversely affect our commercial development efforts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Numerous factors may limit any potential competitive advantage
	provided by our intellectual property rights.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The degree of future protection afforded by our
	intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect
	our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive
	advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be
	able to exercise or extract value from our intellectual property rights fully or at all. The following examples are illustrative:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we might not have been the first to make the inventions covered by a patent or pending patent application that we own;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we might not have been the first to file patent applications covering an invention;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	others may independently develop similar or alternative technologies without infringing our intellectual property rights;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 110 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	110
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	pending patent applications that we own may not lead to issued patents;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	third parties may assert an ownership interest in our intellectual property;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may not develop or in-license additional proprietary technologies that are patentable; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the patents or proprietary rights of others may have an adverse effect on our business.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Should any of these events occur, they could significantly
	harm our business and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
	Risks Related to Our Business
	and Industry
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If we fail to attract and keep senior management and key scientific
	personnel, we may be unable to successfully develop our products, conduct our clinical trials and commercialize our product candidates.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.1PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our future growth and success depend on our ability
	to recruit, retain, manage and motivate our employees. We are highly dependent on our senior management team, in particular, Timothy
	Noyes, our President and Chief Executive Officer, Steven Burke, our Senior Vice President and Chief Medical Officer, George Eldridge,
	our Senior Vice President, Chief Financial Officer, Treasurer and Secretary, Scott Toner, our Senior Vice President of Marketing,
	and Daniel Gottlieb, our Vice President, Corporate Development, as well as the other principal members of our management and scientific
	teams. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating
	their employment with us at any time. The loss of the services of any member of our senior management or scientific team or the
	inability to hire or retain experienced management personnel could adversely affect our ability to execute our business plan and
	harm our operating results.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Because of the specialized scientific and managerial
	nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel.
	We do not currently carry &#8220;key person&#8221; insurance on the lives of members of executive management. The competition for
	qualified personnel in the pharmaceutical field is intense. Due to this intense competition, we may be unable to continue to attract
	and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. In addition,
	we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development
	and commercialization strategy including, F. Nicholas Franano, our scientific founder. Our consultants and advisors may be employed
	by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their
	availability to us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 111 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	111
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We will need to significantly increase the size of our organization,
	and we may experience difficulties in managing growth.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We are currently a small company and in order
	to commercialize our potential products, we will need to increase our operations and expand our use of our third-party contractors.
	We plan to continue to build our compliance, financial and operating infrastructure to ensure the maintenance of a well-managed
	company including hiring additional staff within our regulatory and clinical groups after Phase 3 is complete. We intend to recruit
	an in-house commercial organization in the United States focused on promoting vonapanitase, if it is approved. We currently do
	not have a sales and marketing capability and therefore intend to recruit a specialty sales force of approximately 75-100 representatives
	in anticipation of vonapanitase's approval. We estimate it will take three to six months to recruit this specialty sales force.
	We will need to expand our employment base when we are in the full commercial stages of our current potential product's life cycle.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Future growth will impose significant added responsibilities
	on members of management, including the need to identify, recruit, maintain and integrate additional employees. In addition, to
	meet our obligations as a public company, we will need to increase our general and administrative capabilities. Our management,
	personnel and systems currently in place may not be adequate to support this future growth. Our future financial performance and
	our ability to commercialize our potential products and to compete effectively will depend, in part, on our ability to manage any
	future growth effectively. To that end, we must be able to:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	manage our clinical trials and the regulatory process effectively;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	manage the manufacturing of product candidates and potential products for clinical and commercial use;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	integrate current and additional management, administrative, financial and sales and marketing personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	develop a marketing and sales infrastructure;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	hire new personnel necessary to effectively commercialize vonapanitase and any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	develop our administrative, accounting and management information systems and controls; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	hire and train additional qualified personnel.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 112 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	112
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Product candidates that we may acquire or develop
	in the future may be intended for patient populations that are large. In order to continue development and marketing of these product
	candidates, if approved, we would need to significantly expand our operations. Our staff, financial resources, systems, procedures
	or controls may be inadequate to support our operations and our management may be unable to manage successfully future market opportunities
	or our relationships with customers and other third parties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Our disclosure controls and procedures may not prevent or detect
	all errors or acts of fraud.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Upon completion of our Initial Public Offering, or IPO, we became subject to the periodic reporting requirements
	of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to
	reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated
	and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules
	and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how
	well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are
	met.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	These inherent limitations include the realities
	that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally,
	controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override
	of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may
	occur and not be detected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If product liability lawsuits are successfully brought against
	us, our insurance may be inadequate and we may incur substantial liability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We face an inherent risk of product liability
	claims as a result of the clinical testing of vonapanitase or any additional product candidates. We will face an even greater risk
	if we commercially sell vonapanitase or any additional product candidate that we develop. We maintain primary product liability
	insurance and excess product liability insurance that cover our clinical trials, and we plan to maintain insurance against product
	liability lawsuits for commercial sale of our potential products. Historically, the potential liability associated with product
	liability lawsuits for pharmaceutical products has been unpredictable. Although we believe that our current insurance is a reasonable
	estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to
	the cost of the insurance, we may be subject to claims in connection with our clinical trials and, in the future, commercial use
	of our potential products, for which our insurance coverage may not be adequate, and the cost of any product liability litigation
	or other proceeding, even if resolved in our favor, could be substantial.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 113 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	113
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	For example, we may be sued if any product we
	develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale.
	Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of
	dangers inherent in the product, negligence, strict liability or a breach of warranties. Large judgments have been awarded in class
	action lawsuits based on drugs or biologics that had unanticipated adverse effects. Claims could also be asserted under state consumer
	protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities
	or be required to limit commercialization of vonapanitase or any additional product candidates. Regardless of the merits or eventual
	outcome, liability claims may result in:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reduced resources of our management to pursue our business strategy;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	decreased demand for our product candidates or products that we may develop;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	injury to our reputation and significant negative media attention;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	withdrawal of clinical trial participants;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	termination of clinical trial sites or entire trial programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	initiation of investigations by regulators;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	product recalls, withdrawals or labeling, marketing or promotional restrictions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	significant costs to defend resulting litigation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	diversion of management and scientific resources from our business operations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	substantial monetary awards to trial participants or patients;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	loss of revenue; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the inability to commercialize any products that we may develop.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We currently have a $5 million product liability
	insurance coverage in connection with our clinical trials and we will need to increase our insurance coverage if and when we begin
	selling vonapanitase or any additional product candidates if and when they receive marketing approval. However, the product liability
	insurance we will need to obtain in connection with the commercial sales of vonapanitase or any additional product candidates if
	and when they receive regulatory approval may be unavailable in meaningful amounts or at a reasonable cost. In addition, insurance
	coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable
	cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial
	production and sale of vonapanitase or any additional product candidates if and when they obtain regulatory approval, which could
	materially adversely affect our business, financial condition, results of operations, cash flows and prospects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 114 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	114
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Additionally, we do not carry insurance for all
	categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment
	practices liability, property, auto, workers&#8217; compensation, products liability and directors&#8217; and officers&#8217; insurance.
	We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability
	may require us to pay substantial amounts, which would materially adversely affect our financial position, cash flows and results
	of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If we engage in acquisitions in the future, we will incur a variety
	of costs and we may never realize the anticipated benefits of such acquisitions.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We may attempt to acquire businesses, technologies,
	services, products or product candidates in the future that we believe are a strategic fit with our business. We have no present
	agreement regarding any material acquisitions. If we do undertake any acquisitions, however, the process of integrating an acquired
	business, technology, service, products or product candidates into our business may result in unforeseen operating difficulties
	and expenditures, including diversion of resources and management&#8217;s attention from our core business. In addition, we may
	fail to retain key executives and employees of the companies we acquire, which may reduce the value of the acquisition or give
	rise to additional integration costs. Future acquisitions could result in additional issuances of equity securities that would
	dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, actual or contingent
	liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect our operating
	results. In addition, we may fail to realize the anticipated benefits of any acquisition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We currently have our API produced for us by a contract manufacturer
	exclusively in one manufacturing facility and if this or any future facility, any facility we use for storage of the finished product
	or our equipment were damaged or destroyed, our ability to continue to operate our business would be materially harmed.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our executive offices are located in Waltham,
	Massachusetts, and our API is manufactured at Lonza&#8217;s facility located in Visp, Switzerland. We expect that Lonza plans to
	utilize this facility in the future to support commercial production if our product candidate is approved. We have manufactured
	our entire finished product for the ongoing and planned Phase 3 clinical trials of vonapanitase and currently store the finished
	product in only one location. Extended delays in our Phase 3 clinical trials causing us to need to manufacture new clinical supply
	would cause a significant disruption in our operations and cause us to incur unexpected costs to manufacture new finished product.
	We are vulnerable to natural disasters, such as severe storms and other events that could disrupt our operations. We do not carry
	insurance for natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that
	may occur. If the current manufacturing facility or any future facility, stored product or equipment were damaged or destroyed,
	or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business
	would be materially harmed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 115 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	115
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If supply is interrupted, there could be a significant
	disruption in our clinical development and commercial supply. If the supply is interrupted after approval of the BLA, an alternative
	manufacturer would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may
	also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve
	substantial costs and would likely result in a delay in our desired clinical and commercial timelines.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	These factors could cause the delay of clinical
	trials, regulatory submissions, required approvals or commercialization of vonapanitase or any additional product candidates, cause
	us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet
	contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially
	equivalent cost, our clinical trials may be delayed or we could lose potential revenue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Our business and operations would suffer in the event of system
	failures or security breaches.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Despite the implementation of security measures,
	our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer
	viruses, unauthorized access, cyber attacks, natural disasters, terrorism, war and telecommunication and electrical failures. If
	issues were to arise and cause interruptions in our operations, it could result in a material disruption of our drug and biologic
	development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result
	in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent
	that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure
	of confidential or proprietary information, we could incur liability and the further development of vonapanitase or any additional
	product candidates could be delayed. We may also be vulnerable to cyber attacks by hackers, or other malfeasance. This type of
	breach of our cybersecurity may compromise our confidential information and/or our financial information and detrimentally impact
	our business or result in legal proceedings.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Our employees may engage in misconduct or other improper activities,
	including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 116 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	116
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We are exposed to the risk of employee fraud or
	other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and foreign
	regulators, provide accurate information to the FDA and foreign regulators, comply with healthcare fraud and abuse laws and regulations
	in the United States and abroad, and report financial information or data accurately or disclose unauthorized activities to us.
	In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
	intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict
	or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other
	business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical
	trials, which could result in regulatory sanctions and serious harm to our reputation. We have a Code of Business Conduct and Ethics,
	but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this
	activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
	or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against
	us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
	our business, including the imposition of significant fines or other sanctions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We have broad discretion in our use of our cash and cash equivalents
	and may not use them effectively.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our management has broad discretion to use our
	cash and cash equivalents to fund our operations and could spend these funds in ways that do not improve our results of operations
	or enhance the value of our Common Stock. The failure of our management to apply these funds effectively could result in financial
	losses that could have a material adverse effect on our business, cause the price of our Common Stock to decline and delay the
	development of our product candidates. Pending their use to fund our operations, we may invest our cash and cash equivalents in
	a manner that does not produce income or that loses value.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Recent federal legislation may increase the difficulty and cost
	for us to commercialize vonapanitase and may affect the prices we may obtain, and impair our ability to profitably sell vonapanitase,
	if approved.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In the United States and some foreign jurisdictions,
	there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could
	prevent or delay marketing approval for vonapanitase, restrict or regulate post-approval activities and affect our ability to profitably
	sell vonapanitase, if approved. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict
	sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted,
	or whether the FDA regulations, targets or interpretations will be changed, or what the impact of such changes on the marketing
	approvals of vonapanitase, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA&#8217;s approval
	process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing
	testing and other requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 117 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	117
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In the United States, the pharmaceutical industry
	has been significantly affected by legislative initiatives. For example, the Medicare Prescription Drug, Improvement, and Modernization
	Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare
	coverage for drug and biologic purchases by the elderly and introduced a new reimbursement methodology based on average sales prices
	for drugs and biologics. Cost reduction initiatives and other provisions of this legislation could decrease the coverage of, or
	the reimbursement rate that we receive for, vonapanitase, if approved, and could seriously harm our business. While the MMA applies
	only to reimbursement of drugs and biologics under the Medicare program, private payors often follow Medicare coverage policy and
	payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may
	result in a similar reduction in payments from non-governmental payors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In March 2010, President Obama signed the Patient
	Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 or, collectively,
	the ACA, which substantially changes the way healthcare will be financed by both governmental and private insurers, and significantly
	impacts the pharmaceutical industry. Among the provisions of the ACA of importance to our business, including, without limitation,
	our ability to commercialize, and the prices we may obtain for, vonapanitase, if approved for sale, are the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	increases in the statutory minimum rebates a manufacturer must pay as a condition to having a drug or biologic available for coverage under the Medicaid program;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal Anti-Kickback Statute, and the addition of new government investigative powers and enhanced penalties for non-compliance;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs and biologics dispensed to individuals who are enrolled in Medicaid managed care organizations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new eligibility categories for certain individuals with income at or below 133% of the federal poverty level beginning in 2014, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 118 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	118
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	new requirements under the federal Open Payments program and its implementing regulations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a new requirement to annually report drug and biologic samples that manufacturers and distributors provide to physicians;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	a special Medicare Part B payment rate for biosimilars that favors them over the reference biological product.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition, other legislative changes have been
	proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of
	up to 2% per fiscal year, which went into effect in April 2013. In January 2013, President Obama signed into law the American Taxpayer
	Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute
	of limitations period for the government to recover overpayments to providers from three to five years. The full impact on our
	business of the ACA and other new laws is uncertain but may result in additional reductions in Medicare and other healthcare funding.
	Nor is it clear whether other legislative changes will be adopted, if any, or how such changes would affect the demand for vonapanitase,
	if approved.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Governments outside the United States tend to impose strict price
	controls, which may adversely affect our revenues, if any.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In international markets, reimbursement and health
	care payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and
	therapies. In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is
	subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time
	after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries,
	we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available
	therapies. There can be no assurance that our products will be considered cost-effective by third-party payors, that an adequate
	level of reimbursement will be available or that the third-party payors&#8217; reimbursement policies will not adversely affect
	our ability to sell our products profitably. If reimbursement of our products is unavailable or limited in scope or amount, or
	if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 119 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	119
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0">
<B>
	Risks Related to Our Common
	Stock
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We are an &#8220;emerging growth company&#8221; and as a result
	of the reduced disclosure and governance requirements applicable to emerging growth companies, our Common Stock may be less attractive
	to investors.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We are an &#8220;emerging growth company,&#8221;
	or EGC, as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that
	are applicable to other public companies that are not EGCs, including: not being required to comply with the auditor attestation
	requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic
	reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
	and stockholder approval of any golden parachute payments not previously approved.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We may take advantage of these reporting exemptions
	until we are no longer an EGC. We will remain an EGC until the earlier of (1) the last day of the fiscal year (a) following the
	fifth anniversary of the completion of our IPO, (b) in which we have total annual gross revenue of at least $1 billion, or (c)
	in which we are deemed to be a large accelerated filer, which means the market value of our Common Stock that is held by non-affiliates
	exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1 billion in non-convertible
	debt during the prior three-year period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We cannot predict whether investors will find
	our Common Stock less attractive if we rely on these exemptions. If some investors find our Common Stock less attractive as a result,
	there may be a less active trading market for our Common Stock and our stock price may be more volatile. In addition, the JOBS
	Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards.
	This allows an EGC to delay the adoption of these accounting standards until they would otherwise apply to private companies. We
	have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised
	accounting standards as other public companies that are not EGCs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Even after we no longer qualify as an EGC, we may still qualify as a &ldquo;smaller reporting company&rdquo;
	which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required
	to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations
	regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our Common
	Stock less attractive because we will rely on these exemptions. If some investors find our Common Stock less attractive as a result,
	there may be a less active trading market for our Common Stock and our stock price may be more volatile.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 120 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	120
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	The market price for our Common Stock may be volatile, which could
	contribute to the loss of your investment.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Fluctuations in the price of our Common Stock
	could contribute to the loss of all or part of your investment. Prior to our IPO, there was no public market for our Common Stock.
	We are now listed on NASDAQ, but we cannot predict the extent to which investor interest in our Company will lead to the development
	of or sustain an active trading market on NASDAQ or otherwise or how liquid that market might become. If an active trading market
	for our Common Stock does not develop or is not sustained, the market price and liquidity of our Common Stock will be materially
	and adversely affected and it may be difficult for stockholders to sell their shares of Common Stock at prices that are attractive
	to them, or at all. Further, an inactive market may also impair our ability to raise capital by selling shares of our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If an active market for our Common Stock develops
	and continues, the trading price of our Common Stock is likely to be highly volatile and could be subject to wide fluctuations
	in response to various factors, some of which are beyond our control. Any of the factors listed below could have a material adverse
	effect the price of our Common Stock and stockholders may also be unable to sell their shares of Common Stock at prices that are
	attractive to them due to fluctuations in the market price of our Common Stock. In such circumstances the trading price of our
	Common Stock may not recover and may experience a further decline.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
	Factors affecting the trading price of our Common Stock may
	include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our failure to develop and commercialize vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in the market&#8217;s expectations about our operating results;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	adverse results or delays in preclinical studies or clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	adverse regulatory decisions, including failure to receive regulatory approval for vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	success of competitive products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	adverse developments concerning our collaborations and our manufacturers;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	inability to obtain adequate product supply for any product candidate for clinical trials or commercial sale or inability to do so at acceptable prices;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 121 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	121
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the termination of a collaboration or the inability to establish additional collaborations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	unanticipated serious safety concerns related to the use of any of vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to effectively manage our growth;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the size and growth, if any, of the targeted market;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our operating results failing to meet the expectation of securities analysts or investors in a particular period or failure of securities analysts to publish reports about us or our business;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in financial estimates and recommendations by securities analysts concerning our company, our market opportunity, or the biotechnology and pharmaceutical industries in general;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	operating and stock price performance of other companies that investors deem comparable to us;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	overall performance of the equity markets;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	announcements by us or our competitors of acquisitions, new product candidates or programs, significant contracts, commercial relationships or capital commitments;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to successfully market vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in laws and regulations affecting our business, including but not limited to clinical trial requirements for approvals;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for vonapanitase or any additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	commencement of, or involvement in, litigation involving our company, our general industry, or both;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the volume of shares of our Common Stock available for public sale;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	additions or departures of key scientific or management personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any major change in our board or management;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in accounting practices;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	ineffectiveness of our internal control over financial reporting;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	sales of substantial amounts of Common Stock by our directors, executive officers or significant stockholders or the perception that such sales could occur; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 122 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	122
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Broad market and industry factors may materially
	harm the market price of our Common Stock irrespective of our operating performance. The stock market in general, and NASDAQ and
	the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been
	unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations
	of these stocks, and of ours, may not be predictable. A loss of investor confidence in the market for technology or software stocks
	or the stocks of other companies which investors perceive to be similar to us, the opportunities in the digital simulation market
	or the stock market in general, could depress our stock price regardless of our business, prospects, financial conditions or results
	of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Actual or potential sales of our Common Stock by our employees, including our executive officers, pursuant to
	pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual
	or potential sales by such persons could be viewed negatively by other investors.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 23.1PT; MARGIN: 6.6PT 0 0">
	In accordance with the guidelines specified under Rule 10b5-1 of the Exchange Act and our policies regarding
	stock transactions, a number of our employees, including executive officers, have adopted and may continue to adopt stock trading
	plans pursuant to which they have arranged to sell shares of our Common Stock from time to time in the future. Generally, sales
	under such plans by our executive officers and directors require public filings. Actual or potential sales of our Common Stock
	by such persons could cause the price of our Common Stock to fall or prevent it from increasing for numerous reasons. For example,
	a substantial number of shares of our Common Stock becoming available (or being perceived to become available) for sale in the
	public market could cause the market price of our Common Stock to fall or prevent it from increasing. Also, actual or potential
	sales by such persons could be viewed negatively by other investors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	The issuance of additional sales of our Common Stock, or the perception that such issuances may occur, including
	through our &quot;At-The-Market&quot; offering, could cause the market price of our Common Stock to fall.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 23.1PT; MARGIN: 6.6PT 0 0">
	We
	have entered into a Sales Agreement with Cowen and Company, LLC (&quot;Cowen&quot;), for the offer and
	sale of up to $40&nbsp;million in aggregate amount of our Common Stock from time to time through Cowen, as our sales agent, pursuant
	to a Registration Statement on Form&nbsp;S-3 which became effective on January 12, 2016. Cowen is not required to sell any specific
	number or dollar amount of shares of our Common Stock but will use its reasonable efforts, as our agent and subject to the terms
	of the Sales Agreement, to sell that number of shares up to $40&nbsp;million upon our request. Sales of the shares, if any, may
	be made by any means permitted by law and deemed to be an &quot;at-the-market&quot; offering as defined in Rule&nbsp;415 of the
	Securities Act of 1933, as amended, or the Securities Act, and will generally be made by means of brokers' transactions on the
	NASDAQ Global Market or otherwise at market prices prevailing at the time of sale, or as otherwise agreed with Cowen.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 123 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	123
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 23.1PT; MARGIN: 6.6PT 0 0">
	We
	may terminate the Sales Agreement at any time or it will terminate once proceeds of $40&nbsp;million have been raised. Whether
	we choose to affect future sales under the At-The-Market program will depend upon a variety of factors, including, among others,
	market conditions and the trading price of our Common Stock relative to other sources of capital. The issuance from time to time
	of these new shares of Common Stock through our At-The-Market program or in any other equity offering, or the perception that such
	sales may occur, could have the effect of depressing the market price of our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Our issuance of Common Stock under our &ldquo;At-The-Market&rdquo; offering program may be dilutive, and there
	may be future dilution of our Common Stock.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	After giving effect to the issuance of Common Stock under our At-The-Market offering program and the receipt
	of the expected net proceeds and the use of those proceeds, there may be a dilutive effect on our estimated earnings per share
	and funds from operations per share in years during which an offering is ongoing. The actual amount of potential dilution cannot
	be determined at this time and will be based on numerous factors. Additionally, we are not restricted by our organizational documents,
	contractual arrangements or otherwise from issuing additional Common Stock or preferred stock, including any securities that are
	convertible into or exchangeable or exercisable for, or that represent the right to receive, Common Stock or preferred stock or
	any substantially similar securities in the future. The market price of our Common Stock could decline as a result of issuances
	of a large number of shares of our Common Stock after this offering or the perception that such issuances could occur.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
<B>
<I>
	Our management will have broad discretion with respect to the use of the proceeds resulting from the issuance
	of Common Stock under our &ldquo;At-The-Market&rdquo; offering program.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
	Our management has significant flexibility in applying the net proceeds we expect to receive from the issuance
	of Common Stock under the Sales Agreement. We intend to use the net proceeds from this offering for general corporate purposes,
	which may include repaying debt. However, because the net proceeds are not required to be allocated to any specific investment
	or transaction, investors cannot determine at the time of issuance the value or propriety of our application of the net proceeds,
	and investors may not agree with our decisions. In addition, our use of the net proceeds from the offering may not yield a significant
	return or any return at all. The failure by our management to apply these funds effectively could have an adverse effect on our
	financial condition, results of operations or the trading price of our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 124 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	124
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Raising additional funds through debt or equity financing could
	be dilutive and may cause the market price of our Common Stock to decline.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Until such time, if ever, as we can generate substantial
	product revenues, we expect to finance our cash needs through a combination of equity offerings and debt financings, and potentially
	through strategic partnerships with third parties. To the extent that additional capital is raised through the sale of equity or
	convertible debt securities, the issuance of those securities could result in substantial dilution for our current stockholders
	and the terms may include liquidation or other preferences that adversely affect the rights of our current stockholders. Furthermore,
	the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market
	price of our Common Stock to decline and existing stockholders may not agree with our financing plans or the terms of such financings.
	Moreover, the incurrence of debt financing could result in a substantial portion of our operating cash flow being dedicated to
	the payment of principal and interest on such indebtedness and could impose restrictions on our operations, such as limitations
	on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and
	other operating restrictions that could adversely impact our ability to conduct our business. Additional funding may not be available
	to us on acceptable terms, or at all.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	If securities analysts do not publish research or reports about
	our business or if they downgrade our stock, the price of our Common Stock could decline.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The trading market for our Common Stock will rely
	in part on the research and reports that industry or financial analysts publish about us, our business, our markets and our competitors.
	We do not control these analysts. If securities analysts do not cover our Common Stock, the lack of research coverage may adversely
	affect the market price of our Common Stock. Furthermore, if one or more of the analysts who do cover us downgrade our stock or
	if those analysts issue other unfavorable commentary about us or our business, our stock price would likely decline. If one or
	more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose visibility in the market
	and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline and may also impair
	our ability to expand our business with existing customers and attract new customers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	The concentration of our capital stock ownership with insiders
	will likely limit your ability to influence corporate matters.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As of December 31, 2015, our executive officers,
	directors, current 5% or greater stockholders, and their respective affiliates together beneficially own or control, in aggregate,
	more than 50% of the shares of our outstanding Common Stock. As a result, these executive officers, directors and principal stockholders,
	acting together, will have substantial influence over most matters that require approval by our stockholders, including the election
	of directors, any merger, consolidation or sale of all or substantially all or of our assets or any other significant corporate
	transaction. Corporate action might be taken even if other stockholders oppose such action. These stockholders may delay or prevent
	a change of control or otherwise discourage a potential acquirer from attempting to obtain control of our company, even if such
	change of control would benefit our other stockholders. This concentration of stock ownership may adversely affect investors&#8217;
	perception of our corporate governance or delay, prevent or cause a change in control of our company, any of which could adversely
	affect the market price of our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 125 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	125
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Future sales and issuances of our Common Stock or rights to purchase
	Common Stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership
	of our stockholders and could cause our stock price to fall.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We have filed a registration statement permitting
	shares of Common Stock issued in the future, pursuant to our employee benefit plans, to be freely resold by plan participants in
	the public market, subject to applicable lock-up agreements, applicable vesting schedules and, for shares held by directors, executive
	officers and other affiliates, volume limitations under Rule 144 for shares. Our 2014 Employee Incentive Plan and 2014 Employee
	Stock Purchase Plan also contain a provision for the annual increase of the number of shares reserved for issuance under such plan,
	which shares we also intend to register in the future as such annual increase occurs. If the shares we may issue from time to time
	under our employee benefit plans are sold, or if it is perceived that they will be sold, by the award recipient in the public market,
	the trading price of our Common Stock could decline.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We expect that significant additional capital
	will be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts,
	expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell
	Common Stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine
	from time to time. If we sell Common Stock, convertible securities or other equity securities in more than one transaction, investors
	may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and
	new investors could gain rights, preferences and privileges senior to the holders of our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We will incur significant increased costs as a result of operating
	as a public company, and our management will be required to devote substantial time to new compliance initiatives.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As a newly public company, we have incurred and
	will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition,
	the Sarbanes-Oxley Act, and rules of the SEC and those of NASDAQ impose various requirements on public companies including requiring
	establishment and maintenance of effective disclosure and financial controls. Our management and other personnel devote a substantial
	amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase
	our legal and financial compliance costs and will make some activities more time-consuming and costly.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 126 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	126
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The Sarbanes-Oxley Act requires, among other things,
	that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we
	must perform system and process evaluation and testing of our internal control over financial reporting to allow management to
	report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley
	Act. In addition, we will be required to have our independent registered public accounting firm attest to the effectiveness of
	our internal control over financial reporting the later of our second annual report on Form 10-K or the first annual report on
	Form 10-K following the date on which we are no longer an EGC. Our compliance with Section 404 of the Sarbanes-Oxley Act will require
	that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit
	group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical
	accounting knowledge. If we are not able to comply with the requirements of Section 404 in a timely manner, or if we or our independent
	registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be
	material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by NASDAQ,
	the SEC or other regulatory authorities, which would require additional financial and management resources.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our ability to successfully implement our business
	plan and comply with Section 404 requires us to be able to prepare timely and accurate financial statements. We expect that we
	will need to continue to improve existing, and implement new operational and financial systems, procedures and controls to manage
	our business effectively. Any delay in the implementation of, or disruption in the transition to, new or enhanced systems, procedures
	or controls, may cause our operations to suffer and we may be unable to conclude that our internal control over financial reporting
	is effective and to obtain an unqualified report on internal controls from our auditors as required under Section 404 of the Sarbanes-Oxley
	Act. This, in turn, could have an adverse impact on trading prices for our Common Stock, and could adversely affect our ability
	to access the capital markets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We do not expect to pay any cash dividends for the foreseeable
	future.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	You should not rely on an investment in our Common
	Stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our Common Stock in the
	foreseeable future. Instead, we plan to retain any earnings to maintain and expand our operations. Accordingly, investors must
	rely on sales of their Common Stock after price appreciation, which may never occur, as the only way to realize any return on their
	investment. As a result, investors seeking cash dividends should not purchase our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 127 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	127
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Our ability to use our net operating loss carryovers and certain
	other tax attributes may be limited.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As described above under &ldquo;&mdash;Risks Related to Our Financial Condition and Need for Additional Capital,&rdquo;
	we have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable
	future. Under the Internal Revenue Code, as amended (the &ldquo;Code&rdquo;), a corporation is generally allowed a deduction for
	net operating losses, or NOLs, carried over from a prior taxable year. Under that provision, we can carry forward our NOLs to offset
	our future taxable income, if any, until such NOLs are used or expire. The same is true of other unused tax attributes, such as
	tax credits.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	If a corporation undergoes an &#8220;ownership
	change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, Sections
	382 and 383 of the Code, limit the corporation&#8217;s ability to use carryovers of its pre-change NOLs, credits and certain other
	tax attributes to reduce its tax liability for periods after the ownership change. We completed an analysis to determine if there
	were changes in ownership for tax years through 2014, as defined by Section 382 of the Internal Revenue Code that would limit our
	ability to utilize certain net operating loss and tax credit carryforwards and it was determined there was no change in ownership.
	We are in the process of completing an analysis to determine if there were changes in ownership for tax years through 2015, as
	defined by Section 382. To the extent the Company undergoes a change in ownership, as defined by Section 382, utilization of our
	net operating losses and tax credits carryforwards may become limited. If this were to occur, this could result in increased U.S.
	federal income tax liability for us if we generate taxable income in a future period. Limitations on the use of NOLs and other
	tax attributes could also increase our state tax liability. The use of our tax attributes will also be limited to the extent that
	we do not generate positive taxable income in future tax periods.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	We could be subject to securities class action litigation.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In the past, securities class action litigation
	has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant
	for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation,
	it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 128 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	128
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Provisions in our amended and restated certificate of
	incorporation, our amended and restated bylaws and Delaware law may have anti-takeover effects that could discourage an
	acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our
	stockholders to replace or remove our current management.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our amended and restated certificate of incorporation,
	amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in
	control of us or changes in our management. Our amended and restated certificate of incorporation and bylaws include provisions
	that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	authorize &#8220;blank check&#8221; preferred stock, which could be issued by our Board of Directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our Common Stock;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	create a classified Board of Directors whose members serve staggered three-year terms;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	specify that special meetings of our stockholders can be called only by our Board of Directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	prohibit stockholder action by written consent;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our Board of Directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	provide that our directors may be removed only for cause;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	provide that vacancies on our Board of Directors may be filled only by a majority of directors then in office, even though less than a quorum;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	specify that no stockholder is permitted to cumulate votes at any election of directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	expressly authorize our Board of Directors to modify, alter or repeal our amended and restated bylaws; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 42PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 38PX; TEXT-ALIGN: JUSTIFY">
	&#8226;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	require supermajority votes of the holders of our Common Stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	These provisions, alone or together, could delay
	or prevent hostile takeovers and changes in control or changes in our management.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In addition, because we are incorporated in the
	State of Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability
	of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Any provision of our amended and restated certificate
	of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control
	could limit the opportunity for our stockholders to receive a premium for their shares of our Common Stock, and could also affect
	the price that some investors are willing to pay for our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 129 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	129
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our amended and restated certificate of incorporation
	designates the Court of Chancery of the State of Delaware and federal court within the State of Delaware as the exclusive forum
	for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217;
	ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our amended and restated certificate of incorporation
	provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware and federal court within the State
	of Delaware will be exclusive forums for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting
	a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)
	any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our amended
	and restated certificate of incorporation or our amended and restated bylaws, or (4) any other action asserting a claim against
	us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares
	of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate
	of incorporation described above. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a
	judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage
	such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of
	our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified
	types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which
	could adversely affect our business and financial condition.
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_031416P_HTM_A_030">
</A>
	Item 1B. Unresolved Staff Comments
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; COLOR: #1F497D">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	None.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
<A NAME="F10K_031416P_HTM_A_003">
</A>
	Item
</B>
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
<B>
	2
</B>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	.
</FONT>
	Properties
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our primary facility is located in Waltham, Massachusetts, where we lease approximately 4,943 square feet
	of office space. Our lease expires in June 2018. We also have a facility located in Kansas City, Kansas, where we lease approximately
	80 square feet of office space. Our lease in Kansas City expires in December 2016. We believe that our existing facilities are
	sufficient for our current needs and our needs for the foreseeable future.
</P>
</EFX_PROPERTIES>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
<A NAME="F10K_031416P_HTM_A_004">
</A>
	Item 3. Legal Proceedings
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	From time to time we may become subject to various
	legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and
	claims cannot be predicted with certainty, as of the date of this Annual Report on Form 10-K, we do not believe we are party to
	any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably
	expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on
	us because of defense and settlement costs, diversion of management resources and other factors.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 130 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	130
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_LEGAL_PROCEEDINGS>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
<A NAME="F10K_031416P_HTM_A_005">
</A>
	Item 4. Mine Safety Disclosures
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	PART II
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 3.85PT 0 0">
<A NAME="F10K_031416P_HTM_A_006">
</A>
	Item&nbsp;5. Market for Registrant&#8217;s Common Equity, Related
	Stockholder Matters and Issuer Purchases of Equity Securities
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Market Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our Common Stock has been publicly traded on the NASDAQ Global Market under the symbol &ldquo;PRTO&rdquo;
	since October 22, 2014. Prior to that time, there was no public market for our Common Stock. The following table sets forth, for
	the periods indicated, the high and low sales prices for our Common Stock as reported on the NASDAQ Global Market.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Low
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Year Ended December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	First quarter
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.65
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.88
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Second quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	18.45
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Third quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11.65
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Fourth quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17.76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.57
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Year Ended December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Fourth quarter (from and after October 22, 2014)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.57
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	On March 10, 2016, the last reported sale price for our Common Stock on the NASDAQ Global Market was $6.24
	per share.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Holders
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	As of March 10, 2016, there were approximately 39 holders of record of our Common Stock.&nbsp;&nbsp;The actual
	number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but
	whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders
	whose shares may be held in trust by other entities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 131 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	131
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Dividends
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We have never declared or paid cash dividends on our Common Stock, and we do not expect to pay any cash dividends
	on our Common Stock in the foreseeable future. Payment of future dividends, if any, on our Common Stock will be at the discretion
	of our Board of Directors after taking into account various factors, including our financial condition, operating results, anticipated
	cash needs, and plans for expansion.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Comparative Stock Performance Graph
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The following graph shows a comparison from October
	22, 2014, the date on which our Common Stock first began trading on the NASDAQ Global Market, of the cumulative total return on
	an assumed investment of $100.00 in cash on October 22, 2014, in our Common Stock as compared to the same investment in the NASDAQ
	Composite Index and the NASDAQ Biotechnology Index, all through December&nbsp;31, 2015. These returns are based on historical
	results and are not intended to suggest future performance. Data assumes the reinvestment of dividends.&nbsp;&nbsp;The graph assumes
	our closing sales price on October 22, 2014 of $10.03 per share as the initial value of our Common Stock and not the initial offering
	price to the public of $10.00 per share.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The comparisons shown in the graph below are
	based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative
	of, nor is it intended to forecast, the potential future performance of our Common Stock. Information used in the graph was obtained
	from the Nasdaq Stock Market LLC, a source believed to be reliable. The Nasdaq Stock Market LLC is not responsible for any errors
	or omissions in such information.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 132 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	132
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
	COMPARISON OF CUMULATIVE TOTAL RETURN*
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Proteon Therapeutics Inc., the NASDAQ Composite
	Index,
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
	and the NASDAQ Biotechnology Index
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/14/0001171843-16-008541_IMAGE8.JPG">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	* $100 invested on October 22, 2014
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Cumulative Total Return Comparison
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	10/22/2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	12/31/2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	3/31/2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	6/30/2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	9/30/2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	12/31/2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 28%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Proteon Therapeutics, Inc.
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	103.69
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	115.95
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	178.07
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	138.68
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	154.64
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	NASDAQ Composite
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	108.06
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	111.82
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	113.78
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	105.41
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	114.25
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	NASDAQ Pharmaceutical
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	104.64
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	111.83
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	112.59
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	102.70
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106.34
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	The performance graph in this Item&nbsp;5 is not deemed to be &quot;soliciting material&quot; or to be &quot;filed&quot;
	with the Security and Exchange Commission, or the SEC, for purposes of Section&nbsp;18 of the Securities and Exchange Act of 1934,
	as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed incorporated
	by reference into any filing of Proteon Therapeutics,&nbsp;Inc. under the Securities Act of 1933 or the Exchange Act, except to
	the extent we specifically incorporate it by reference into such a filing.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 133 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	133
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Securities Authorized for Issuance Under Equity Compensation Plans
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The following table contains information about
	our equity compensation plans as of December&nbsp;31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number&nbsp;of&nbsp;securities
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Weighted-
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	remaining&nbsp;available
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Number&nbsp;of&nbsp;securities
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	average&nbsp;exercise
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	for&nbsp;future&nbsp;issuance
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	to&nbsp;be&nbsp;issued&nbsp;upon
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	price&nbsp;of
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	under&nbsp;equity
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	exercise&nbsp;of
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	outstanding
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	compensation&nbsp;plans
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	outstanding&nbsp;stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	options,
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(excluding&nbsp;securities
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	options,&nbsp;warrants&nbsp;and
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	warrants&nbsp;and
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	reflected&nbsp;in&nbsp;column
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Plan category
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	rights
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	rights
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	(a))
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Equity compensation plans approved by security holders (1)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,200,369
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.52
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	516,921
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Equity compensation plans not approved by security holders
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,200,369
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	516,921
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 66PX; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Includes information regarding our Amended and Restated 2006 Equity Incentive Plan.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0">
<I>
	Stockholders.
</I>
	&nbsp;As of&nbsp;March 10, 2016,
	we had 39 holders of record of our Common Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0">
<I>
	Dividends
</I>
	. We have never declared or paid
	cash dividends on our capital stock, and we have no plan to pay any cash dividends in the foreseeable future. We currently intend
	to retain any future earnings to finance our operations and future growth.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Purchases of Equity Securities
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We did not purchase any of our registered equity
	securities during the period covered by this Annual Report on Form&nbsp;10-K.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Use of Proceeds from Initial Public Offering
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	On October 27, 2014, we completed the sale of 6,110,000 shares of Common Stock and, on November 21, 2014,
	we completed the sale of 916,500 shares of Common Stock upon the exercise of an option by our underwriters to purchase additional
	shares, in each case at a public offering price of $10 per share for aggregate gross proceeds of $70,265,000. The offer and sale
	of all of the shares in the Initial Public Offering, or IPO, were registered under the Securities Act of 1933, as amended, or the
	Securities Act, pursuant to a registration statement on Form S-1, as amended (File No. 333-198777), which was declared effective
	by the SEC on October 21, 2014. The joint book-running managers for the IPO were Stifel, Nicolaus &amp; Company, Incorporated and
	JMP Securities LLC. The co-managers for the IPO were Robert W. Baird &amp; Co. Incorporated and Oppenheimer &amp; Co. Inc. Following
	the sale of the shares in connection with the closing of the IPO, the offering terminated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 134 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	134
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We received net proceeds from the IPO, including
	the exercise of the underwriter&#8217;s over-allotment, of approximately $62,500,000, after deducting underwriting discounts and
	commissions of approximately $4,919,000 and offering-related expenses of approximately $2,830,000 payable by us. None of the expenses
	associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their
	associates, or to our affiliates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	There has been no material change in the planned
	use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities
	Act on October 22, 2014. We are holding the balance of the net proceeds from the IPO in investments in U.S.&nbsp; Treasuries, certificates
	of deposit, corporate bonds and U.S. government-backed and agency securities. As of February 29, 2016, we estimate that we have
	used approximately $24.7 million of the net proceeds from the IPO to fund the clinical development of vonapanitase and for other
	general corporate purposes.
</P>
</EFX_MARKET>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<A NAME="F10K_031416P_HTM_A_007">
</A>
	Item 6.&nbsp; Selected Financial Data
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The selected consolidated statements of operations data for each of the three years ended December&nbsp;31,
	2015, 2014 and 2013, and the selected consolidated balance sheet data at December&nbsp;31, 2015 and 2014 have been derived from
	our audited consolidated financial statements included elsewhere in this Annual Report on Form&nbsp;10-K. The selected consolidated
	statement of operations data for the year ended December 31, 2012 and the selected consolidated balance sheet data at December
	31, 2013 and 2012 have been derived from our audited consolidated financial statements for such years not included in this Annual
	Report on Form 10-K. Our historical results for any prior period are not necessarily indicative of results to be expected in any
	future period, and our interim period results are not necessarily indicative of results to be expected in any future period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The information set forth below should be read
	in conjunction with the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
	section of this Annual Report on Form&nbsp;10-K and with our consolidated financial statements and notes thereto included elsewhere
	in this Annual Report on Form&nbsp;10-K. The selected consolidated financial data in this section are not intended to replace the
	consolidated financial statements and are qualified in their entirety by the consolidated financial statements and related notes
	included elsewhere in this Annual Report on Form&nbsp;10-K.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 135 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	135
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Proteon Therapeutics, Inc.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2012
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(in thousands, except share and per share data)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Revenue
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,948
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	12,381
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,432
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,994
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	5,907
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	8,489
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,128
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,089
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	20,870
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	10,528
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,122
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,996
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(20,870
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,580
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,122
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,996
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Other income (expense):
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Investment income
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	144
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Interest expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(857
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(861
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Other (expense) income
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(651
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	5,071
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	67
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Total other (expense) income
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(507
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,238
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(790
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	26
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,970
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Unrealized loss on available-for-sale investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,382
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,348
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,913
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,975
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Reconciliation of net loss to net loss attributable to common stockholders:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,970
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Accretion of redeemable convertible preferred stock to redemption value
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,353
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,119
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,133
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net loss attributable to common stockholders
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(9,695
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(14,031
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(14,103
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net loss per share attributable to common stockholders - basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1.30
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3.16
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(59.66
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(61.16
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,464,123
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,064,507
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	235,184
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	230,607
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Supplemental disclosure of stock-based compensation expense:
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	Included in operating expenses, above, are the following amounts for
	non-cash stock based compensation expense:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	650
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	114
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	46
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,514
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	345
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,164
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	459
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	155
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	110
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2012
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Balance Sheet Data:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash, cash equivalents and available-for-sale investments
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	65,263
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	83,595
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	5,152
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,471
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Working capital
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	62,475
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	82,263
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(4,438
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,499
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	67,538
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	84,798
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	5,659
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,782
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Preferred stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	96,405
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	90,286
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Common stock and additional paid-in-capital
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	194,667
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	192,340
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total stockholders&#8217; equity (deficit)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	63,405
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	82,460
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(100,514
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(86,656
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 136 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	136
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-TOP: 3.85PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<A NAME="F10K_031416P_HTM_A_008">
</A>
	Item 7. Management&#8217;s Discussion and Analysis of
	Financial Condition and Results of Operations
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0.05PT 0 0">
<I>
	You should read the following discussion
	and analysis of our financial condition and results of operations together with the section entitled &#8220;Selected Financial
	Data&#8221; and our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K.&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	Our actual results and timing of certain events
	may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. Some
	of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including
	information with respect to our plans and strategy for our business and related financing, includes forward-looking statements
	that involve risks and uncertainties. As a result of many factors, including those factors set forth in the "Risk Factors"
	section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied
	by the forward-looking statements contained in the following discussion and analysis. In addition, even if our results of operations,
	financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking
	statements contained in this Annual Report on Form 10-K , they may not be predictive of results or developments in future periods.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	We are a late-stage biopharmaceutical company
	focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular
	disease. Our product candidate, vonapanitase (formerly PRT-201), is a recombinant human elastase that we are developing to improve
	arteriovenous fistula, or AVF patency in patients with chronic kidney disease undergoing or preparing for hemodialysis, a lifesaving
	treatment that cannot be conducted without a functioning vascular access. We believe the data from our completed Phase 2 trial
	of vonapanitase in patients undergoing creation of an arteriovenous fistula, or AVF, support that a one-time, local application
	of vonapanitase during AVF surgical placement reduces AVF failure, thereby improving patient outcomes and reducing the burden on
	patients and the healthcare system. We are not aware of any approved preventative treatments to reduce the failure rate of AVFs.
	We enrolled the first patient in the first of two Phase 3 trials, named PATENCY-1, for vonapanitase in radiocephalic AVFs, our
	initial indication, in the third quarter of 2014, completed patient enrollment in October 2015 and expect to release top-line data
	in December 2016. We enrolled the first patient in our second Phase 3 trial, named PATENCY-2, in August 2015 and expect to complete
	enrollment in the first quarter of 2017.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 137 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	137
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We commenced business operations in June 2001
	and incorporated in March 2006. Our operations to date have been limited to organizing and staffing our company, business planning,
	raising capital, undertaking preclinical studies and clinical trials of vonapanitase, protecting our intellectual property and
	providing general and administrative support for these operations. To date, we have not generated any product revenue and have
	primarily financed our operations through the private placement of our equity securities, business development activities, convertible
	note financings, and our initial public offering, or IPO, completed in October 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	On October 1, 2014, the Board of Directors and on October 3, 2014, the stockholders approved a 1-for-15.87
	reverse stock split of our Common Stock and a proportional adjustment to the existing conversion ratios for each series of preferred
	stock. The effective date of the reverse stock split was October 6, 2014. All share, share equivalent and per share amounts have
	been adjusted to reflect the reverse stock split. The ratios by which shares of preferred stock were convertible into shares of
	Common Stock have been adjusted to reflect the effects of the reverse stock split.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As of December 31, 2015, we had received an
	aggregate of $174.4 million in net proceeds comprised of $94.0 million from the issuance of private equity securities, $7.7
	million from the issuance of convertible notes, $10.0 million from business development activities, $0.2 million from
	government grants and $62.5 million from our IPO.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	We have never been profitable and have
	incurred net losses in each year since inception. As of December 31, 2015, we had an accumulated deficit of $131.3 million and
	our net loss for the year ended December 31, 2015 was $21.4 million. We expect to incur significant expenses and increasing operating
	losses for the foreseeable future. We expect our research and development expenses to increase as we continue the clinical trials
	of, and seek regulatory approval for, vonapanitase. If we obtain regulatory approval for vonapanitase, we expect to incur significant
	commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect that our
	general and administrative costs will increase as we grow and operate as a public company. As a result, we will need to generate
	significant revenue if we are to achieve profitability, and we may never be able to do so.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	We believe that our cash and cash equivalents
	and available-for-sale investments at December 31, 2015 will be sufficient to fund our operating expenses and capital expenditure
	requirements into the fourth quarter of 2017, thus allowing us to obtain results from our first Phase 3 clinical trial of vonapanitase
	in radiocephalic AVFs, to enroll patients in our second Phase 3 trial of vonapanitase in radiocephalic AVFs and to fund our chemistry,
	manufacturing and controls, or CMC, activities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 138 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	138
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We do not expect to generate revenue from product
	sales unless and until we successfully complete development and obtain regulatory approval for vonapanitase, which we expect will
	take a number of years and is subject to significant uncertainty. We have no manufacturing facilities and all of our manufacturing
	activities are contracted out to third parties. Additionally, we currently use third-party clinical research organizations, or
	CROs, to carry out our clinical development activities and we do not yet have a sales organization. If we obtain regulatory approval
	for vonapanitase, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing
	and distribution. Accordingly, we may seek to further fund our operations through public or private equity or debt financings or
	other sources, including strategic collaborations. We may, however, be unable to raise additional funds or enter into such other
	arrangements when needed on favorable terms or at all. Our failure to raise additional capital or enter into such other arrangements
	as and when needed would have a negative impact on our financial condition and our ability to develop vonapanitase or any additional
	product candidates, if developed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Financial Overview
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Revenue
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0">
	To date, our revenue has been derived from revenue
	related to the expiration of any rights and obligations under the 2009 agreement with a major pharmaceutical entity and from government
	grants. In the third quarter of 2014 we recognized $2.9 million of revenue related to the expiration in August 2014 of any rights
	and obligations related to the 2009 agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
	Research and development expenses consist primarily of costs
	incurred for the development of vonapanitase, which include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
	&nbsp;
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	employee-related
	expenses, including salaries, benefits, travel and stock-based compensation expense;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
	&nbsp;
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	expenses incurred under agreements with CROs and investigative sites that will conduct our clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
	&nbsp;
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	t
<FONT STYLE="FONT-SIZE: 10PT">
	he cost of acquiring, developing and manufacturing clinical
	trial materials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
	&nbsp;
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	costs associated with regulatory operations; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
	&nbsp;
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 139 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	139
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We expense research and development costs to operations
	as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress
	to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us
	by our vendors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We cannot determine with certainty the duration
	and completion costs of the current or future clinical trials or if, when, or to what extent we will generate revenues from the
	commercialization and sale of vonapanitase. We may never succeed in achieving regulatory approval for vonapanitase. The duration,
	costs and timing of clinical trials and development of vonapanitase will depend on a variety of factors, which include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the scope, rate of progress and expense of our ongoing as well as any additional clinical trials and other research and development activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	uncertainties in clinical trial enrollment rate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	future clinical trial results;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	significant and changing government regulation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the timing and receipt of any regulatory approvals.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	A change in any of these factors could mean a
	significant change in the costs and timing associated with the development of vonapanitase. For example, if the FDA, or another
	regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for
	the completion of clinical development or if we experience significant delays in enrollment in any of our clinical trials, we could
	be required to expend significant additional financial resources and time on the completion of clinical development. We expect
	our research and development expenses to increase for the foreseeable future as we continue the development of vonapanitase. Our
	current development activities and future plans include the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	we commenced our first Phase 3 clinical trial of vonapanitase for patients undergoing creation of a radiocephalic
	AVF in the third quarter of 2014
<FONT STYLE="FONT-SIZE: 10PT">
	, completed patient enrollment in October 2015 and expect to release
	top-line data in December 2016. We enrolled the first patient in our second Phase 3 trial in August 2015 and expect to complete
	enrollment in the first quarter of 2017. If the results from the first Phase 3 trial are sufficiently compelling, we intend to
	meet with the FDA to discuss the possibility of submitting a BLA, supported by the single Phase 3 trial and may decide to submit
	a BLA to the FDA prior to completing the second Phase 3 trial;
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 140 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	140
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	we may, based on additional data including the data from our Phase 3 clinical trials and if sufficient funds become available, choose to conduct a clinical trial of vonapanitase in Europe;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	we may, based on additional data including the data from our Phase 3 clinical trials and if sufficient funds become available, study the effects of vonapanitase versus placebo on brachiocephalic AVFs and in patients undergoing placement of an arteriovenous graft, or AVG; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 76PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	we expect to continue to manufacture clinical trial materials
	in support of our clinical trials and to also perform process validation activities in anticipation of a potential BLA filing.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 3.85PT 0 0 22.6PT">
<B>
<I>
	General and Administrative Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	General and administrative expenses consist
	principally of salaries and related costs for personnel, including stock-based compensation and travel expenses, in executive
	and other administrative functions. Other general and administrative expenses also include professional fees for legal,
	patent review, consulting and accounting services as well as facility related costs. We anticipate increased expenses related
	to audit, legal, regulatory and tax-related services associated with maintaining compliance with our NASDAQ listing and SEC
	requirements, director and officer liability insurance premiums and investor relations costs associated with being a public
	company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Additionally, if and when we believe a regulatory
	approval of vonapanitase appears likely, we anticipate that we will increase our salary and personnel costs and other expenses
	as a result of our preparation for commercial operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Investment Income
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT; MARGIN: 0">
	Investment income consists of interest income earned
	on our cash, cash equivalents and marketable securities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Interest Expense
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Interest expense consists of interest incurred
	on debt instruments, amortized deferred financing costs and amortized debt discount. The debt discount primarily consists of the
	fair value of the bifurcated features embedded in the convertible notes issued in September 2013 and converted in May 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 141 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	141
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage142"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 2.65PT 0 0 22.6PT">
<B>
<I>
	Other (Expense) Income, Net
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
	Other (expense)
	income, net consists of the gain realized by the sale of fixed assets, changes in the fair value of the derivative liability associated
	with the convertible notes, changes in the fair value of the investors&rsquo; rights and obligations issued in connection with
	the Series D redeemable convertible preferred stock, non-cash gains and losses from currency exchange rate fluctuations on transactions
	or balances denominated in a foreign currency and realized and unrealized gains and losses on the forward foreign currency contracts
	we entered into in the second quarter of 2015 to purchase Swiss Francs to reduce our foreign currency exposure through 2016. This
	foreign currency exposure is the result of a contract with the manufacturer of our active pharmaceutical ingredient (&ldquo;API&rdquo;)
	which requires us to make payments in Swiss Francs. The derivative liability associated with the convertible notes was extinguished
	upon the conversion of the notes into Series D redeemable convertible preferred stock in May 2014. The Series D investors&rsquo;
	rights and obligations were either exercised or extinguished upon the completion of our IPO in October 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Accretion of Preferred Stock
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Subsequent to the May 2014 Series D redeemable
	convertible preferred stock financing, our shares of preferred stock were redeemable beginning in 2019 at their original issuance
	price plus any declared or accrued but unpaid dividends upon written election of the preferred stockholders in accordance with
	the terms of our certificate of incorporation. Accretion of preferred stock reflects the accretion of issuance costs and cumulative
	dividends on our preferred stock based on their respective redemption values. On October 27, 2014, we closed our IPO and all shares
	of preferred stock were converted into 8,651,805 shares of our Common Stock. No accretion of preferred stock has been recorded
	after this date as no shares of preferred stock were outstanding after such date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Critical Accounting Policies and Significant Judgments and Estimates
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our management&rsquo;s discussion and analysis of our financial position and results of operations is based
	on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United
	States of America, or GAAP. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions
	that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, we evaluate estimates,
	which include estimates related to clinical trial accruals, stock-based compensation expense, embedded derivatives and reported
	amounts of revenues and expenses during the reported period. We base our estimates on historical experience and other market-specific
	or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from
	those estimates or assumptions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 142 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	142
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage143"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	While our significant accounting policies are described
	in more detail in the notes to our consolidated
<I>
	&nbsp;
</I>
	financial statements and related notes appearing elsewhere in this
	Annual Report, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation
	of our financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
<I>
	Accrued Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	As part of the process of preparing our consolidated
<I>
	&nbsp;
</I>
	financial
	statements, we are required to estimate our accrued expenses. This process involves reviewing open contracts and purchase orders,
	communicating with our personnel to identify services that have been performed for us and estimating the level of service performed
	and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The
	majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met.
	We make estimates of our accrued expenses as of each balance sheet date in our consolidated
<I>
	&nbsp;
</I>
	financial statements based
	on facts and circumstances known to us at that time. We routinely confirm the accuracy of our estimates with the service providers
	and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to CROs in
	connection with clinical trials and vendors related to manufacturing, development and distribution of clinical supplies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We base our expenses related to clinical trials
	on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage
	clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract
	and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services
	provided and result in a prepayment of the clinical expense (prepaid expense). Payments under some of these contracts depend on
	factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees,
	we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level
	of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from
	our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different
	from amounts actually incurred, if our estimates of the status and timing of services performed differs from the actual status
	and timing of services performed we may report amounts that are too high or too low in any particular period. To date, there have
	been no material differences from our estimates to the amount actually incurred.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<B>
<I>
	Derivative Financial Instruments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	We enter into forward foreign currency
	contracts to reduce our foreign currency exposure. We record these derivative financial instruments on the consolidated balance
	sheet at fair value. Although these derivative contracts are intended to economically hedge foreign exchange risk, we have not
	elected to apply hedge accounting. As such, changes in the fair value of these instruments are recorded directly in earnings as
	a component of other income (expense) as they occur. We execute derivative instruments with financial institutions that we judge
	to be credit-worthy, defined as institutions that hold an investment-grade credit rating.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 143 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	143
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage144"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We issue stock-based awards to employees and non-employees,
	generally in the form of stock options. We account for our stock-based awards in accordance with FASB ASC Topic 718,
<I>
	Compensation&#8212;Stock
	Compensation
</I>
	, (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, including grants of employee
	stock options and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive
	loss based on their fair values. We account for stock-based awards to non-employees in accordance with FASB ASC Topic 505-50,
<I>
	Equity-Based
	Payments to Non-Employees
</I>
	, which requires the fair value of the award to be remeasured at fair value as the award vests.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Our stock-based awards are subject to either service
	or performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting
	conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the
	award, which is generally the vesting term. Compensation expense related to awards to non-employees with service-based vesting
	conditions is recognized on the then-current fair value at each financial reporting date prior to the measurement date over the
	associated service period of the award, which is generally the vesting term, using the accelerated attribution method. Compensation
	expense related to awards to employees with performance-based vesting conditions is recognized based on the grant date fair value
	over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition
	is probable. Compensation expense related to awards to non-employees with performance-based vesting conditions is recognized based
	on the then-current fair value at each financial reporting date prior to the measurement date over the requisite service period
	using the accelerated attribution method to the extent achievement of the performance condition is probable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Described below is the methodology we have utilized
	in measuring stock-based compensation expense. Following the consummation of our IPO, stock option values have been determined
	based on the quoted market price of our common stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We estimate the fair value of our stock-based awards
	to employees and non-employees using the Black-Scholes option pricing model, which requires the input of highly subjective assumptions,
	including (i) the expected volatility of our stock, (ii) the expected term of the award, (iii) the risk-free interest rate and
	(iv) expected dividends. Due to the lack of a public market for the trading of our common stock and a lack of company specific
	historical and implied volatility data, we based our estimate of expected volatility on the historical volatility of a group of
	similar companies that are publicly traded. For these analyses, we select companies with comparable characteristics to ours including
	enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the
	expected life of the stock-based awards. We compute the historical volatility data using the daily closing prices for the selected
	companies&#8217; shares during the equivalent period of the calculated expected term of our stock-based awards. We will continue
	to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes
	available. We estimate the expected life of our employee stock options using the &#8220;simplified&#8221; method, whereby, the
	expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates
	for periods within the expected life of the option were based on the U.S. Treasury yield curve in effect during the period the
	options were granted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 144 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	144
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage145"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We are also required to estimate forfeitures at
	the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from its estimates. We use historical
	data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected
	to vest. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment
	in the period the estimates were revised. Stock-based compensation expense recognized in the financial statements is based on awards
	that are ultimately expected to vest.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	We have computed the fair value of employee and
	director stock options at date of grant using the following weighted-average assumptions:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Weighted average expected volatility
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	79.80
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	79.50
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected term (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.11
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Risk free interest rate
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected dividend yield
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Prior to our IPO, the estimated fair value of our
	common stock was determined contemporaneously by our Board of Directors based on valuation estimates provided by management and
	prepared in accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid,
	Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or AICPA Practice Aid, as well as independent third-party
	valuations. Our contemporaneous valuations of our common stock were based on a number of objective and subjective factors, including
	external market conditions affecting the biotechnology industry sector and the prices at which we sold shares of preferred stock,
	the superior rights and preferences of securities senior to our common stock at the time of each grant and the likelihood of achieving
	a liquidity event such as an IPO. Consequently, after the IPO the fair value of the shares of common stock underlying the stock
	options is the closing price on the option grant date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 0.5PT 0 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 145 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	145
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage146"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0.5PT 0 0">
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Comparison of the Years Ended December 31, 2015 and 2014
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The following table summarizes our results of
	operations for the years ended December 31, 2015 and 2014 (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.35PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.35PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	Years
	Ended December 31,
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="COLOR: BLACK">
	Period-to-Period
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	2014
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	Change
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	Revenue
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	2,948
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(2,948
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	Operating expenses:
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
<FONT STYLE="COLOR: BLACK">
	Research and development
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	12,381
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	6,432
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	5,949
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
<FONT STYLE="COLOR: BLACK">
	General and administrative
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	8,489
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	4,096
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	4,393
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
<FONT STYLE="COLOR: BLACK">
	Total operating expenses
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	20,870
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	10,528
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	10,342
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
<FONT STYLE="COLOR: BLACK">
	Loss from operations
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(20,870
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(7,580
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(13,290
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
<FONT STYLE="COLOR: BLACK">
	Other income (expense):
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
<FONT STYLE="COLOR: BLACK">
	Investment income
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	144
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	24
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	120
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
<FONT STYLE="COLOR: BLACK">
	Interest expense
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(857
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	857
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
<FONT STYLE="COLOR: BLACK">
	Other (expense) income, net
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(651
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	5,071
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(5,722
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
<FONT STYLE="COLOR: BLACK">
	Total other (expense) income
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(507
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	4,238
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(4,745
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
<FONT STYLE="COLOR: BLACK">
	Net Loss
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(21,377
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(3,342
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: RED; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	(18,035
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.35PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.35PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.35PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	Revenue
</I>
	. During the years ended December
	31, 2015, our revenue was $2.9 million lower as compared to the year ended December 31, 2014 due to the recognition of $2.9 million
	of deferred revenue related to the expiration in August 2014 of any rights and obligations under the aforementioned 2009 agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 146 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	146
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage147"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<I>
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	Research and Development Expenses
</I>
	. The
	following table identifies research and development expenses on both an external and internal basis for the years ended December
	31, 2015 and 2014 (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Period-to-Period
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Change
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	External PRT-201 research and development expenses
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,580
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,096
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,484
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Internal research and development expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,801
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,336
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,465
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total research and development expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,381
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,432
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,949
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	During the year ended December 31, 2015, our total
	research and development expenses increased by $5.9 million compared to the year ended December 31, 2014 primarily due to $4.5
	million in increased external expenses. The increase of $4.5 million in external expenses was primarily driven by $3.4 million
	in increased expenses for our ongoing radiocephalic AVF Phase 3 clinical trials and $1.0 million in increased expenses for our
	manufacturing pre-validation and other efforts. Our internal research and development expenses increased by $1.4 million in the
	year ended December 31, 2015 as compared to the year ended December 31, 2014 due primarily to increased personnel costs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0">
<I>
	General and Administrative Expenses.
</I>
	During
	the year ended December 31, 2015, our total general and administrative expenses were $4.4 million higher as compared to the year
	ended December 31, 2014 primarily due to $2.6 million of additional overhead and personnel costs to support our ongoing corporate
	activities and $1.8 million in increased expenses associated with being a public company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	Investment Income.
</I>
	During the year ended
	December 31, 2015, investment income increased by $0.1 million due to the increase in interest income earned on our higher cash,
	cash equivalents and marketable securities balances during the year ended December 31, 2015 as compared to the year ended December
	31, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	Interest Expense.
</I>
	During the year ended
	December 31, 2015, interest expense was $0.9 million lower as compared to the year ended December 31, 2014 due to the decrease
	of $0.9 million in interest expense related to our convertible notes which were extinguished in May 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<I>
	Other (Expense) Income, Net.
</I>
	During the
	year ended December 31, 2015, other (expense) income, net changed by $5.7 million as compared to the year ended December 31, 2014
	primarily due to a decrease of $5.0 million in income related to the change in fair market value of the Series D preferred stock
	investor rights obligation in 2014 and an increase of $0.7 million expense related to the change in the fair value associated with
	the forward foreign currency contracts we entered into in second quarter of 2015 and the Swiss Francs denominated currency we held
	as of the period end.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 147 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	147
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage148"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Comparison of the Years Ended December 31, 2014 and 2013
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December&nbsp;31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Period-to-Period
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Change
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT">
	Revenue
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,948
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,948
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,432
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,994
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,438
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,128
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	968
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,528
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,122
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,406
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Loss from operations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,580
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,122
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(458
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Other income (expense):
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Investment income
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Interest expense
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(857
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(861
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Other income, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,071
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	67
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,004
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Total other income (expense)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,238
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(790
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,028
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net Loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,570
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	Revenue.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue
	increased by $2.9 million for the year ended December 31, 2014 from the year ended December 31, 2013.&nbsp;&nbsp;This increase
	was due to the recognition of $2.9 million of deferred revenue related to the expiration in August 2014 of any rights and obligations
	under the aforementioned 2009 agreement with a major pharmaceutical entity.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	Research and Development Expenses.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;The
	following table identifies research and development expenses on both an external and internal basis for the years ended December
	31, 2014 and 2013:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Period-to-Period
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Change
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	External PRT-201 research and development expenses
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,096
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,962
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,134
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Internal research and development expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,336
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,032
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	304
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total research and development expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,432
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,994
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,438
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	During the year ended December 31, 2014, our total
	research and development expenses increased by $2.4&nbsp;million compared to the year ended December 31, 2013 primarily due to
	$2.1&nbsp;million in increased external expenses. The increase of $2.1&nbsp;million in external expenses was driven by $2.2 million
	in increased expenses for our ongoing radiocephalic AVF Phase&nbsp;3 clinical trial, $0.1&nbsp;million in increased external clinical
	expenses related to preparation for our second radiocephalic AVF Phase&nbsp;3 clinical trial and $0.2 million in increased expenses
	for our manufacturing support of the radiocephalic AVF Phase&nbsp;3 clinical trials offset by $0.4 million in lower external clinical
	expenses related to our AVF Phase 2 and AVG clinical trials which were completed in 2013. Our internal research and development
	expenses increased by $0.3 million in the year ended December 31, 2014 as compared to the year ended December 31, 2013 due primarily
	to personnel costs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 148 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	148
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage149"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	General and Administrative Expenses.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;During
	the year ended December 31, 2014, our total general and administrative expenses were $1.0 million higher as compared to the year
	ended December 31, 2013 primarily due to additional overhead and personnel costs in the year ended December 31, 2014 of $0.7&nbsp;million
	to support our on-going corporate activities and $0.3 million in expenses associated with being a public company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	Investment Income.
</I>
	During the year ended
	December 31, 2014, investment income increased by an immaterial amount.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	Interest Expense.
</I>
	&nbsp;&nbsp;&nbsp;During
	the year ended December 31, 2014, interest expense decreased by an immaterial amount.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<I>
	Other Income, Net.&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	During
	the year ended December 31, 2014, other income, net increased by $5.0&nbsp;million as compared to the year ended December 31, 2013
	primarily due to the change in fair value of the investor rights and obligations issued in connection with the Series D preferred
	stock.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The Series D Preferred Stock investor rights were either exercised or extinguished
	upon the closing of our IPO.
</FONT>
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Overview
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Since our inception and through the year ended December 31, 2015, we had received $174.4 million in net proceeds
	comprised of $94.0 million from the issuance of private equity securities, $7.7 million from the issuance of convertible notes,
	$10.0 million from business development activities, $0.2 million from government grants and $62.5 million from our IPO. At December
	31, 2015, our cash and cash equivalents and available-for-sale investments totaled $65.3 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Initial Public Offering
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	On October 27, 2014, we completed our IPO whereby
	we sold 7,026,500 shares of Common Stock (including 916,500 shares of Common Stock sold by us pursuant to the full exercise of
	an overallotment option granted to our underwriters in connection with the IPO) at a price of $10.00 per share. The shares began
	trading on the NASDAQ Global Market on October 22, 2014. The aggregate net proceeds resulting from the IPO were $62.5 million after
	deducting underwriting discounts and commissions and offering-related expenses paid by us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 149 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	149
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage150"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Warrants Exercises
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Prior to the closing of our IPO, 498,889 shares
	of our Common Stock were issued upon the exercise of warrants with a weighted-average exercise price of $4.60 per share.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
<B>
<I>
	Series D Financing
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	On May 13, 2014, we received net proceeds of approximately
	$24.5 million from the issuance of Series D redeemable convertible preferred stock to new and existing investors at a price per
	share of $0.588656. In aggregate, we issued 52,813,827 shares of Series D redeemable convertible preferred stock including 10,344,201
	shares for the conversion of $4.6 million of convertible notes and accrued interest at a conversion price of $0.4414 per share.
	As provided by the Series D stock purchase agreement, the investors in the Series D redeemable convertible preferred stock had
	the potential opportunity to invest an additional $20.0 million in Series D redeemable convertible preferred stock at $0.588656
	per share. Upon the closing of our IPO, all shares of preferred stock were converted into 8,651,805 shares of our Common Stock
	and the Series D investors&#8217; rights to purchase additional shares of Series D redeemable convertible preferred stock were
	terminated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
<B>
<I>
	Operating Capital Requirements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We expect to incur increasing operating losses
	for at least the next several years as we (i) conduct our Phase 3 clinical trials for vonapanitase in radiocephalic AVFs, thereafter
	seeking marketing approval for vonapanitase in radiocephalic AVFs assuming successful trial outcomes, and (ii) pursue development
	of vonapanitase for additional indications, including brachiocephalic AVFs and AVGs. We may not be able to complete the development
	and initiate commercialization of vonapanitase if, among other things, our clinical trials are not successful, and the FDA does
	not approve vonapanitase or does not approve vonapanitase when we expect.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 0.5PT 0 5.95PT">
	We believe that our cash and cash
	equivalents and available-for-sale investments as of December 31, 2015 will be sufficient to fund our operations into the fourth
	quarter of 2017. We believe that these funds will be sufficient to enable us to obtain results from our first Phase 3 clinical
	trial of vonapanitase in radiocephalic AVFs, to enroll patients in our second Phase 3 trial of vonapanitase in radiocephalic AVFs,
	and to fund our CMC activities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 150 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	150
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage151"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Our forecast of the period of time through which
	our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties,
	and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to
	be wrong and we could exhaust our available capital resources sooner than we currently expect. Our future funding requirements,
	both near and long-term, will depend on many factors, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.1PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the timing and costs of our planned Phase 3 clinical trials of vonapanitase in radiocephalic AVFs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the timing and costs of developing vonapanitase for additional indications;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the outcome, timing and costs of seeking regulatory approvals;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the costs of commercialization activities for vonapanitase in radiocephalic AVFs and other indications if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	subject to receipt of marketing approval, revenue received from commercial sales of vonapanitase;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	the terms and timing of any future collaborations, licensing,
	consulting or other arrangements that we may establish;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights, including royalty payments that we are obligated to pay to Johns Hopkins University pursuant to our assignment agreement related to vonapanitase;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 99PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	t
<FONT STYLE="FONT-SIZE: 10PT">
	he extent to which we in-license or acquire other products and
	technologies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 8PT">
<B>
<I>
	Cash Flows
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The following table summarizes our sources and
	uses of cash for the years ended December 31, 2015 and 2014 (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net cash used in operating activities
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(17,566
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(9,990
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net cash used in investing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,331
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(12,483
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	163
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88,520
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Effect of exchange rate changes on cash
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(75
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net (decrease) increase in cash and cash equivalents
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(28,809
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	66,047
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 151 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	151
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage152"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 3.85PT 0 0 22.6PT">
<B>
<I>
	Comparison of the Years Ended December 31, 2015
	and 2014
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0.5PT 0 0">
	Net cash used in operating activities was
	$17.6 million for the year ended December 31, 2015 compared to $10.0 million for the year ended December 31, 2014. The increase
	of $7.6 million in cash used in operating activities was driven by an increase in our net loss of $18.0 million and offset by an
	increase of $10.4 million in non-cash operating expenses as compared to the year ended December 31, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Net cash used in investing activities was $11.3
	million for the year ended December 31, 2015 compared to $12.5 million for the year ended December 31, 2014. The decrease of $1.2
	million in cash used by investing activities was primarily driven by an increase in maturities and sale of investments of $55.0
	million offset by an increase in the purchases of available-for-sale investments of $53.7 million and an increase in capital equipment
	purchases of $0.1 million as compared to the year ended December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Net cash provided by financing activities was
	$0.2 million during the year ended December 31, 2015 compared to $88.5 million for the year ended December 31, 2014. The decrease
	in cash provided by financing activities of $88.3 million was primarily driven by the proceeds of our Series D Preferred Stock
	issuance and our IPO during the year ended December 31, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The following table summarizes our sources and
	uses of cash for the years ended December 31, 2014 and 2013:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net cash used in operating activities
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(9,990
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,657
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net cash used in investing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(12,483
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,727
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	88,520
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,314
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net (decrease) increase in cash and cash equivalents
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	66,047
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	384
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 152 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	152
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage153"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<B>
<I>
	Comparison of the Years Ended December 31,
	2014 and 2013
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Net cash used in operating activities was $10.0
	million for the year ended December 31, 2014 compared to $6.7 million for the year ended December 31, 2013. The increase of $3.3
	million in cash used in operating activities was primarily driven by an increase in our operating expenses of $3.4 million and
	offset by a decrease in working capital balances and a decrease in non-cash operating expenses of $0.1 million as compared to the
	year ended December 31, 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Net cash used in investing activities was $12.5
	million for the year ended December 31, 2014 compared to net cash provided by investing activities of $2.7 million for the year
	ended December 31, 2013. The increase of $15.2 million in cash used by investing activities was primarily driven by an increase
	in the purchases of available-for-sale investments of $31.1 million offset by an increase in maturities of investments of $16.0
	million as compared to the year ended December 31, 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Net cash provided by financing activities during
	the year ended December 31, 2014 was $88.5 million and resulted primarily from the proceeds from our Series D Preferred Stock issuance
	and our IPO.&nbsp;&nbsp;Net cash provided by financing activities during the year ended December 31, 2013 of approximately $4.3
	million was attributable to our September 2013 convertible promissory note financing.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0PT">
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We did not have during the periods presented,
	and we do not currently have, any off-balance sheet arrangements, as defined under the applicable regulations of the SEC.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Contractual Obligations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	The following table summarizes
	our outstanding contractual obligations as of payment due date by period at December 31, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0; BACKGROUND-COLOR: WHITE">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	Total
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	Less
	than 1 Year
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	1
	to 3 Years
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	3
	to 5 Years
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="COLOR: BLACK">
	More
	than 5 Years
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 45%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	Operating leases (1)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	420
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	168
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: RED">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	252
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: RED; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	Purchase obligations (2)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	1,917
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	1,917
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PX; TEXT-ALIGN: JUSTIFY">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In July 2009 we entered into a multi-year non-cancelable lease for our offices in Waltham, Massachusetts. In October 2011, we amended the lease extending its expiration to December 2014. In August 2014, we amended the lease extending its expiration to June 2018 with one optional one-year extension period. The minimum lease payments above do not include common area maintenance charges or real estate taxes.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 153 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	153
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage154"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 36PX">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In July 2015, we entered into a manufacturing services agreement with Lonza Ltd (&ldquo;Lonza&rdquo;) for
	the processing, development and manufacture of the API in its lead product candidate, vonapanitase. Purchase obligations include
	a contractual arrangement in the form of purchase orders with Lonza, where there is a fixed non-cancelable payment schedule.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 13.5PT">
	In addition, as of December
	31, 2015, we had the following outstanding forward foreign currency contracts that were not designated for hedge accounting and
	that were used to reduce the exposure to fluctuations in the U.S dollar value of forecasted transactions denominated in Swiss Franc
	(dollars in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 13.5PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Notional Amount
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Effective Date
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Maturity Date
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Number of Instruments
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="WIDTH: 28%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Foreign currency contracts
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5,713
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 8%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	June 12, 2015
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 22%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Various dates through December 15, 2016
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	4
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 13.5PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
	The contractual obligations
	tables do not include any potential future royalty payments we may be required to make under our license assignment with Johns
	Hopkins University, due to the uncertainty of the occurrence of the events requiring payment under that agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	JOBS Act
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In April 2012, the Jumpstart Our Business Startups Act, or JOBS Act was enacted in the United States. Section
	107 of the JOBS Act provides that an &ldquo;emerging growth company,&rdquo; or EGC, can take advantage of the extended transition
	period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging
	growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
	We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised
	accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth public companies.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 3.85PT 0 0">
<A NAME="F10K_031416P_HTM_A_009">
</A>
	Item 7A. Qualitative and Quantitative Disclosures about Market
	Risk
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The market risk inherent in our financial instruments
	and in our financial position represents the potential loss arising from adverse changes in interest rates. As of December 31,
	2015, we had cash equivalents and available-for-sale investments of $65.3 million consisting primarily of investments in U.S. Treasuries
	and certificates of deposit. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in
	the general level of U.S. interest rates, particularly because our investments are in short-term marketable securities. Our marketable
	securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration
	of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have
	a material effect on the fair market value of our investment portfolio. We have the ability to hold our marketable securities until
	maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the
	effect of a change in market interest rates on our investments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 154 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	154
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage155"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We contract with CROs and contract manufacturers
	internationally. Transactions with one of our contract manufacturers is settled in Swiss Francs and therefore, while we believe
	we have some foreign currency exposure, we have entered into forward foreign currency contracts to purchase Swiss Francs to manage
	this risk.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 3.85PT 0 0">
<A NAME="F10K_031416P_HTM_A_010">
</A>
	Item 8. Financial Statements and Supplementary Data
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The consolidated
<I>
	&nbsp;
</I>
	financial statements together with the report of our independent registered public
	company accounting firm, required to be filed pursuant to this Item 8 are appended to this Annual Report. An index of those consolidated
<I>
	&nbsp;
</I>
	financial
	statements is found in Item 15.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 3.85PT 0 0">
<A NAME="F10K_031416P_HTM_A_011">
</A>
	Item 9. Changes in and Disagreements with Accountants and Accounting
	and Financial Disclosure
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	None.
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 3.85PT 0 0">
<A NAME="F10K_031416P_HTM_A_012">
</A>
	Item 9A. Controls and Procedures
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Management&#8217;s Evaluation of our Disclosure Controls and Procedures
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We maintain disclosure controls and procedures
	(as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be
	disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized, and reported within
	the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including
	our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As of December 31, 2015, our management, with
	the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure
	controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Our management recognizes that
	any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their
	objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and
	procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described
	above that, as of December 31, 2015, our disclosure controls and procedures were effective at the reasonable assurance level.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 155 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	155
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage156"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	We continue to review and document our disclosure
	controls and procedures, including our internal controls and procedures for financial reporting, and may from time to time make
	changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
<B>
	Management&#8217;s Annual Report on Internal
	Controls Over Financial Reporting
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.25IN">
	Our management is responsible for establishing and maintaining adequate internal control over our financial
	reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as the
	process designed by, or under the supervision of, our Chief Executive Officer, and effected by our Board of Directors, management
	and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of
	our financial statements for external purposes in accordance with generally accepted accounting principles, and includes those
	policies and procedures that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
	the transactions and dispositions of assets;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 2.25PT; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	provide reasonable assurance that transactions are recorded as necessary to permit preparation
	of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being
	made only in accordance with the authorizations of management and directors; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 2.25PT; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition,
	use or disposition of assets that could have a material effect on our financial statements.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	Under the supervision and with the participation of our management, including our Chief Executive Officer, we
	conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework provided in
<I>
	Internal Control&mdash;Integrated Framework (2013)
</I>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission,
	or COSO. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as
	of December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; COLOR: RED">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 156 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	156
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage157"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; COLOR: RED">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	Changes in Internal Control Over Financial Reporting.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	During the year ended December 31, 2015, there
	have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15 (f) and 15(d)-15(f)
	promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal
	control over financial reporting.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 3.85PT 0 0">
<A NAME="F10K_031416P_HTM_A_013">
</A>
	Item 9B. Other Information
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Not applicable.
</P>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
<B>
	PART III
</B>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
<A NAME="F10K_031416P_HTM_A_014">
</A>
	Item 10. Directors, Executive Officers and Corporate Governance
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The information required by
	this Item is set forth in our Proxy Statement for the 2016 Annual Meeting of Stockholders to be filed with the SEC within 120 days
	of December 31, 2015, and is incorporated into this Annual Report on Form 10-K by reference.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
<A NAME="F10K_031416P_HTM_A_015">
</A>
	Item 11. Executive and Director Compensation&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The information required
	by this Item is set forth in our Proxy Statement for the 2016 Annual Meeting of Stockholders to be filed with the SEC within 120
	days of December 31, 2015, and is incorporated into this Annual Report on Form 10-K by reference.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
<A NAME="F10K_031416P_HTM_A_016">
</A>
	Item 12. Security Ownership of Certain Beneficial
	Owners and Management and Related Stockholder Matters Securities Authorized for Issuance Under Equity Compensation Plans&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	See &#8220;Securities Authorized
	for Issuance Under Equity Compensation Plans&#8221; in Item 5 of this Annual Report on Form 10-K.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The other information required
	by this Item is set forth in our Proxy Statement for the 2016 Annual Meeting of Stockholders to be filed with the SEC within 120
	days of December 31, 2015, and is incorporated into this Annual Report on Form 10-K by reference.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
<A NAME="F10K_031416P_HTM_A_017">
</A>
	Item 13. Certain Relationships and Related
	Party Transactions and Director Independence&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The information required
	by this Item is set forth in our Proxy Statement for the 2016 Annual Meeting of Stockholders to be filed with the SEC within 120
	days of December 31, 2015, and is incorporated into this Annual Report on Form 10-K by reference.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
<A NAME="F10K_031416P_HTM_A_018">
</A>
	Item 14. Principal Accounting Fees and Services
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The information required
	by this Item is set forth in our Proxy Statement for the 2016 Annual Meeting of Stockholders to be filed with the SEC within 120
	days of December 31, 2015, and is incorporated into this Annual Report on Form 10-K by reference.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 157 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	157
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage158"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	PART IV
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 3.85PT 0 0">
<A NAME="F10K_031416P_HTM_A_019">
</A>
	Item 15. Exhibits and Financial Statement Schedules
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0; MARGIN-TOP: 0PT">
<B>
	(a)(1) Financial Statements
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0.25IN">
	The financial statements listed below are
	filed as part of this Annual Report on Form 10-K.
</P>
</EFX_EXHIBITS>
</EFX_PART_IV>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 0.25IN">
	Report of Independent Registered Public Accounting Firm
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 0.25IN">
	Consolidated Balance Sheets at December 31, 2015 and 2014
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 0.25IN">
	Consolidated Statements of Operations and Comprehensive Loss
	for the years ended December 31, 2015, 2014 and 2013
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 0.25IN">
	Consolidated Statements of Redeemable Convertible Preferred
	Stock and Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2015, 2014 and 2013
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 0.25IN">
	Consolidated Statements of Cash Flows for the years ended
	December 31, 2015, 2014 and 2013
</P>
</EFX_AUDITORS_OPINION>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 0.25IN">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
<B>
	(a)(2) Financial Statement Schedules
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0; TEXT-INDENT: 0.5IN">
	All financial schedules have
	been omitted because the required information is either presented in the Consolidated Financial Statements or the Notes thereto
	or is not applicable or required.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
<B>
	(a)(3) Exhibits
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The exhibits required by Item 601 of Regulation
	S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the exhibits and are
	incorporated herein.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	(b) Exhibits
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT; MARGIN: 0PT 0">
	The exhibits required by Item 601 of Regulation
	S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the exhibits and are
	incorporated herein.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 158 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	158
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage159"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Proteon Therapeutics,&nbsp;Inc.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Index to Consolidated Financial Statements
</B>
<B>
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Pages
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_020">
	Report of Independent Registered Public Accounting Firm
</A>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_020">
	F-2
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#F10K_031416P_HTM_A_021">
	Consolidated Balance Sheets at December&nbsp;31, 2015 and 2014
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_021">
	F-3
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<A HREF="#F10K_031416P_HTM_A_022">
	Consolidated Statements of Operations and Comprehensive Loss for the years ended December&nbsp;31, 2015, 2014 and 2013
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_022">
	F-4
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<A HREF="#F10K_031416P_HTM_A_023">
	Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the years ended December&nbsp;31, 2015, 2014 and 2013
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_023">
	F-5
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<A HREF="#F10K_031416P_HTM_A_024">
	Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2015, 2014 and 2013
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_024">
	F-6
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<A HREF="#F10K_031416P_HTM_A_025">
	Notes to Consolidated Financial Statements
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<A HREF="#F10K_031416P_HTM_A_025">
	F-7
</A>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 159; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="eolPage160"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="F10K_031416P_HTM_A_020">
</A>
<B>
	Report of Independent Registered Public
	Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	The Board of Directors and Stockholders Proteon Therapeutics, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	We have audited the accompanying consolidated balance sheets of Proteon Therapeutics, Inc. (the Company) as of December 31, 2015 and 2014, and the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&rsquo; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2015. These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these financial statements based on our audits.
</P>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company&rsquo;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Proteon Therapeutics, Inc. at December 31, 2015 and 2014, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2015, in conformity with U.S. generally accepted accounting principles.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	/s/ Ernst &amp; Young
	LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	Boston, Massachusetts
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	March 14, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 160; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage161"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
<B>
	Proteon Therapeutics, Inc.
</B>
</P>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
<A NAME="F10K_031416P_HTM_A_021">
</A>
	Consolidated Balance Sheets
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<I>
	(in thousands, except share and per share data)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="BALANCE-SHEET">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
<BR>
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	Assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Current assets:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	40,031
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	68,840
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Available-for-sale investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	25,232
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	14,755
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,345
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,006
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Total current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	66,608
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	84,601
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Property and equipment, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	224
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	83
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Other non-current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	706
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	114
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	67,538
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	84,798
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Liabilities and stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Current liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,020
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	917
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,576
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,421
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Other current liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Total current liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,133
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,338
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Total liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,133
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,338
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Commitments and contingencies (Note 7)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Stockholders&#8217; equity:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2015 and 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Common stock, $0.001 par value, 100,000,000 shares authorized at December&nbsp;31, 2015 and 2014; 16,501,500 and 16,448,455 shares issued and outstanding at December&nbsp;31, 2015 and&nbsp;&nbsp;2014, respectively
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Additional paid-in capital
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	194,651
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	192,324
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Accumulated deficit
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(131,251
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(109,874
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Accumulated other comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(11
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Total stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	63,405
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	82,460
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total liabilities and stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	67,538
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	84,798
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BALANCE_SHEET>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 3.85PT 0 0">
<I>
	See accompanying notes to these consolidated financial statements.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 161; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage162"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
</B>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Proteon Therapeutics, Inc.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<A NAME="F10K_031416P_HTM_A_022">
</A>
<B>
	Consolidated Statements of Operations and Comprehensive Loss
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<I>
	(in thousands, except share and per share data)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; COLOR: RED">
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="INCOME">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 57%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Revenue
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,948
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	12,381
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,432
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,994
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	8,489
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,128
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	20,870
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	10,528
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,122
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(20,870
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,580
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,122
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Other income (expense):
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Investment income
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	144
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Interest expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(857
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(861
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Other (expense) income, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(651
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	5,071
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	67
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Total other (expense) income
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(507
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,238
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(790
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Unrealized loss on available-for-sale investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Comprehensive loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,382
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,348
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,913
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Reconciliation of net loss to net loss attributable to common stockholders:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Accretion of redeemable convertible preferred stock to redemption value
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,353
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,119
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net loss attributable to common stockholders
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(9,695
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(14,031
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net loss per share attributable to common stockholders - basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1.30
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3.16
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(59.66
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,464,123
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,064,507
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	235,184
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; FONT-STYLE: NORMAL; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
<FONT STYLE="COLOR: BLACK">
	Supplemental disclosure of stock-based compensation expens
<FONT STYLE="FONT-SIZE: 10PT; FONT-STYLE: NORMAL">
<B>
	e and loss from currency forward contracts:
</B>
</FONT>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Included in operating expenses, above, are the following amounts for non-cash stock based compensation expense:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	650
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	114
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,514
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	345
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,164
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	459
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	155
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Included in other expense, above, are the following amounts from forward foreign currency&nbsp;&nbsp;contracts:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Realized losses from forward foreign currency contracts
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(52
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Unrealized losses from forward foreign currency contracts
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(537
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(589
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; COLOR: RED">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 3.85PT 0 0">
<I>
	See accompanying notes to these consolidated financial statements.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 162; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage163"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Proteon Therapeutics, Inc.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<A NAME="F10K_031416P_HTM_A_023">
</A>
<B>
	Statements of Redeemable Convertible Preferred Stock and Stockholders'
	Equity (Deficit)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<I>
	(in thousands, except share and per share data)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="STOCKHOLDERS-EQUITY">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Series A Redeemable Convertible Preferred Stock
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Series A-1 Redeemable Convertible Preferred Stock
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Series B Redeemable Convertible Preferred Stock
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Series C Redeemable Convertible Preferred Stock
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Series D Redeemable Convertible Preferred Stock
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Common Stock
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER">
	Additional
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER">
	Accumulated Other Comprehensive
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER">
	Total Stockholders&#8217;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amount
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amount
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amount
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amount
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amount
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	$0.001
<BR>
	Par Value
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Paid-in
<BR>
	Capital
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Accumulated
<BR>
	Deficit
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Income
<BR>
	(Loss)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Equity
<BR>
	(Deficit)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 36%; FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Balance at December 31, 2012
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	22,638,465
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	32,633
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	10,909,091
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,526
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	20,754,461
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	24,926
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	13,202,932
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,201
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	230,607
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(86,657
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(86,656
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Accretion of Series A, A-1, B and C redeemable convertible preferred stock to redemption value
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,597
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	848
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,475
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,199
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(174
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5,945
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,119
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Exercise of common stock options
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	9,298
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	155
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	155
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Unrealized gain (loss) on short term investments
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Balance at December 31, 2013
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	22,638,465
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	34,230
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	10,909,091
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	17,374
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	20,754,461
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	27,401
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	13,202,932
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	17,400
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	239,905
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(100,514
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(100,514
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Issuance of Series D redeemable convertible preferred stock net of $6,639 discount associated with investors rights and obligations and issuance costs of $452
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	52,813,827
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	24,078
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Accretion of Series A, A-1, B, C and D redeemable convertible preferred stock to redemption value
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,304
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	691
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,832
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	948
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,578
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(335
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,018
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,353
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Exercise of common stock options
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	31,356
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	459
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	459
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Unrealized gain (loss) on short term investments
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; PADDING-LEFT: 10PT">
	Exercise of warrants
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	498,889
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,428
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,428
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Conversion of redeemable convertible preferred stock into common stock
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(22,638,465
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(35,534
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(10,909,091
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(18,065
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(20,754,461
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(29,233
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(13,202,932
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(18,348
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(52,813,827
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(25,656
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	8,651,805
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	126,827
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	126,836
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Exercise of investors rights and obligations
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,408
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,408
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Issuance of Common Stock from Initial Public Offering, net of underwriters discounts and issuance costs
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,026,500
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	62,478
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	62,485
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Balance at December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,448,455
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	192,324
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(109,874
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	82,460
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Exercise of common stock options
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	45,413
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Issuance of common stock upon ESPP purchase
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,632
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Stock-based compensation expense
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,164
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,164
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Unrealized gain on short term investments
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,501,500
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	194,651
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(131,251
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(11
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 8PT; COLOR: BLACK; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	63,405
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 8PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 3.85PT 0 0">
<I>
	See accompanying notes to these consolidated financial statements.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 3.85PT 0 0">
<I>
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 163; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage164"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 3.85PT 0 0">
<I>
</I>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<B>
	Proteon Therapeutics, Inc.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<A NAME="F10K_031416P_HTM_A_024">
</A>
<B>
	Condensed Consolidated Statements of Cash Flows
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0">
<I>
	(in thousands)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="CASH-FLOWS">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Operating activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(21,377
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,342
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,912
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Reconciliation of net loss to net cash used in operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Depreciation
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Amortization of premium/discount on available-for-sale securities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	651
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Gain on sale of fixed assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(65
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accretion of discount and debt issuance cost of convertible notes payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	742
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	749
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Unrealized loss on forward foreign currency contracts included in net income
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Foreign currency remeasurement loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,164
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	459
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	155
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Change in fair value of investor rights/obligation
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5,151
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Change in fair value of derivative liability
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	81
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Changes in:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Prepaid expenses and other assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(899
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(961
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	72
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Interest receivable
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(32
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Accounts payable and accrued expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,258
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	955
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	177
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Accrued interest payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	112
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Deferred revenue from sale of acquisition option to acquire company
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(2,948
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(17,566
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(9,990
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,657
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Investing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Purchases of available-for-sale investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(88,644
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(34,950
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,878
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Proceeds from maturities of available-for-sale investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	75,505
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	22,518
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,550
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Proceeds from sale of available-for-sale investments
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,006
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Purchase of property and equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(198
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(51
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(10
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Sale of property and equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	65
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Net cash (used in) provided by investing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(11,331
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(12,483
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,727
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Financing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Proceeds from issuance of Series D preferred stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	25,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Issuance costs for preferred stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(452
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Proceeds from issuance of common stock under ESPP
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Net proceeds from IPO
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	62,485
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Proceeds from issuance of convertible notes payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,339
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Payments for debt issuance costs
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(46
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Exercise of stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	Exercise of warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,428
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	163
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	88,520
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,314
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Effect of exchange rate changes on cash
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(75
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	(Decrease) increase in cash and cash equivalents
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(28,809
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	66,047
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	384
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Cash and cash equivalents, beginning of period
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	68,840
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,793
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,409
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Cash and cash equivalents, end of period
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	40,031
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	68,840
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,793
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Supplemental disclosure of non-cash investing and financing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Accretion of redeemable convertible preferred stock to redemption value
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,353
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,119
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Conversion of convertible notes, including accrued interest, into Series D Redeemable Convertible Preferred Stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,089
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Fair value of derivative embedded within convertible notes payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,445
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Conversion of redeemable convertible preferred stock into common stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	126,836
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Fair value of investors' rights/ obligations reclassified to equity upon IPO
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,408
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 3.85PT 0 0">
<I>
	See accompanying notes to these consolidated financial statements.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 164; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage165"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 2.65PT 144.15PT 0">
<B>
	Proteon Therapeutics, Inc.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0.05PT 0 0">
<B>
<A NAME="F10K_031416P_HTM_A_025">
</A>
	Notes to Consolidated Financial Statements
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0.05PT 0 0">
<I>
	(amounts in thousands, except share and per share data)
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	1.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Organization and Operations
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	The Company
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Proteon Therapeutics, Inc. (the &#8220;Company&#8221;)
	is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the medical
	needs of patients with kidney and vascular disease. The Company was formed in June 2001 and incorporated on March 24, 2006. During
	2013, the Company formed a wholly-owned subsidiary, organized in the United Kingdom, Proteon Therapeutics Limited. As of December
	31, 2015, there has been no activity in this subsidiary other than its formation. During 2014, the Company formed a wholly-owned
	Massachusetts Securities Corporation subsidiary as a holding company for its available-for-sale investments, Proteon Securities
	Corp. The Company completed its initial public offering of its common stock, $0.001 par value per share (&#8220;Common Stock&#8221;)
	on October 27, 2014 (the &#8220;IPO&#8221;). Since inception, the Company has been primarily involved in research and development
	activities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The Company devotes substantially all of its efforts
	to product research and development, initial market development and raising capital. The Company has not generated any product
	revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other development
	stage companies, including dependence on key individuals, competition from other companies, the need for development of commercially
	viable products and the need to obtain adequate additional financing to fund the development of its product candidates. The Company
	is also subject to a number of risks similar to other companies in the biotechnology industry, including regulatory approval of
	products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to
	obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third
	parties, product liability and dependence on key individuals.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As of December 31, 2015, the Company had cash,
	cash equivalents and available-for-sale investments of $65.3 million. The Company believes that its existing cash, cash equivalents
	and available-for-sale investments will be sufficient to fund operations and capital expenditures into the fourth quarter of 2017.
	The Company had an accumulated deficit of $131.3 million as of December 31, 2015.&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 165 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage166"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	2.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Summary of Significant Accounting Policies
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Initial Public Offering
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	On October 27, 2014, the Company completed the
	IPO of its Common Stock, pursuant to a registration statement on Form S-1, as amended. An aggregate of 7,026,500 shares of Common
	Stock registered under the registration statement were sold at a price of $10.00 per share (including 916,500 shares of Common
	Stock sold by the Company pursuant to the full exercise of an overallotment option granted to the Company&#8217;s underwriters
	in connection with the IPO). Net proceeds of the IPO were $62.5 million, after deducting underwriting discounts, commissions and
	offering-related expenses payable by the Company of approximately $7.8 million. In this transaction, all shares of the Company&#8217;s
	redeemable convertible preferred stock (the &#8220;Preferred Stock&#8221;) were automatically converted into an aggregate of 8,651,805
	shares of its Common Stock and the Series D redeemable convertible preferred stock (the &#8220;Series D Preferred Stock&#8221;)
	investors&#8217; rights and obligations were either exercised or extinguished.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	At-The-Market Equity Offering Program
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-LEFT: 0">
	On November
	12,&nbsp;2015, the Company filed a shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;), and entered
	into a Sales Agreement with Cowen and Company, LLC (the "Sales Agreement") to establish an at-the-market (&#8220;ATM&#8221;)
	equity offering program pursuant to which they are able, with the Company&#8217;s authorization, to offer and sell up to $40 million
	of the Company&#8217;s Common Stock at prevailing market prices from time to time. As of December 31, 2015, the Company had not
	commenced sales under this program. The Registration Statement became effective on January 12, 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Reverse Stock Split
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	On October 1, 2014, the Board of Directors, and
	on October 3, 2014, the stockholders, approved a 1-for-15.87 reverse stock split of the Company&#8217;s Common Stock, resulting
	in a proportional adjustment to the existing conversion ratios for each series of Preferred Stock. The effective date of the reverse
	stock split was October 6, 2014. All share, share equivalent and per share amounts have been adjusted to reflect the reverse stock
	split. The ratios by which shares of Preferred Stock are convertible into shares of Common Stock were also adjusted to reflect
	the effects of the reverse stock split.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 166 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage167"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Basis of Presentation and Principles of Consolidation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The accompanying consolidated financial statements
	include the accounts of the Company and its wholly-owned subsidiaries, Proteon Therapeutics Limited and Proteon Securities Corp.
	All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have
	been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).
	Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting
	principles as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;)
	of the Financial Accounting Standards Board (&#8220;FASB&#8221;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Use of Estimates
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The preparation of financial statements in conformity
	with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and
	accompanying notes. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include, but are not limited
	to, estimates related to convertible notes, stock-based compensation expense, clinical trial accruals and reported amounts of revenues
	and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or
	other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates
	or assumptions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The Company historically utilized significant
	estimates and assumptions in determining the fair value of its Common Stock. The Company utilized various valuation methodologies
	in accordance with the framework of the 2004 and 2013 American Institute of Certified Public Accountants Technical Practice Aids,
<I>
	Valuation of Privately-Held Company Equity Securities Issued as Compensation
</I>
	, to estimate the fair value of its Common Stock
	prior to its IPO. Each valuation methodology included estimates and assumptions that required the Company&#8217;s judgment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	These estimates and assumptions included a number
	of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices
	at which the Company sold shares of Preferred Stock, the superior rights and preferences of securities senior to the Company&#8217;s
	Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or a sale of the
	Company. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of Common
	Stock at each valuation date and materially affected the financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 167 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage168"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Segment Information
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.25IN">
	Operating segments are defined as components of
	an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making
	group, in deciding how to allocate resources and in assessing performance. The Company and the Company's chief operating decision
	maker view the Company's operations and manage its business in one operating segment, which is the business of developing and commercializing
	vonapanitase for the treatment of renal and vascular disease. Currently, the Company operates in only one geographic segment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Fair Value of Financial Instruments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.25PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The Company&#8217;s financial instruments consist
	of cash and cash equivalents, available-for-sale investments, forward foreign currency contracts (see Note 6), accounts payable,
	accrued liabilities, convertible promissory notes (&#8220;Convertible Notes&#8221;) and features embedded in the Convertible Notes.
	The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment
	of the inputs used in determining the reported fair values. FASB ASC Topic 820,
<I>
	Fair Value Measurement and Disclosures
</I>
	,
	established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use
	of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market
	participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company.
	Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use
	in pricing the financial instrument and are developed based on the best information available under the circumstances. The fair
	value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial
	instruments and is not a measure of the investment credit quality. Fair value measurements are classified and disclosed in one
	of the following three categories:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.3PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 59PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 59PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 2&#8212;Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 59PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 21PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 3&#8212;Valuations that require inputs that reflect the Company&#8217;s own assumptions that are both significant to the fair value measurement and unobservable.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	To the extent that valuation is based on models
	or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly,
	the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A
	financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant
	to the fair value measurement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 168 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage169"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Financial instruments measured at fair value on
	a recurring basis include cash equivalents, short-term investments and forward foreign currency contracts (see Note 6). There have
	been no changes to the valuation methods utilized by the Company during the years ended December 31, 2015 and 2014. The Company
	evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between
	levels during the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 17.75PT 0 5.95PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 17.75PT 0 0">
<B>
<I>
	Derivative Financial Instruments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0 17.75PT 0 5.95PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	The Company enters into forward foreign currency
	contracts to mitigate its exposure to fluctuations in the exchange rates between the Swiss Franc and the U.S. dollar (see Note
	6). The Company records these derivative financial instruments on the consolidated balance sheets at fair value. Although these
	derivative contracts are intended to economically hedge foreign exchange risk, the Company has not elected to apply hedge accounting.
	As such, changes in the fair value of these instruments are recorded directly in earnings as a component of other income (expense),
	as they occur. The Company executes its derivative instruments with financial institutions that the Company judges to be credit-worthy,
	defined as institutions that hold an investment-grade credit rating.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Recent Accounting Pronouncements
</I>
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0.2PT 0 0">
	In May 2014, the FASB issued ASU 2014-09,
<I>
	&#8220;Revenue from Contracts with Customers&#8221;
</I>
	(&#8220;ASU 2014-09&#8221;), a new standard on revenue recognition providing
	a single, comprehensive revenue recognition model for all contracts with customers. The new revenue standard is based on the principle
	that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects
	the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard is effective
	beginning January 1, 2018, with no early adoption permitted. Earlier application is permitted only as of annual reporting periods
	beginning after December 15, 2016, including interim reporting periods within that reporting period. The amendments may be applied
	retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial
	application. The Company is currently evaluating the impact of the new guidance on its condensed consolidated financial statements,
	if any.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 169 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage170"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0.05PT 0 0">
	In August 2014, the FASB issued ASU 2014-15,
<I>
	&#8220;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern&#8221;
</I>
	(&#8220;ASU 2014-15&#8221;).
	ASU 2014-15 is authoritative guidance on determining when and how reporting entities must disclose going-concern uncertainties
	in their financial statements, including requiring management to perform interim and annual assessments of an entity&#8217;s ability
	to continue as a going concern within one year of the date of issuance of the entity&#8217;s financial statements and providing
	certain disclosures if there is substantial doubt about the entity&#8217;s ability to continue as a going concern. This guidance
	will be effective for the Company&#8217;s fiscal year 2016 and for interim periods beginning in the first quarter of fiscal 2017.
	The Company is still evaluating the impact of this guidance on its financial statement disclosures. &nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The adoption of this accounting
	standard may affect the Company&rsquo;s financial statement disclosures in future periods.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	In November 2015, the FASB issued ASU No. 2015-17,&nbsp;
<I>
	Income
	Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes
</I>
	&nbsp;(&#8220;ASU 2015-17&#8221;), which simplifies the presentation
	of deferred income taxes. ASU 2015-17 requires that deferred tax assets and liabilities be classified as noncurrent in a classified
	statement of financial position. ASU 2015-17 is effective for financial statements issued for fiscal years beginning after December
	15, 2016 (and interim periods within those fiscal years) with early adoption permitted. ASU 2015-17 may be either applied prospectively
	to all deferred tax assets and liabilities or retrospectively to all periods presented. The Company has elected to early adopt
	ASU 2015-17 prospectively in the fourth quarter of 2015. As a result, the Company has presented all deferred tax assets and liabilities
	as noncurrent on the consolidated balance sheet as of December 31, 2015, but have not reclassified current deferred tax assets
	and liabilities on the consolidated balance sheet as of December 31, 2014. There was no impact on the Company&#8217;s results of
	operations as a result of the adoption of ASU 2015-17.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Cash and Cash Equivalents
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company considers all highly liquid investments
	with maturities of 90 days or less from the purchase date to be cash equivalents. Cash and cash equivalents are held in depository
	and money market accounts and are reported at fair value.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Short-Term Investments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company classifies its investments as available-for-sale
	and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported
	as a component of other comprehensive income (loss) within the consolidated statements of operations and comprehensive loss and
	as a separate component of stockholders' equity (deficit). The Company invests its excess cash balances primarily in government
	debt securities, money market funds and corporate bonds with strong credit ratings and maturities of less than one year. There
	have been no realized gains and losses for the years ended December 31, 2015, 2014 and 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 170 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage171"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	At each balance sheet date, the Company assesses
	available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary.
	The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors
	contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security
	has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market
	volatility and the market and economy in general. When the Company determines that a decline in the fair value below its cost basis
	is other-than-temporary, the Company recognizes an impairment loss in the year in which the other-than-temporary decline occurred.
	There have been no other-than-temporary declines in value of short-term investments for the years ended December 31, 2015, 2014
	and 2013, as it is more likely than not the Company will hold the securities until maturity or a recovery of the cost basis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Concentrations of Credit Risk and Off-Balance Sheet Risk
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Financial instruments that potentially subject
	the Company to concentrations of credit risk are primarily cash, cash equivalents and short-term investments. The Company's cash
	and cash equivalents are held in accounts with financial institutions that management believes are creditworthy. The Company's
	investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments
	that the Company believes minimizes the exposure to concentration of credit risk. These amounts at times may exceed federally insured
	limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant
	credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Deferred Financing Costs
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	At December 31, 2015, the Company had $0.1 million
	of deferred offering costs, which primarily consist of direct incremental legal and accounting fees related to the Registration
	Statement. These costs are recorded as a non-current asset.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Property and Equipment
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Property and equipment is stated at cost, less
	accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed
	to operations as incurred. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting
	gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated
	useful lives of the respective assets, which are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="WIDTH: 60%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; WIDTH: 60%">
	Asset
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 40%">
	Estimated Useful Life
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT">
	Computer equipment and software (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-SIZE: 10PT">
	Furniture, fixtures and other (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT">
	Laboratory equipment (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	7
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 171 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage172"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Revenue
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In general, the Company recognizes revenue when
	all of the following criteria are met: persuasive evidence of arrangement exists; delivery has occurred or services have been rendered;
	the Company's price to the customer is fixed or determinable and collectability is reasonably assured. During 2014, the Company
	recognized $2.9 million of revenue related to the expiration of residual rights to license the Company&#8217;s technology.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Research and Development Costs
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Research and development costs are charged to expense
	as incurred in performing research and development activities. The costs include employee compensation costs, facilities and overhead,
	clinical study and related clinical manufacturing costs, regulatory and other related costs. Nonrefundable advanced payments for
	goods or services to be received in the future for use in research and development activities are deferred and capitalized. The
	capitalized amounts are expensed as the related goods are delivered or the services are performed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Stock-Based Compensation Expense
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company accounts for its stock-based compensation
	awards to employees and directors in accordance with FASB ASC Topic 718,
<I>
	Compensation-Stock Compensation
</I>
	("ASC 718").
	ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock, to be
	recognized in the consolidated statements of operations and comprehensive loss based on their grant date fair values. Compensation
	expense related to awards to employees is recognized on a straight-line basis based on the grant date fair value over the associated
	service period of the award, which is generally the vesting term. Share-based payments issued to non-employees are recorded at
	their fair values and are periodically revalued as the equity instruments vest and are recognized as expense over the related service
	period in accordance with the provisions of ASC 718 and FASB ASC Topic 505,
<I>
	Equity
</I>
	and are expensed using an accelerated
	attribution model.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 172 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage173"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company estimates the fair value of its stock
	options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (a)&nbsp;the
	expected stock price volatility, (b)&nbsp;the expected term of the award, (c)&nbsp;the risk-free interest rate, (d)&nbsp;expected
	dividends and (e)&nbsp;the estimated fair value of its Common Stock on the measurement date. Due to the lack of company specific
	historical and implied volatility data of its Common Stock, the Company has based its estimate of expected volatility on the historical
	volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based
	its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise
	value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected
	term of the stock based awards. The Company computes historical volatility data using the daily closing prices for the selected
	companies' shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue
	to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes
	available. Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee
	stock options using the "simplified" method, whereby, the expected term equals the arithmetic average of the vesting
	term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term
	of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the
	expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future.
	Refer to Note&nbsp;2, "
<I>
	Use of Estimates
</I>
	," for a discussion of the Company's estimated fair value of its Common
	Stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company is also required to estimate forfeitures
	at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from its estimates. The Company
	uses historical data to estimate forfeitures and records stock-based compensation expense only for those awards that are expected
	to vest. To the extent that actual forfeitures differ from the Company's estimates, the differences are recorded as a cumulative
	adjustment in the period the estimates were revised. Stock-based compensation expense recognized in the financial statements is
	based on awards that are ultimately expected to vest.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Income Taxes
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Income taxes are recorded in accordance with FASB
	ASC Topic 740,
<I>
	"Income Taxes"
</I>
	("ASC 740"), which provides for deferred taxes using an asset and liability
	approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting
	and tax reporting basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in
	effect when the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence,
	it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated available
	evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance
	has been established for the full amount of the deferred tax assets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 173 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage174"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company accounts for uncertain tax positions
	in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax
	positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit
	will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available
	facts and circumstances. As of December&nbsp;31, 2015 and 2014, the Company did not have any significant uncertain tax positions.
	The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. See Note&nbsp;10
	for further details.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Net Income (Loss) per Share Attributable to Common Stockholders
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Basic net income (loss) per share is calculated
	by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during
	the period. Diluted net income per share is calculated by dividing the net income attributable to common stockholders by the weighted-average
	number of common equivalent shares outstanding for the period, including any dilutive effect from outstanding stock options and
	warrants using the treasury stock method.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company follows the two-class method when computing
	net income (loss) per share in periods when issued shares that meet the definition of participating securities are outstanding.
	The two-class method determines net income (loss) per share for each class of common and participating securities according to
	dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available
	to common stockholders for the period to be allocated between common and participating securities based upon their respective rights
	to receive dividends as if all income for the period had been distributed. Accordingly, in periods in which the Company reports
	a net loss attributable to common stockholders when participating securities are outstanding, losses are not allocated to the participating
	securities.&nbsp;&nbsp;For purposes of calculating diluted net income per share attributable to common shareholders, preferred
	stock, stock options, warrants and convertible debt are considered common stock equivalents.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Comprehensive Loss
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Comprehensive loss consists of net income or loss
	and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources. The
	Company's net loss equals comprehensive loss, net of any changes in the unrealized gains and losses of the Company's short-term
	investments, held as available-for-sale, for all periods presented.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 174 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage175"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Subsequent Events
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company considers events or transactions that
	occur after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential
	recognition or disclosure in the financial statements. The Company has completed an evaluation of all subsequent events after the
	consolidated balance sheet date of December 31, 2015 to ensure that this filing includes appropriate disclosure of events both
	recognized in the consolidated financial statements as of December 31, 2015 and events which occurred subsequently but were not
	recognized in the consolidated financial statements. See Note&nbsp;13 for further details concerning events subsequent to the consolidated
	balance sheet dates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	3.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Fair Value Measurements
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Below is a summary of assets and liabilities measured
	at fair value (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	As of December 31, 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Quoted Prices&nbsp; in Active Markets (Level 1)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Significant Observable Inputs (Level 2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Significant Unobservable Inputs (Level 3)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash equivalents
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39,233
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39,233
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Government securities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,232
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,232
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64,465
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64,465
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Foreign currency forward contracts
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	As of December 31, 2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Quoted Prices&nbsp; in Active Markets (Level 1)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Significant Observable Inputs (Level 2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Significant Unobservable Inputs (Level 3)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash equivalents
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	68,830
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	68,830
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Government securities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,508
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,508
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Corporate bonds
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,247
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,247
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	75,338
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,247
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	83,585
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	As of December 31, 2015 and 2014, the Company&#8217;s
	cash equivalents consist principally of money market funds and government debt securities with original maturities of 90 days or
	less. Government securities consist principally of government debt securities and money market funds which are classified as available-for-sale.
	Corporate bonds consist of bonds issued by highly-rated corporate entities which are classified as available-for-sale. Forward
	foreign currency contracts consist of contracts with credit-worthy financial institutions to buy Swiss Francs with U.S. dollars
	in the future at agreed upon exchange rates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18.1PT; MARGIN: 3.85PT 14.85PT 0 4.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 175 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage176"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 3.85PT 14.85PT 0 4.5PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Forward foreign currency contracts are stated
	at fair value and consist of Level 2 financial instruments in the fair value hierarchy. The Company determines the fair value of
	its forward foreign currency contracts based on pricing from a service provider. The service provider values the instruments based
	on market prices from a variety of industry-standard independent data providers. Such market prices are based on inputs other than
	quoted prices included within Level 1 that are observable for the asset, either directly or indirectly (Level 2 inputs). Cash equivalents
	and government securities are stated at fair value and consist of Level 1 financial instruments in the fair value hierarchy
<FONT STYLE="COLOR: RED">
	.
</FONT>
	The Company determined the fair value of its debt security holdings and corporate bonds based on pricing from a service
	provider. The service provider values the securities based on market prices from a variety of industry-standard independent data
	providers. These market prices are quoted prices in active markets for identical assets (Level 1 inputs). Corporate bonds are stated
	at fair value and consist of Level 2 financial instruments in the fair value hierarchy. The Company determines the fair value of
	its corporate bonds holdings based on pricing from a service provider. The service provider values the securities based on market
	prices from a variety of industry-standard independent data providers. Such market prices are based on inputs other than quoted
	prices included within Level 1 that are observable for the asset, either directly or indirectly (Level 2 inputs).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 0">
	Available-for-sale securities at December 31,
	2015 and 2014 consist of the following (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amortized Cost
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Unrealized Gains
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Unrealized Losses
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Fair Value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Government securities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	(Due within 1 year)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,243
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(12
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,232
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,243
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(12
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,232
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Government securities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(Due within 1 year)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,510
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,508
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Corporate bonds
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	(Due within 1 year)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,251
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,247
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,761
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,755
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 176 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage177"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
</B>
</TD>
</TR>
</TABLE>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	4.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Property and Equipment, net
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Property and equipment, net consists of the following
	(in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	As of December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Computer equipment and software
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	167
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	135
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Furniture, fixtures, and other
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	244
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Laboratory equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	254
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	248
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	665
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	467
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Accumulated Depreciation
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(441
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(384
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Property and equipment, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	224
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	83
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Depreciation expense for the years ended December 31, 2015, 2014 and 2013 was $57,000, $30,000, and $27,000, respectively.
	During 2013, the Company sold fully depreciated fixed assets with an original cost basis of $0.2 million and a net book value of
	$0, recognizing a gain on sale of $0.1 million. The Company did not sell or dispose of any fixed assets during the years ended
	December 31, 2015 or 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	5.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Accrued Expenses
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	Accrued expenses consist of the following (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	As of December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Payroll and employee-related costs
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,058
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	641
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Contracted service costs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,040
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	494
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Professional fees and other
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	478
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	286
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,576
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,421
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	6.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Derivative Financial Instruments
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0">
	The Company enters into forward foreign currency
	contracts to mitigate its exposure to fluctuations in the U.S dollar value of forecasted transactions denominated in Swiss Franc.
	During the year ended December 31, 2015, the Company had forward foreign currency contract activity for which it did not elect
	hedge accounting for the forward foreign currency contracts outstanding as of December 31, 2015, but may elect to apply hedge accounting
	in the future. As a result, during the year ended December 31, 2015, the Company experienced unrealized losses within other expense
	in the consolidated statements of operations from the mark-to-market of outstanding forward foreign currency contracts. The Company
	expects potential volatility within other income (expense) in future periods for contracts for which the Company does not apply
	hedge accounting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 177 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage178"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	As of December 31, 2015, the Company had the following
	outstanding forward foreign currency contracts that were not designated for hedge accounting and that were used to reduce the exposure
	to fluctuations in the U.S dollar value of forecasted transactions denominated in Swiss Franc (dollars in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Notional Amount
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Effective Date
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Maturity Date
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Number of Instruments
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 20%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5,713
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	June 12, 2015
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 31%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	Various dates through December 15, 2016
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	4
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	No forward foreign currency contracts were held
	by the Company prior to May 2015. The table below presents the fair value of the Company&#8217;s derivative financial instruments
	as well as their classification on the balance sheet as of December 31, 2015 (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Balance Sheet line item
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Gross amounts of recognized liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Gross amount offset in consolidated balance sheet
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Net Amount
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 40%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Forward foreign currency contracts
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Other current liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	537
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	7.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Commitments and Contingencies
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Significant Contracts and Agreements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0PT 0 0">
	In February 2002, the Company entered
	into an agreement to license certain intellectual property with Johns Hopkins University. The agreement calls for payments to be
	made by the Company upon the commencement of product sales, in the form of a royalty of 2.5% on net sales of the product. As of
	December 31, 2015 the Company has not commenced product sales and therefore has recognized no royalties on product sales.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 15.55PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT; MARGIN: 0 0PT 0 0">
	In July 2015, the Company entered into a manufacturing services agreement with Lonza Ltd for the processing,
	development and manufacture of the active pharmaceutical ingredient (&ldquo;API&rdquo;) in its lead product candidate, vonapanitase.
	Under the agreement, the Company will execute purchase orders authorizing Lonza to manufacture the batches and will pay for the
	services and batches in accordance with terms and assumptions in the agreement and to be set forth in a project plan. As of December
	31, 2015, the Company has executed one purchase order of $1.9 million for the manufacturing of one batch to commence in July 2016.
	In addition, management expects to pay $0.3 million to Lonza in the second quarter of 2016 for Lonza&rsquo;s acquisition of raw
	materials in connection with this purchase order.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 178 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage179"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Operating Leases
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company has various non-cancellable operating leases for facilities and office equipment that expire at
	various dates through 2018. In August 2014, the Company entered into an Amendment (the &quot;Lease Amendment&quot;) to the existing
	Lease Agreement dated July 13, 2009 (the &quot;Lease Agreement&quot;), with Boston Properties Limited Partnership (&quot;Lessor&quot;)
	pursuant to which the Company has agreed to extend the lease for approximately 5,000 square feet of property to be used for office
	space (the &quot;Leased Property&quot;) located at 200 West St., Waltham, Massachusetts. The term of the Lease Amendment commences
	on January 1, 2015 (the &quot;Commencement Date&quot;) and expires in June 2018, approximately three years and six months from
	the Commencement Date. The Company has the option to extend the term for an additional one-year period upon the Company's written
	notice to the Lessor at least nine months in advance of the extension. Rental expense for the years ended December 31, 2015, 2014
	and 2013 was $0.2 million, $0.2 million and $0.2 million, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Future minimum payments required under operating
	leases as of December 31, 2015 are summarized as follows (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ending December 31:
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amount
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 60%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	2016
</TD>
<TD STYLE="WIDTH: 20%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 18%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	168
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	2017
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	168
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	2018
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Total minimum lease payments
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	420
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 16.65PT; MARGIN: 2.75PT 11PT 0 5.95PT">
	In addition to the base rent,
	the Company is also responsible for its share of operating expenses and real estate taxes, in accordance with the terms of the
	lease agreement. As of December 31, 2015, the Company has provided a security deposit in the amount of $14,000 to the lessor.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Restricted cash related to facilities leases
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	At December 31, 2015 and 2014, the Company had
	$14,000 and $38,000, respectively, in an outstanding letter of credit to be used as collateral for leased premises. At December
	31, 2015 and 2014, the Company pledged an aggregate of $14,000 and $39,000, respectively, to the bank as collateral for the letter
	of credit, which is included in long-term assets and both short-term deposits and long-term assets, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 179 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage180"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0">
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	8.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Common Stock
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	General
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	At December 31, 2015, the Company has 100,000,000 shares of Common Stock
	authorized for issuance, $0.001 par value per share, of which 16,501,500 shares were issued and outstanding.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;The
	Common Stock has the following characteristics:
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Voting
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The holders
	of shares of Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders and written
	action in lieu of meetings. There is no cumulative voting.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Dividends
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The holders
	of shares of Common Stock are entitled to receive dividends, if and when declared by the Board of Directors. Cash dividends may
	not be declared or paid to holders of shares of Common Stock until paid on outstanding Preferred Stock. As of December 31, 2015,
	no dividends have been declared or paid since the Company's inception.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Liquidation
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Upon the
	dissolution or liquidation or winding up of the affairs of the Company, whether voluntary or involuntary, holders of Common Stock
	will be entitled to receive all assets of the Company available for distribution to its stockholders equally on a per share basis,
	subject to any preferential rights of any then outstanding shares of Preferred Stock and after payment or provision for payment
	of the Company&#8217;s debts.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 180 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage181"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Reserved for Future Issuance
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	At December 31, 2015, the Company has 100,000,000 shares of Common Stock authorized for issuance, $0.001
	par value per share, of which 16,501,500 shares were issued and outstanding. After the
<FONT STYLE="FONT-SIZE: 10PT">
	1,768
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	shares issued in the fourth quarter for the ESPP plan, the Company has the following shares of Common Stock reserved for future
	issuance:
</FONT>
</FONT>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
<BR>
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Stock-based compensation awards
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,419,901
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,807,349
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Employee Stock Purchase Plan
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	297,359
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	140,500
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,717,260
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,947,849
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	9.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Stock-based Compensation
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	On August
	21, 2014, the Company&#8217;s Board of Directors adopted the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), the 2014
	Employee Stock Purchase Plan (the &#8220;2014 ESPP&#8221;) and the 2006 Equity Incentive Plan (the &#8220;2006 Plan&#8221;), as
	amended and restated (collectively the &#8220;Plans&#8221;). On October 3, 2014, the stockholders approved these plans.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The Plans
	provide for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit
	awards, performance units, stock grants and qualified performance-based awards. Under the 2006 Plan, no new stock compensation
	awards will be granted subsequent to the completion of the Company&#8217;s IPO.&nbsp;&nbsp;The Company initially reserved 704,000
	shares of Common Stock for issuance under the 2014 Plan.&nbsp;&nbsp;&nbsp;The 2014 Plan provides that the number of shares reserved
	and available for issuance under the 2014 Plan will automatically increase each January 1, beginning January 1, 2015 by four percent
	of the outstanding shares of Common Stock on the immediately preceding December 31 or such lesser number of shares as determined
	by the Company&#8217;s Board of Directors prior to each such January 1st.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Terms of
	the stock awards, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the Plans.
	Options granted by the Company typically vest over three to four years. Certain awards provide for accelerated vesting if there
	is a change in control as defined in the Plans. Stock options outstanding under the 2006 Plan are exercisable from the date of
	grant for a period of ten years. Stock options granted under the 2014 Plan are exercisable only upon vesting. For options granted
	to date, the exercise price equaled the fair value of the Common Stock as determined by the Board of Directors on the date of grant.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 181 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage182"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Stock-based compensation
	expense
</I>
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Total stock-based
	compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#8217;s
	consolidated statements of operations as follows (in thousands):
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	650
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	114
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,514
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	345
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,164
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	459
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	155
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company estimates the fair value of each employee
	stock award on the grant date using the Black-Scholes option-pricing model based on the following assumptions regarding the fair
	value of the underlying Common Stock on each measurement date:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Weighted average expected volatility
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	79.8
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	79.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	91.1
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected term (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.11
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.95
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Risk free interest rate
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.03
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected dividend yield
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; COLOR: RED">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Stock options issued to non-employees
	are accounted for using the fair value method of accounting; they are periodically revalued as the options vest and are recognized
	as expense over the related service period. The total expense related to all options granted to non-employees for the years ended
	December 31, 2015, 2014 and 2013 was $2,000, $4,000 and $32,000, respectively.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Stock Options
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0 0 0 22.6PT">
	The following table summarizes stock option activity for
	employees and non-employees:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Options
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Weighted-Average Exercise Price
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Weighted-Average Remaining Contractual Term (years)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Aggregate Intrinsic Value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT">
	Outstanding at December 31, 2014
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,235,526
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.19
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.1
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,709
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 20PT">
	Granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,010,256
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13.52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Exercised
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(45,413
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.96
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	Outstanding at December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,200,369
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.8
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	15,705
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	Exercisable at December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	812,891
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.53
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.3
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9,755
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Vested or expected to vest at December 31, 2015 (1)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,991,131
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,926
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	_________________________
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	(1) Represents the number of vested options at December 31, 2015 plus the number of unvested options expected
	to vest based on the unvested options outstanding at December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 182 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage183"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	During the year ended December 31, 2015, the Company
	granted stock options to purchase an aggregate of 1,010,256 shares of its Common Stock with a weighted-average exercise price of
	$13.52 and a weighted-average grant date fair value of $9.34. During the year ended December 31, 2014, the Company granted stock
	options to purchase an aggregate of 659,865 shares of its Common Stock with a weighted-average grant date fair value of $4.07.
	During the year ended December 31, 2013, the Company granted stock options to purchase an aggregate of 3,150 shares of its Common
	Stock with a weighted-average grant date fair value of $16.50.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The total intrinsic value of options exercised
	in the years ended December 31, 2015 and 2014 was $0.5 million and $0.2 million, respectively. As of December 31, 2015, there was
	$9.6 million of total unrecognized compensation cost related to employee non-vested stock options. As of December 31, 2015, total
	compensation cost related to non-employee, non-vested stock options was fully recognized. The total unrecognized compensation cost
	for employee awards will be adjusted for future forfeitures. The Company expects to recognize its remaining stock-based compensation
	expense over a weighted-average period of 3.0 years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
<I>
	Employee Stock Purchase Plan
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	The 2014 ESPP initially authorized the issuance of up to 140,500 shares of Common Stock. The number of shares
	increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the
	lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 281,000 shares and any
	lower amount determined by the Company&rsquo;s Board of Directors prior to each such January 1st. As of December 31, 2015, as a
	result of an increase of 164,491 shares on January 1, 2015 of one percent of the outstanding shares as of the end of the fiscal
	year ending December 31, 2014, the 2014 ESPP authorized the issuance of up to 304,991 shares of Common Stock. The Company&rsquo;s
	Board of Directors has determined there was to be no increase on January 1, 2016. The first offering under the 2014 ESPP began
	on January 1, 2015 and ended on June 30, 2015. The second offering under the 2014 ESPP began on July 1, 2015 and ended on December
	31, 2015. During the year ended December 31, 2015, 7,632 shares were issued under the 2014 ESPP resulting in 297,359 shares remaining
	for future issuance under the plan as of December 31, 2015. The Company incurred $32,000 in stock-based compensation expense related
	to the 2014 ESPP for the year ended December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28PX; TEXT-ALIGN: JUSTIFY">
<B>
	10.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Income Taxes
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	For the years ended
	December 31, 2015, 2014 and 2013, the Company has not recorded a provision for federal or state income taxes as it has had cumulative
	net operating losses since inception. The Company's losses before income taxes consist solely of domestic losses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 183 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage184"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	A reconciliation of income taxes computed using
	the U.S. federal statutory rate to that reflected in operations follows (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Income tax benefit using U.S. federal statutory rate
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,315
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1,136
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(2,690
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Permanent differences
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	260
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	124
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	299
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Orphan Drug credit permanent addback
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,310
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	674
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	State income taxes, net of federal benefit
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(808
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(303
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(389
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Tax credits
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(4,219
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(2,176
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(7,164
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Expired net operating losses and tax credits
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	312
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,566
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Change in valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	9,782
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,394
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7,286
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Mark-to-market derivative liability
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(1,779
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	Other
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	990
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(110
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	92
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	The
</FONT>
	significant
	components of the Company's deferred tax assets are as follows (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Net operating loss carryforwards
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	34,488
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	29,217
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	26,304
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Federal and state tax credits
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,404
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	12,126
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	9,941
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Deferred revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,147
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Accrued expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	478
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	332
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Patents
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	443
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	531
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	612
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	596
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	92
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	Other
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	276
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	52,234
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	42,452
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	38,636
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(52,234
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(42,452
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(38,636
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net deferred tax asset
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	In November 2015, the FASB issued ASU No. 2015-17,
<I>
	Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes
</I>
	(&#8220;ASU 2015-17&#8221;), which simplifies the
	presentation of deferred income taxes. ASU 2015-17 requires that deferred tax assets and liabilities be classified as noncurrent
	in a classified statement of financial position. ASU 2015-17 is effective for financial statements issued for fiscal years beginning
	after December 15, 2016 (and interim periods within those fiscal years) with early adoption permitted. ASU 2015-17 may be either
	applied prospectively to all deferred tax assets and liabilities or retrospectively to all periods presented. The Company has elected
	to early adopt ASU 2015-17 prospectively in the fourth quarter of 2015. As a result, the Company has presented all deferred tax
	assets and liabilities as noncurrent on the consolidated balance sheet as of December 31, 2015, but have not reclassified current
	deferred tax assets and liabilities on the consolidated balance sheet as of December 31, 2014. There was no impact on the Company&#8217;s
	results of operations as a result of the adoption of ASU 2015-17.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 184 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage185"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Management of the Company has evaluated the positive
	and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company's history of operating losses,
	management of the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be
	realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December 31, 2015, 2014
	and 2013.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The valuation allowance increased approximately $9.8 million during the year ended December 31, 2015, due
	primarily to the addition of Orphan Drug tax credits and the generation of net operating losses. The valuation allowance increased
	approximately $3.8 million during the year ended December 31, 2014, due primarily to the addition of Orphan Drug tax credits and
	the generation of net operating losses. The valuation allowance increased approximately $7.3 million during the year ended December
	31, 2013, due primarily to the addition of Orphan Drug tax credits for 2009 through 2012 as well as the generation of net operating
	losses during the year ended December 31, 2013, both of which have a full valuation allowance.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Subject to the limitations described below, as of December 31, 2015, 2014 and 2013, the Company has net operating
	loss carryforwards of approximately $94.4 million, $78.1 million and $69.9 million, respectively, to offset future federal taxable
	income, which will expire at various times between 2026 and 2035. The Company has an additional $0.4 million of net operating losses
	in 2015 that are attributable to excess stock option deductions which would be recorded as an increase in additional paid-in capital
	upon reducing cash taxes paid. As of December 31, 2015, 2014 and 2013, the Company has state net operating loss carryforwards of
	approximately $46.4 million, $55.1 million and $45.4 million, respectively, to offset future state taxable income, which will expire
	at various times between 2026 and 2035. As of December 31, 2015, 2014 and 2013, the Company has tax credit carryforwards of approximately
	$16.9 million, $12.5 million and $10.3 million, respectively, to offset future federal and state income taxes, which will expire
	at various times between 2023 and 2035.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	Net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal
	Revenue Service (the &ldquo;IRS&rdquo;) and may become subject to an annual limitation in the event of certain cumulative changes
	in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and
	383 in the Internal Revenue Code. The Company is in the process of completing an analysis to determine if there were changes in
	ownership for tax years through 2015, as defined by Section 382. To the extent that the Company undergoes a change in ownership,
	this could substantially limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax
	liabilities. If this were to occur, this could result in increased U.S. federal income tax liability for the Company if it generates
	taxable income in a future period. Limitations on the use of NOLs and other tax attributes could also increase the state tax liability.
	The use of tax attributes will also be limited to the extent that the Company does not generate positive taxable income in future
	tax periods. The amount of the annual limitation is determined based on the Company's value immediately prior to any ownership
	change.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 185 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage186"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company had no unrecognized tax benefits or
	related interest and penalties accrued during the years ended December 31, 2015, 2014 and 2013. The Company will recognize interest
	and penalties related to uncertain tax positions in income tax expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company is subject to U.S. federal income
	tax and primarily Massachusetts state income tax. The statute of limitations for assessment by the IRS and state tax authorities
	is open for tax years ending December 31, 2012 through 2015, although carryforward attributes that were generated prior to tax
	year 2012 may still be adjusted upon examination by the IRS or state tax authorities if they either have been or will be used in
	a future period. Currently, no federal or state income tax returns are under examination by the respective taxing authorities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	11.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Net Loss per Share Attributable to Common Stockholders
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	As described in Note 2, Summary of Significant
	Accounting Policies, the Company computes basic and diluted loss per share using a methodology that gives effect to the impact
	of outstanding participating securities (the &#8220;two-class method&#8221;). As the years ended December 31, 2015, 2014 and 2013
	resulted in net losses, there is no income allocation required under the two-class method or dilution attributed to weighted-average
	shares outstanding in the calculation of diluted loss per share.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.05PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	The following Common Stock equivalents, presented
	on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive
	effect (in thousands):
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="11" STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Year Ended December 31,
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2014
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2013
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Convertible preferred stock
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,581
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,254
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Common stock warrants
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	660
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	660
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Outstanding stock options
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,200
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,236
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	607
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Convertible notes
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	243
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	243
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,200
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9,720
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,764
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	(a) These instruments were either exercised or converted to Common Stock during 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 186 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage187"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0">
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	12.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Quarterly Financial Information (unaudited, in thousands, except share and per share data)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	The Company uses the two-class method to
	calculate net income (loss) per share.&nbsp;&nbsp;During the fourth quarter of the year ended December 31, 2014, the Company recorded
	net income, although for the full year the Company recorded a net loss.&nbsp;&nbsp;For purposes of calculating basic net income
	per share for the fourth quarter of 2014, the Company excluded from the numerator $1.3 million of net income attributable to participating
	securities.&nbsp;&nbsp;The Company calculated diluted net income per share under both the if-converted method and the two-class
	method noting a greater dilutive effect under the two-class method. For the purposes of calculating diluted net income per share
	under the two-class method for the fourth quarter of 2014, the Company excluded from the numerator $1.3 million of net income attributable
	to participating securities and did not assume the conversion of Preferred Stock in the denominator on an as if-converted basis.&nbsp;&nbsp;Shares
	of Common Stock issuable upon exercise of outstanding stock options and warrants were included in the denominator on an as-if converted
	basis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Three Months Ended
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	March 31,
<BR>
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	June 30,
<BR>
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	September 30,
<BR>
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; COLOR: BLACK; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
<BR>
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Operating expenses
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,620
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,981
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	5,082
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6,187
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Net loss attributable to common stockholders
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(4,580
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5,072
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5,383
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,342
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Net loss per share attributable to common stockholders:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Basic and Diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(0.28
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(0.31
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(0.33
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(0.38
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Weighted-average common shares outstanding used in net loss per share attributable to common stockholders:
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	Basic and Diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,448,688
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,449,937
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,466,945
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,490,430
</TD>
<TD STYLE="FONT-SIZE: 10PT; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 187 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage188"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.2PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Three Months Ended
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	March 31,
<BR>
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	June 30,
<BR>
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	September 30,
<BR>
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
<BR>
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Revenue
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,948
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,933
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,508
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,814
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,273
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net (loss) income
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,831
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,563
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(5,181
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,233
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net (loss) income attributable to common stockholders - basic
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,343
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,460
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,458
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,938
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net (loss) income attributable to common stockholders - diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,343
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,460
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,458
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,938
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net (loss) income per share attributable to common stockholders:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Basic
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18.09
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18.55
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(31.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18.09
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18.55
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(31.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.48
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Weighted-average common shares outstanding used in net (loss) income per share attributable to common stockholders:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Basic
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	240,138
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	240,374
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	240,610
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,444,807
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(a)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	240,138
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	240,374
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	240,610
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,295,431
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(a)
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	(a) In October 2014, the Company completed its initial public offering of common stock
	which resulted in net proceeds of approximately $62.5 million from the issuance of 7,026,500 shares of common stock, which includes
	the sale of 916,500 shares under the underwriter's over allotment option. Immediately prior to the closing of the Company&#8217;s
	IPO, 498,889 shares of Common Stock were issued upon the exercise of warrants with aggregate proceeds of $1.4 million. In connection
	with the public offering, all of the Company's outstanding redeemable convertible preferred stock was converted to 8,651,805 shares
	of common stock.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0.2PT 0 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PX; TEXT-ALIGN: JUSTIFY">
<B>
	13.
</B>
</TD>
<TD STYLE="WIDTH: 7PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Subsequent Events
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN; MARGIN: 0">
	The Company has evaluated all activity that occurred
	subsequent to quarter end but prior to issuance of the condensed consolidated financial statements for events or transactions
	that could require disclosure or that could impact the carrying value of assets or liabilities as of the balance sheet date. In
	the judgment of management, there were no material events that impacted the unaudited condensed financial statements or disclosures.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 188 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage189"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25.55PT; MARGIN: 0">
	&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25PT; MARGIN: 0">
	Pursuant to the requirements of Section 13 or 15(d)
	of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
	thereunto duly authorized.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.4PT 0 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD COLSPAN="2">
	PROTEON THERAPEUTICS, INC.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 45%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 27%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	By:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Timothy P. Noyes
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	Timothy P. Noyes
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	President, Chief Executive Officer and Director
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 25PT; MARGIN: 3.85PT 16.25PT 0 5.95PT">
	Pursuant to the requirements
	of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the
	capacities and on the dates indicated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 35%">
	Signatures
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 40%">
	Title
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 15%; TEXT-ALIGN: LEFT">
	Date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Timothy P. Noyes
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	President, Chief Executive Officer and Director&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-TOP-COLOR: BLACK; BORDER-TOP-WIDTH: 1PT">
	Timothy P. Noyes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	(Principal Executive Officer)
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ George A. Eldridge
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Senior Vice President, Chief Financial Officer,
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	George A. Eldridge
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Treasurer and Secretary
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	(Principal Financial and Accounting Officer)
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Hubert Birner, Ph.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-TOP-COLOR: BLACK; BORDER-TOP-WIDTH: 1PT">
	Hubert Birner, Ph.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Garen Bohlin
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	Garen Bohlin
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Scott Canute
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	Scott Canute
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ John G. Freund, M.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-TOP-COLOR: BLACK; BORDER-TOP-WIDTH: 1PT">
	John G. Freund, M.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Tim Haines
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-TOP-COLOR: BLACK; BORDER-TOP-WIDTH: 1PT">
	Tim Haines
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Stuart A. Kingsley
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-TOP-COLOR: BLACK; BORDER-TOP-WIDTH: 1PT">
	Stuart A. Kingsley
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Dmitry Kobyzev, Ph.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	Dmitry Kobyzev, Ph.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Brendan M. O&rsquo;Leary, Ph.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	Brendan M. O&rsquo;Leary, Ph.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Gregory D. Phelps
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	March 14, 2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	Gregory D. Phelps
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_SIGNATURES>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 189 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage190"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<B>
	EXHIBIT INDEX
</B>
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; WIDTH: 5%; VERTICAL-ALIGN: TOP">
	Exhibit
<BR>
	No.
</TD>
<TD STYLE="WIDTH: 3%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 92%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
	Description
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	3.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP-COLOR: BLACK; BORDER-TOP-WIDTH: 1PT; TEXT-ALIGN: JUSTIFY">
	Sixth Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 27, 2014 (File No. 001-36694)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	3.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on October 27, 2014 (File No. 001-36694)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	4.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	4.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Fourth Amended and Restated Investors' Rights Agreement, dated May&nbsp;13, 2014, between the Company and certain investors named therein (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	4.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Series&nbsp;D Preferred Stock Purchase Agreement, dated May&nbsp;13, 2014, between the Company and certain investors named therein (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	2006 Equity Incentive Plan, as amended and restated August&nbsp;21, 2014 (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	2014 Equity Incentive Plan, Form of Stock Option Agreement and Form of Option Exercise Notice under the Company's 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Letter Agreement by and between the Company and F.&nbsp;Nicholas Franano, dated August&nbsp;22, 2014 (incorporated by reference to Exhibit 10.8 to&nbsp;the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 190 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage191"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP; WIDTH: 5%">
	10.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP; WIDTH: 3%">
	&#8225;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 92%">
	Process Development and Manufacturing Services Agreement by and between the Company and Lonza&nbsp;Ltd., dated September&nbsp;1, 2009 (as amended by that Amendment No.&nbsp;1 entered into as of February&nbsp;21, 2012) (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Lease Agreement by and between the Company and Boston Properties Limited Partnership, dated July&nbsp;13, 2009, as amended by that Amendment No. 1 dated September&nbsp;14, 2012, as amended by that Amendment No.&nbsp;2 dated October&nbsp;17, 2013, as amended by that Amendment No.&nbsp;3 dated August&nbsp;4, 2014 (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Assignment of Rights/License Agreement, effective as of February&nbsp;4, 2002, by and between Johns Hopkins University and F.&nbsp;Nicholas Franano (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Assignment of Patent made and entered into as of December&nbsp;30, 2002, by and between F.&nbsp;Nicholas Franano and Proteon Therapeutics, L.L.C (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Letter Agreement, dated October&nbsp;1, 2010, among the National Institutes of Health, F.&nbsp;Nicholas Franano and the Company (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Letter Agreement, dated January&nbsp;12, 2009, by and between F.&nbsp;Nicholas Franano and the Company (as successor-in-interest to Proteon Therapeutics, L.L.C.) (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Quitclaim Deed, dated January&nbsp;17, 2011, by F.&nbsp;Nicholas Franano to the Company (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.11
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Form of Stock Option Grant Notice and Stock Option Agreement under the Company's 2006 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014 (File No. 333-198777)).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 191 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage192"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP; WIDTH: 5%">
	10.12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP; WIDTH: 3%">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 92%">
	2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.25 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amended and Restated Employment Agreement by and between the Company and Timothy P. Noyes, dated October 1, 2014 (incorporated by reference to Exhibit 10.26 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amended and Restated Employment Agreement by and between the Company and Steven Burke, dated October 1, 2014 (incorporated by reference to Exhibit 10.27 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amended and Restated Employment Agreement by and between the Company and George Eldridge, dated October 1, 2014 (incorporated by reference to Exhibit 10.28 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8224;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amended and Restated Employment Agreement by and between the Company and Daniel Gottlieb, dated October 1, 2014 (incorporated by reference to Exhibit 10.29 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Form of Amended and Restated Indemnification Agreement (incorporated by reference to Exhibit 10.30 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1/A filed on October 7, 2014 (File No. 333-198777)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	10.18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&#8225;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Manufacturing Services Agreement by and between the Company and Lonza Ltd, dated as of June 30, 2015 and
	signed July 9, 2015 (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Quarterly Report on Form 10-Q for the quarter
	ended September 30, 2015 filed on November 12, 2015 (File No. 001-36694)).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	21.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	*&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	List of Subsidiaries.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	23.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	*&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	31.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	*&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	31.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	*&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	32.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	**&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. &#167;1350.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 192 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage193"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP; WIDTH: 5%">
	101
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP; WIDTH: 3%">
	*&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 92%">
	Interactive Data Files Pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T: (i)&nbsp;the Consolidated Balance Sheets as of December&nbsp;31, 2014 and 2013; (ii)&nbsp;the Consolidated Statements of Operations and Comprehensive Loss for the years ended December&nbsp;31, 2015, 2014 and 2013; (iii) the Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the years ended December&nbsp;31, 2015, 2014 and 2013; (iv)&nbsp;the Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2015, 2014 and 2013;&nbsp;&nbsp;and (v)&nbsp;the notes to the Consolidated Financial Statements.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0.15PT 0 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	*Exhibits filed herewith
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	** Exhibits furnished herewith.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&#8224;Indicates management contract or compensation
	plan
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&#8225;Indicates confidential treatment has
	been requested with respect to specific portions of this exhibit. Omitted portions have been filed with the Securities and Exchange
	Commission pursuant to Rule&nbsp;406 of the Securities Act of 1933, as amended.
</P>
</EFX_EXHIBIT_INDEX>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage194"></A>
<A NAME="EXH_211_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 21.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	List of Subsidiaries
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: UNDERLINE; WIDTH: 30%">
	Name of Subsidiary
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: UNDERLINE; WIDTH: 70%">
	Jurisdiction
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-SIZE: 10PT">
	Proteon Therapeutics Limited&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	United Kingdom
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-SIZE: 10PT">
	Proteon Securities Corp.&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	Massachusetts
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	All subsidiaries are 100% owned.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage195"></A>
<A NAME="EXH_231_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 23.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Consent of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We consent to the incorporation by reference
	in the Registration Statement (Form S-8 No. 333-200587) pertaining to the 2014 Equity Incentive Plan, the 2014 Employee Stock Purchase
	Plan, and the Amended and Restated 2006 Equity Incentive Plan of Proteon Therapeutics, Inc.; and the Registration Statement (Form
	S-3 No. 333- 207965) of Proteon Therapeutics, Inc. and in the related Prospectus of our report dated March 14, 2016, with respect
	to the consolidated financial statements of Proteon Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year
	ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	/s/ Ernst &amp; Young LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Boston, Massachusetts
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 14, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage196"></A>
<A NAME="EXH_311_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; MARGIN: 0PT 5.9PT 0PT 0">
	Exhibit 31.1
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 4.5PT; MARGIN: 0PT 5PT 0PT 13.5PT">
<B>
	CERTIFICATION PURSUANT TO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 4.5PT; MARGIN: 0PT 5PT 0PT 13.5PT">
<B>
	SECURITIES EXCHANGE ACT RULES
	13a-14(a) and 15d-14(a) AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 4.5PT; MARGIN: 0PT 5PT 0PT 13.5PT">
<B>
	SECTION 302 OF THE SARBANES-OXLEY
	ACT OF 2002
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 5.95PT">
	I, Timothy P. Noyes, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12.2PT">
</TD>
<TD STYLE="WIDTH: 10.4PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	I have reviewed this Annual Report on Form 10-K of Proteon Therapeutics,
	Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12.2PT">
</TD>
<TD STYLE="WIDTH: 10.4PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 5.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, this report does not
	contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light
	of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12.2PT">
</TD>
<TD STYLE="WIDTH: 10.4PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 5.9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Based on my knowledge, the financial statements,
	and other financial information included in this report, fairly present in all material respects the financial condition, results
	of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12.2PT">
</TD>
<TD STYLE="WIDTH: 10.4PT">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 5.9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The registrant&rsquo;s other certifying officer
	and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15I
	and 15d-15(e)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 22.6PT">
</TD>
<TD STYLE="WIDTH: 16.7PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 11.4PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
	others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 22.6PT">
</TD>
<TD STYLE="WIDTH: 16.7PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 11.4PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Evaluated the effectiveness of the registrant&rsquo;s
	disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
	and procedures as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 22.6PT">
</TD>
<TD STYLE="WIDTH: 16.7PT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 17.75PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Disclosed in this report any change in the
	registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
	(the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
	to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12.2PT">
</TD>
<TD STYLE="WIDTH: 10.4PT">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 5.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The registrant&rsquo;s other certifying officer
	and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
	auditors and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28.15PT">
</TD>
<TD STYLE="WIDTH: 11.15PT">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 11.4PT">
<FONT STYLE="FONT-SIZE: 10PT">
	All significant deficiencies and material
	weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
	the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 27.45PT">
</TD>
<TD STYLE="WIDTH: 11.85PT">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 7.9PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Any fraud, whether or not material, that involves
	management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Timothy P. Noyes
</TD>
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	Timothy P. Noyes
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<I>
	President, Chief Executive Officer and Director (Principal Executive Officer)
</I>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20.95PT; MARGIN: 0PT 92.35PT 0PT 256.05PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 65.15PT 0PT 277PT">
<I>
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
	Date: March 14, 2016
</P>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage197"></A>
<A NAME="EXH_312_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 31.2
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 144.15PT">
<B>
	CERTIFICATION PURSUANT TO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 156.3PT 0PT 157.1PT">
<B>
	SECURITIES EXCHANGE ACT RULES 13a-14(a) and
	15d-14(a) AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 144.15PT 0PT 144.8PT">
<B>
	SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 5.95PT">
	I, George A. Eldridge, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 0 0PT 5.95PT">
	1.
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	I have reviewed this Annual Report on Form 10-K of Proteon Therapeutics, Inc.;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 16.25PT 0PT 5.95PT">
	2.
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
	to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
	the period covered by this report;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 11.4PT 0PT 5.95PT">
	3.
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
	material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
	in this report;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 16.25PT 0PT 5.95PT">
	4.
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
	procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))) for the registrant and have:
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 16.25PT 0PT 39.3PT">
	a)
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
	others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 16.25PT 0PT 39.3PT">
	b)
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
	such evaluation; and
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 24.6PT 0PT 39.3PT">
	c)
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
	registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that
	has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
	and
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 16.25PT 0PT 5.95PT">
	5.
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
	financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s Board of Directors (or
	persons performing the equivalent functions):
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 24.6PT 0PT 39.3PT">
	a)
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; MARGIN: 0PT 35PT 0PT 39.3PT">
	b)
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ George A. Eldridge
</TD>
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	George A. Eldridge
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<I>
	Senior Vice President, Chief Financial Officer, Treasurer and Secretary (Principal Financial Officer)
</I>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
	Date: March 14, 2016
</P>
</EFX_CERTIFICATION>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage198"></A>
<A NAME="EXH_321_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; MARGIN: 0PT 9.9PT 0PT 0">
	Exhibit 32.1
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	CERTIFICATION PURSUANT TO SECTION
	1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 20.95PT; MARGIN-BOTTOM: 0PT">
	In connection with the Annual
	Report of Proteon Therapeutics, Inc. (the &ldquo;Corporation&rdquo;) on Form 10-K for the fiscal year ended December 31, 2015,
	as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Timothy P. Noyes, as President
	and Chief Executive Officer of the Corporation, and I, George A. Eldridge, Senior Vice President, Chief Financial Officer, Treasurer
	and Secretary of the Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002, that to my knowledge:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 23.9PT">
</TD>
<TD STYLE="WIDTH: 21.55PT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Report fully complies with the requirements of Section 13(a)
	or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 23.9PT">
</TD>
<TD STYLE="WIDTH: 21.55PT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 20.95PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The information contained in the Report fairly
	presents, in all material respects, the financial condition and results of operations of the Corporation.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY; WIDTH: 50%">
	Date: March 14, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY; WIDTH: 3%">
	By:
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY; WIDTH: 27%; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ Timothy P. Noyes&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	Timothy P. Noyes
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	President, Chief Executive Officer and Director
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	(Principal Executive Officer)
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	Date: March 14, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	By:
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/s/ George A. Eldridge&nbsp;&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	George A. Eldridge
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	Senior Vice President, Chief Financial Officer, Treasurer and Secretary
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: JUSTIFY">
	(Principal Financial Officer)
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 20.95PT; MARGIN-BOTTOM: 0PT">
	A signed original of this written
	statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities
	and Exchange Commission or its staff upon request.
</P>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
